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predict relative metabolite production rates in TCGA patient tumors. 
(Right) Model-predicted production of 871 metabolites between 
radiation-sensitive and radiation-resistant tumors. Values are the log2 
ratio of average production of the metabolite in radiation-resistant 
tumors divided by average production in radiation-sensitive tumors; 
log2(Predicted Resistant/Sensitive) < 0 signifies that a metabolite has 
greater maximum production in radiation-sensitive tumors, 
log2(Predicted Resistant/Sensitive) > 0 signifies that a metabolite has 
greater maximum production in radiation-resistant tumors. 
Metabolites are rank ordered based on increasing ratio value. Colors 
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indicate metabolite classes (cyan: sulfur-containing metabolites; 
green: eicosanoids; orange: lipids and fatty acids; purple: 
nucleotides). 
Figure 5-18 (Left) Correlation between metabolite concentration and surviving 
fraction at 2 Gy radiation (SF2) among 139 experimentally-
measured metabolites in the NCI-60 panel of cancer cell lines. 
Metabolites are ranked by the correlation coefficient between 
concentration and SF2. Metabolite classes are colored as in (B). 
(Right) Example regression between concentration and SF2 for 
cholesterol. 
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Figure 5-19 (Left) Schematic showing the comparison of model-predicted 
metabolite production in radiation-sensitive and -resistant TCGA 
tumors, with experimentally-measured metabolite concentrations in 
matched radiation-sensitive and -resistant cell lines from four 
different cancer types. (Right) Comparison of model-predicted and 
experimentally-measured (“FBA”) metabolite levels, expressed as 
the log2 of the ratio of metabolite levels in radiation-resistant versus 
radiation-sensitive tumor models or cell lines. Experimentally-
measured values are shown for each individual cell line pair, as well 
as averaged across all 4 cell line pairs (“MEAN EXP”). Statistically-
significant differences in experimentally-measured metabolite levels 
within each cell line pair are represented by green (Sensitive > 
Resistant) or red (Resistant > Sensitive) box outlines. Metabolites 
are grouped by metabolite classes and ordered by experimentally-
measured mean ratio values within each class. 
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Figure 5-20 Experimentally-measured levels of nucleotide metabolites in 
radiation-sensitive and -resistant cell lines across four cancer types 
from untargeted metabolomics. (Left) Replicate metabolite 
concentrations from all four cell line pairs, with values expressed as 
the log10 of the normalized area from LC-MS/MS. Statistical 
significance of the difference between radiation-sensitive and -
resistant cell line values is shown. 
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Figure 5-21 Experimentally-measured levels of lipid metabolites in radiation-
sensitive and -resistant cell lines across four cancer types from 
untargeted metabolomics. (Left) Replicate metabolite concentrations 
from all four cell line pairs, with values expressed as the log10 of the 
normalized area from LC-MS/MS. Statistical significance of the 
difference between radiation-sensitive and -resistant cell line values 
is shown. 
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Figure 5-22 Experimentally-measured levels of cysteine/antioxidant metabolites 
in radiation-sensitive and -resistant cell lines across four cancer types 
from untargeted metabolomics. (Left) Replicate metabolite 
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concentrations from all four cell line pairs, with values expressed as 
the log10 of the normalized area from LC-MS/MS. Statistical 
significance of the difference between radiation-sensitive and -
resistant cell line values is shown. 
Figure 5-23 Experimentally-measured levels of immune system-mediating 
metabolites in radiation-sensitive and -resistant cell lines across four 
cancer types from untargeted metabolomics. (Left) Replicate 
metabolite concentrations from all four cell line pairs, with values 
expressed as the log10 of the normalized area from LC-MS/MS. 
Statistical significance of the difference between radiation-sensitive 
and -resistant cell line values is shown. 
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Figure 5-24 Receiver operating characteristic (ROC) curve, averaged across 20 
training+validation/testing splits. Blue line represents the mean 
value across all splits, with the light blue error band representing +/- 
1 standard deviation. The points on the ROC curve signifying both 
the p=0.5 threshold and optimal threshold (that which maximizes 
Youden’s index) for differentiating radiation-sensitive and -resistant 
samples are shown, with associated sensitivity and specificity values. 
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Figure 5-25 (Left; black overlay) Feature importance scores for individual 
features, calculated as the average absolute SHAP value (mean |ΔP|) 
across all tumor samples. Features are ordered by decreasing feature 
importance score. (Right; gray overlay) Cumulative sum of feature 
importance scores. Those features within the 95% cumulative sum 
of feature importance scores (bolded number) are kept for further 
analysis. 
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Figure 5-26 List of top 50 features with largest feature importance scores, colored 
based on their original dataset. (Inset, Left) Number of features 
contributing to the 725 total important features from each individual 
dataset. (Inset, Right) Relative contribution of features from each 
dataset to the sum of absolute SHAP values, averaged across all 
samples. 
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Figure 5-27 (Left) Relative contribution of features from each dataset to the sum 
of absolute SHAP values for each individual sample. (Right) 
Clustering of samples into “Low”, “Medium”, and “High” clinical 
groups based on the relative contribution of features from the clinical 
dataset toward the sum of absolute SHAP values. The optimal 
number of clusters was calculated based on maximizing the gap 
statistic from k-means clustering (Figure 5-28). 
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Figure 5-28 Gap statistic associated with k-means clustering of clinical dataset 
contributions for each sample from the multi-omic classifier, as a 
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function of number of clusters (k). The optimal number of clusters is 
that which yields the largest gap statistic. 
Figure 5-29 List of top 50 features with largest feature importance scores among 
samples within the “Low Clinical” cluster. (Inset) Relative 
contribution of features from each dataset to the sum of absolute 
SHAP values, averaged across all samples within the “Low Clinical” 
cluster. 
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Figure 5-30 Statistical significance of patient clustering into 
“Low/Medium/High” clinical groups based on different clinical 
factors, as calculated by the chi-squared test with Yates’ correction. 
Only statistically significant (p ≤ 0.05) clinical factors are shown. 
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Figure 5-31 (Left) Heterogeneity of samples from different cancer types in terms 
of clinical dataset contribution and distribution into 
“Low/Medium/High” clinical groups. (Right) Heterogeneity of 
samples from different histological subtypes of breast cancer 
(BRCA) in terms of clinical dataset contribution and distribution into 
“Low/Medium/High” clinical groups. 
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Figure 5-32 Using the meta learner weight for the clinical dataset (probability 
that the clinical dataset is the optimal dataset for each individual 
sample) to determine a priori clustering into the “Low Clinical” or 
“Medium/High Clinical” groups. Dotted line signifies the optimal 
threshold separating “Low Clinical” or “Medium/High Clinical” 
groups, which maximizes the accuracy of predicting clinical cluster 
based on meta learner weight. 
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Figure 5-33 Metabolite-set enrichment analysis of the 236 significant metabolic 
features from the multi-omic classifier into Recon3D metabolic 
subsystems. The statistical significance and number of metabolites 
in each subsystem are shown. Only statistically significant (p ≤ 0.05) 
subsystems are shown. 
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Figure 5-34 Regression between metabolic feature SHAP value and predicted 
metabolite production for a representative metabolite (butyric acid), 
showing values for each individual patient tumor, as well as the 
Spearman correlation coefficient. 
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Figure 5-35 Overview of significant metabolic biomarkers and their 
interconnections within the human metabolic network. Different 
metabolic pathways are shown with colored backgrounds. 
Significant metabolic features are denoted by colored boxes, where 
the color indicates the Spearman correlation coefficient between the 
SHAP value for that feature and predicted metabolite production rate 
(see Figure 5-34); metabolites with positive correlations (red) are 
202 
 xxii 
predicted to have higher production in radiation-resistant tumors, 
whereas metabolites with negative correlations (green) are predicted 
to have greater production in radiation-sensitive tumors. Significant 
gene expression and mutation features are denoted by colored 
reaction arrows, either in red (higher gene expression or mutation 
rate in radiation-resistant tumors) or in green (higher gene expression 
or mutation rate in radiation-sensitive tumors). 
Figure 5-36 Spearman correlation coefficients of significant metabolic 
biomarkers involved in fatty acid and cholesterol metabolism. 
204 
Figure 5-37 Spearman correlation coefficients of significant metabolic 
biomarkers involved in sphingolipid metabolism. 
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Figure 5-38 Spearman correlation coefficients of significant metabolic 
biomarkers involved in (left) nucleotide metabolism, and (right) 
energy metabolism. 
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Figure 5-39 Maximal conversion of ADP to ATP in radiation-sensitive and -
resistant tumors, predicted from FBA metabolic models. 
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Figure 5-40 Metabolic pathway of eicosanoid production, highlighting 
significant metabolite features (colored boxes) and gene expression 
features (colored arrows). 
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Figure 5-41 Spearman correlation coefficients of significant sulfur-containing 
metabolic biomarkers. Colored dots signify metabolites within the 
top 50 of all features among “Low Clinical” samples in the multi-
omic classifier. 
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Figure 5-42 Inclusion of non-invasive clinical features and blood-based 
metabolic features, with exclusion of invasive clinical features and 
non-blood-based metabolic features. 
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Figure 5-43 Comparison of model AUROC, sensitivity, and specificity between 
multi-omic and non-invasive classifiers. 
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Figure 5-44 (Left; black overlay) Feature importance scores for individual 
features, calculated as the average absolute SHAP value (mean |ΔP|) 
across all tumor samples. Features are ordered by decreasing feature 
importance score. (Right; gray overlay) Cumulative sum of feature 
importance scores. Those features within the 95% cumulative sum 
of feature importance scores (bolded number) are kept for further 
analysis. 
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Figure 5-45 (Left) Clustering of samples into “Low” and “High” clinical groups 
based on the relative contribution of features from the clinical dataset 
toward the sum of absolute SHAP values. The optimal number of 
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clusters was calculated based on maximizing the gap statistic from 
k-means clustering (Right). 
Figure 5-46 Analysis of clinical and metabolic feature contributions among the 
“Low” clinical group. Features with mean absolute SHAP values 
above 1% are explicitly shown. 
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Figure 5-47 (Left) Breakdown of feature contributions towards prediction of 
radiation resistance in a representative radiation-resistant patient 
(TCGA-S9-A7IY). (Upper) Contribution of each data type towards 
the progression from prior to posterior probability of radiation 
resistance. (Lower) SHAP values of individual features for this 
patient. (Right) Plots of feature SHAP value versus predicted 
metabolite production rate for two features, illustrating (upper) a 
feature whose absolute SHAP value for patient TCGA-S9-A7IY is 
larger than average, and (lower) a feature whose absolute SHAP 
value for patient TCGA-S9-A7IY is smaller than average. 
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Figure 5-48 Comparison of (left) plasma total cholesterol levels, and (right) 
plasma HDL cholesterol levels, in radiation-sensitive BALB/cByJ 
mice versus radiation-resistant SPRET/EiJ mice from the 
CGDpheno1 and Paigen4 datasets in the Mouse Phenome Database. 
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Figure 6-1 Overview of the objective function screen pipeline. 231 
Figure 6-2 Optimal objective function for cisplatin response, highlighting the 
features involved (bolded metabolites and reaction arrows) and their 
relative weights. Features are colored based on relative weight values 
(largest value = dark red, lowest value = light orange). 
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Figure 6-3 Optimal objective function for cyclophosphamide response, 
highlighting the features involved (bolded metabolites and reaction 
arrows) and their relative weights. Features are colored based on 
relative weight values (largest value = dark red, lowest value = light 
orange). 
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Figure 6-4 Optimal objective function for doxorubicin response, highlighting 
the features involved (bolded metabolites and reaction arrows) and 
their relative weights. Features are colored based on relative weight 
values (largest value = dark red, lowest value = light orange). 
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Figure 6-5 Comparison of ROC curves and AUROC values between the top 
single-feature objective function (light blue) and top multi-feature 
objective function (dark blue) for each drug module. The p-value of 
the DeLong test comparing the two AUROC values is shown. Dark 
blue dot represents the point on the ROC curve which maximizes 
Youden’s J statistic. 
235 
 xxiv 
Figure 6-6 Separation of model-predicted drug-sensitive and drug-resistant 
classes based on the optimal objective value threshold which 
maximizes Youden’s J statistic. 
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Figure 6-7 Prediction of chemotherapeutic response in radiation-resistant 
patient tumors. Optimal objective value thresholds separating drug-
sensitive and -resistant classes are shown, with the number and 
percentage of radiation-resistant tumors predicted to be drug-
sensitive. 
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Figure 6-8 Predicted effect of maintaining chemotherapy objective value on 
maximal production of reduced redox cofactors in radiation-resistant 
drug-resistant tumor models. 
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Figure 6-9 Comparison of machine learning regressor-predicted (y-axis) and 
FBA model-calculated (x-axis) radiation-sensitizing effects of each 
chemotherapy. Error bars signify ± 1 standard error for each patient 
tumor across 20 training+validation/testing splits. Red dotted line: 
1:1 line. 
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Figure 6-10 Pearson and Spearman correlation values (and associated p-values) 
for the regression of machine learning regression-predicted (y-axis) 
vs. FBA model-calculated (x-axis) radiation-sensitizing effects of 
each chemotherapy. All testing set performance values across 20 
training+validation/testing splits are shown. 
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Figure 6-11 Top 50 features with largest mean absolute SHAP values for the 
cisplatin sensitizing-effect regressor, colored based on each feature’s 
original dataset. (Inset) Relative contribution of features from each 
dataset to the sum of absolute SHAP values, averaged across all 
samples. 
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Figure 6-12 Top 50 features with largest mean absolute SHAP values for the 
cyclophosphamide sensitizing-effect regressor, colored based on 
each feature’s original dataset. (Inset) Relative contribution of 
features from each dataset to the sum of absolute SHAP values, 
averaged across all samples. 
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Figure 6-13 Top 50 features with largest mean absolute SHAP values for the 
doxorubicin sensitizing-effect regressor, colored based on each 
feature’s original dataset. (Inset) Relative contribution of features 
from each dataset to the sum of absolute SHAP values, averaged 
across all samples. 
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Figure 6-14 Comparison of NOS3 and POR flux magnitudes in doxorubicin-
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SUMMARY 
 Despite being one of the oldest forms of cancer therapy and still a primary treatment 
modality, radiation therapy is not effective across all cancer types and tumor resistance to 
radiation is still not well understood. As our ability to characterize tumor pathophysiology 
increases with new -omic technologies, a broad clinical goal is prognostic indicators of 
therapeutic outcomes for personalizing therapeutic regimens. While redox metabolism is a 
known factor, methods for analyzing systems-level involvement of cellular metabolism in 
radiation response have not been previously developed. This dissertation presents the 
construction of novel genome-scale Flux Balance Analysis (FBA) models of individual 
radiation-sensitive and -resistant patient tumors from The Cancer Genome Atlas (TCGA) 
to explore the role of redox metabolism in radiation sensitivity, to identify diagnostic and 
therapeutic biomarkers for radiation response, and to predict response to radiation-
sensitizing chemotherapies in radiation-resistant tumors. 
A novel bioinformatics platform was developed to integrate genomic, 
transcriptomic, kinetic, and thermodynamic parameters from 716 radiation-sensitive and 
199 radiation-resistant TCGA tumors into personalized genome-scale FBA models. Pan-
cancer model predictions identified increased mitochondrial production of redox cofactors, 
including NADPH and glutathione, as well as increased H2O2-scavenging fluxes in 
radiation-resistant tumors. Simulated gene knockout screens were utilized to discover 
novel targets in redox metabolism, central carbon metabolism, and folate metabolism 
which differentially impact antioxidant production and ROS clearance in radiation-
resistant tumors; these targets were experimentally validated through siRNA gene 
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knockdown in matched radiation-sensitive and -resistant cancer cell lines among multiple 
cancer types. Finally, personalized metabolic flux profiles were generated for individual 
radiation-resistant cancer patients to identify optimal targets for radiation sensitization. 
This work not only improved upon methodological shortcomings of previous FBA models 
of cancer metabolism, but is the first to utilize genome-scale modeling for identifying 
metabolic differences between radiation-sensitive and -resistant tumors that could be 
exploited for improving radiation sensitivity. 
 Machine learning classifiers were developed which integrate multi-omic data from 
TCGA patients and novel metabolic outcomes from personalized FBA models to predict 
radiation sensitivity. A dataset-independent ensemble architecture with gradient boosting 
models and Bayesian optimization yielded improved predictive accuracy and biomarker 
detection compared to previously-developed classifiers for radiation response. 
Experimentally-validated predictions of metabolite production from radiation-sensitive 
and -resistant FBA tumor models were integrated into multi-omic classifiers; metabolites 
involved in lipid metabolism, nucleotide metabolism, and immune modulation were 
identified as having significant associations with radiation response. Subgroups of patients 
with differing utilities of clinical versus metabolomic datasets for radiation response 
prediction were discovered, and personalized panels of multi-omic and non-invasive 
biomarkers with optimal diagnostic utility were developed. This work made significant 
advancements by being the first to integrate FBA model predictions into machine learning 
classifiers for cancer treatment outcomes. 
 Finally, FBA models of radiation-resistant TCGA tumors were used to predict 
response to radiation-sensitizing chemotherapies and investigate their effects on tumor 
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redox metabolism. A novel multi-feature FBA objective function screen was developed, 
resulting in significant improvements in model predictions of treatment response, as well 
as identification of redox cofactors directly involved in drug metabolism. The radiation-
sensitizing effect of chemotherapeutic treatment was predicted in radiation-resistant 
tumors by assessing drug-associated decreases in antioxidant levels, and machine learning 
regressors were utilized to identify multi-omic biomarkers from patient tumors which are 
associated with increased radiation sensitization. This work was the first to utilize genome-
scale modeling to assess the role of chemotherapeutic treatment on tumor redox 
metabolism and radiation sensitization. 
 In summary, a generalizable framework for creating genome-scale metabolic 
models of individual patient tumors was developed. The collective properties of these 
personalized models improved pathophysiological insights into the role of redox 
metabolism in the tumor responses to radiation and radiation-sensitizing chemotherapies. 
This framework resulted in a reduced set of clinically-useful biomarkers for both the a 
priori prediction of radiation response as well as targeted sensitization of radiation-resistant 
tumors to radiation therapy. This personalized medicine approach represents a paradigm 
shift in how diagnostic and treatment strategies for radiation-resistant cancer patients are 
developed, ultimately improving the standard of care for these patients.
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CHAPTER 1. INTRODUCTION 
Tumor resistance to radiation therapy remains a significant obstacle to long-term 
cancer patient survival [1, 2]. As multi-omic characterizations of patient tumors are 
currently being developed, personalized biomarkers with diagnostic and therapeutic utility 
in the management of radiation-resistant cancer patients are under investigation [3]. Redox 
metabolism, involving the production of reducing cofactors and scavenging of reactive 
oxygen species (ROS), has been previously implicated in the mechanism of action of 
ionizing radiation therapy as well as the cellular response to both radiation treatment and 
radiation-sensitizing chemotherapies [4-6]. However, because redox cofactors such as 
NADPH, NADH, and GSH are involved in hundreds of interconnected reactions 
throughout the human metabolic network, experimental studies focusing on individual 
metabolic targets have not yielded much success for improving radiation sensitivity in 
patient tumors [7]. Additionally, previous approaches to biomarker detection which 
utilized only single -omics datatypes lack the predictive accuracy and applicability 
necessary for clinical use [8]. Instead, computational approaches which integrate multi-
omic tumor data with genome-scale metabolic networks are needed to model redox 
metabolism and its involvement in the tumor response to radiation therapy. 
Flux balance analysis (FBA) is a metabolic modeling approach for integrating 
biological information from samples of interest to predict steady-state reaction fluxes 
throughout the human metabolic network [9]. While FBA has been used previously to 
model cancer metabolism, personalized FBA models of patient tumors have not been 
previously developed to study the role of redox metabolism in radiation sensitivity [10]. 
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Also, FBA models have yet to be integrated with machine learning classifiers for the 
prediction of novel diagnostic biomarkers, nor have they been used to model tumor 
chemotherapy response and radiation sensitization. Methodological shortcomings in FBA 
model development, including non-physiological utilization of gene expression data and 
failure to integrate kinetic and thermodynamic constraints, have limited the clinical utility 
of previous modeling attempts towards identifying diagnostic and therapeutic targets in 
cancer [11, 12]. 
 
1.1 Research Objectives and Specific Aims 
The objective of this project was to develop a novel FBA-based bioinformatics 
platform for integrating multi-omic tumor data from The Cancer Genome Atlas (TCGA) 
into personalized models of radiation-sensitive and radiation-resistant tumors. These 
models would be used to 1) identify novel targets of redox metabolism in radiation-resistant 
tumors, 2) integrate metabolic information from patient tumors into machine learning 
models for prediction of radiation therapy response, and 3) model radiation-sensitizing 
chemotherapies to identify in which radiation-resistant patient tumors these therapies 
would be optimal alone or in conjunction with radiation treatment. The outcomes of this 
project are 1) a generalizable framework for developing accurate genome-scale metabolic 
models of individual patient tumors, 2) improved pathophysiological insights into the role 
of redox metabolism in the tumor response to radiation and radiation-sensitizing 
chemotherapies, and 3) identification of a reduced set of clinically-useful biomarkers for 
both the a priori prediction of radiation response as well as targeted sensitization of 
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radiation-resistant tumors to radiation therapy. This objective was addressed by the 
following three aims: 
Aim 1: Generate personalized FBA metabolic models of patient tumors using 
multi-omic data from TCGA and compare differences in redox metabolism between 
radiation-sensitive and radiation-resistant tumors. The technical hypothesis was that 
methodological improvements to FBA model development would allow for accurate 
predictions of redox metabolism in patient tumors that could be experimentally validated 
in radiation-sensitive and -resistant cancer cell lines. The biological hypothesis was that 
radiation-resistant tumors are capable of upregulating production of redox cofactors for 
antioxidant defense against ROS-generating ionizing radiation, and that the enzymes 
involved in cofactor production are essential for viability of radiation-resistant cancers. 
Chapter 3 details early development of FBA models for matched radiation-sensitive (SCC-
61) and radiation-resistant (rSCC-61) HNSCC cell lines through the novel integration of 
transcriptomic, kinetic, and thermodynamic data from these individual cell lines into 
maximum reaction flux constraints. These models demonstrated re-routing of NADPH-
producing metabolic flux in rSCC-61 and accurately predicted gene targets which 
selectively impacted NADPH-driven sensitization to the redox-cycling chemotherapeutic 
ß-lapachone. Chapter 4 details the extension of this modeling framework for integrating 
multi-omic data into personalized FBA models of individual radiation-sensitive and -
resistant TCGA patient tumors. Tumor-specific models were used to identify novel targets 
in the redox metabolic network which differentially impacted redox cofactor production 
and ROS-scavenging in radiation-resistant tumors; these targets were experimentally 
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validated through siRNA gene knockdown experiments in matched radiation-sensitive and 
-resistant cancer cell lines from multiple cancer types. 
Aim 2: Develop machine learning classifiers for identification of novel multi-
omic biomarkers for radiation therapy response. The technical hypothesis was that 
integration of metabolic predictions from FBA models of TCGA tumors into machine 
learning classifiers would yield novel multi-omic biomarkers that could be used for a priori 
prediction of radiation sensitivity. The biological hypothesis was that radiation-sensitive 
and -resistant tumors display differences in genomic, transcriptomic, and metabolomic 
features involved in redox biology and metabolism that enrich top predictive factors for 
machine learning classifiers of radiation response. Chapter 5 details the development of a 
dataset-independent ensemble architecture for integrating multi-omic datasets into 
machine learning models, yielding improved predictive accuracy and biomarker 
identification compared to previous radiation response classifiers. Additionally, FBA 
models were shown to accurately predict relative metabolite production between radiation-
sensitive and -sensitive tumors, which was validated by experimental metabolomics in 
matched radiation-sensitive and -resistant cancer cell lines from multiple cancer types; 
these features were integrated into machine learning models to yield novel metabolic 
biomarkers for prediction of radiation response, including in non-invasive applications. 
Aim 3: Incorporate the mechanism of action of radiation-sensitizing 
chemotherapies into FBA models to identify therapeutic strategies in individual 
radiation-resistant patients. The technical hypothesis was that utilization of a multi-
feature objective function screen would significantly improve the accuracy of FBA model-
predicted sensitivity to radiation-sensitizing chemotherapies. The biological hypothesis 
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was that tumor response to radiation-sensitizing chemotherapy relies on network-level 
metabolism of redox cofactors that are upregulated in radiation-resistant tumors. Chapter 
6 details the integration of chemotherapy mechanisms of action into FBA models and 
identification of optimal FBA objective functions for prediction of chemotherapy response 
in radiation-resistant tumors. Additionally, possible mechanisms of redox-based radiation 
sensitization by these chemotherapies were identified and used to discover novel multi-
omic biomarkers predictive for enhanced radiation-sensitizing effect in individual 
radiation-resistant tumors.  
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CHAPTER 2. BACKGROUND 
2.1 Radiation Therapy 
2.1.1 Epidemiology 
Radiation therapy remains a cornerstone of cancer treatment; approximately 50% 
of all cancer patients receive radiation as part of their treatment regimen, and radiation 
therapy contributes an estimated 40% towards curative treatment in these patients [1, 13, 
14]. However, tumor resistance to radiation therapy remains a significant obstacle to long-
term cancer patient survival. Among cancer patients in The Cancer Genome Atlas (TCGA) 
database, 28.0% of patients did not show complete resolution of their tumor after treatment 
with radiation therapy [2]. Figure 2-1 shows that the proportion of radiation-resistant 
patients (RECIST criteria: stable disease or progressive disease) compared to radiation-
sensitive patients (RECIST criteria: complete response or partial response) varies 
significantly between different cancer types; while more than 90% of TCGA patients with 
breast and thyroid cancers are sensitive to radiation therapy, over 70% of low-grade and 
high-grade glioma patients are radiation-resistant. Despite this observed variability in 
radiation response between cancer types, generalized pathophysiological principles of 
radiation resistance that apply across cancer types have been identified, and approaches for 
identifying novel biomarkers for improved diagnosis and treatment have included both 
cancer-specific and pan-cancer strategies [15, 16]. 
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Figure 2-1. Comparison of number of radiation-sensitive and radiation-resistant 
TCGA patients between different cancer types. 
2.1.2 Mechanism of action 
Ionizing radiation from X-rays, gamma rays, or other sources kill cancer cells 
through damage to cellular structures, most notably DNA [17]. Radiation can act directly 
on DNA to cause damage, or can act indirectly through the production of reactive oxygen 
species (ROS) such as hydroxyl radical (•OH) and hydrogen peroxide (H2O2) derived from 
ionization of water.  An estimated 60% of DNA damage from low-LET (linear energy 
transfer) radiations including X-rays and gamma rays is caused by indirect rather than 
direct effects [18]. Multiple types of DNA damage can occur; however, double-stranded 
breaks (DSB’s) are considered the most lethal [19]. ROS cause single-stranded breaks 
(SSB’s) through a Fenton reaction involving metal ions such as iron [4, 20]: 
 Fe2++H2O2+H




A second H2O2 molecule can react at the same site to produce a DSB: 
 Fe2++H2O2+H
+ → Fe3++ •OH+H2O
SSB+•OH→DSB
 (2) 
Once DNA damage is recognized, signaling through ATM, ATR, and/or DNA-PK lead to 
increased activity of Chk1/2 and p53, resulting in cell cycle arrest and DNA damage repair 
[21-24]. If DNA damage cannot be repaired, cell death ensues via one of a number of 
possible mechanisms, including senescence, intrinsic apoptosis, mitotic catastrophy, 
autophagy, or necrosis [25-27]. 
2.1.3 Predictors of radiation therapy response 
Early attempts at identifying predictive markers for radiation sensitivity in patient 
tumors began with the law of Bergonié and Tribondeau, who in 1906 stated that “X-rays 
act on cells inasmuch efficiently as cells have a greater reproductive activity, their 
karyokinetic fate is longer, their morphology and function are at least definitively fixed” 
[28, 29]. In 1927, Kimbrough et al. found that while 76% of cervical cancers of embryonal 
origin were sensitive to radiation therapy, only 51% of those with mature-cell composition 
were radiosensitive [30]. Kistner et al. later identified correlations between radiation 
sensitivity in cervical cancer with histologic grade [31]. These early studies validated the 
connection between tumor radiation response and cellular/molecular characteristics. 
 Later studies identified correlations between tumor radiation response and patient 
clinical factors. Kagan et al. found that success of radiation therapy for brain metastasis 
was 80% in patients with initial Karnofsky performance score greater than 60, but only 
18% in patients with initial score of 50 or below [32]. Griffin et al. similarly found that 
initial Karnofsky score, as well as anatomical location and tumor staging, were 
independently prediction of radiation sensitivity in head and neck cancer [33]. Other 
 9 
studies confirmed in vitro experiments dating back to 1936, when Mottram et al. showed 
that cancer cells in anaerobic conditions were more radiation resistant than in aerobic 
conditions [34]. Decreased patient survival was correlated with lower pretreatment 
oxygenation status by Nordsmark et al. in head and neck cancer patients, and later by Fyles 
et al. in cervical cancer patients [35, 36]. 
As the molecular basis of radiation therapy response and DNA damage repair in 
cancer cells was being studied, mutations in key enzymes which affect radiation response 
were identified. Homozygous mutations in the ATM gene (causing ataxia telangiectasia) 
and the LIG4 gene (causing DNA ligase IV syndrome) result in significant radiation 
sensitization, leading to an a surviving fraction at 2 Gy (SF2) of about 1-3%; however, the 
incidence of these mutations are extremely rare [37, 38]. Heterozygous mutations in 
BRCA1, BRCA2, and TP53 have also been associated with radiation sensitivity, although 
to a much lesser extent [37]. On the other hand, KRAS mutations in lung cancer and 
NFE2L2/KEAP1 mutations in head and neck cancers have been associated with increased 
resistance to radiation therapy; KRAS mutations result in increased osteopontin production 
which promotes stem-ness and represses DNA DSB induction, while activating mutations 
in NFE2L2 cause increased protection against oxidative damage from ionizing radiation 
[39, 40]. 
 Currently, gene expression markers are most commonly studied for their diagnostic 
utility in predicting radiation response in tumors [8]. Choudhury et al. identified that pre-
treatment expression of the MRE11 gene, involved in DNA damage repair, was predictive 
of survival following radiation therapy in bladder cancer patients [41]. Torres-Roca later 
developed a radiosensitivity panel composed of 10 genes (ABL1, AR, CDK1, HDAC1, 
 10 
IRF1, JUN, PRRT2, RELA, STAT1, SUMO1) for prediction of progression-free survival 
in radiation-treatment patients compared to un-treated patients; this panel was validated in 
multiple cancer types, including breast cancer, NSCLC, and prostate cancer [42-45]. Most 
of these genes were previously implicated in the cell cycle, DNA damage response, 
immune system regulation, and tumorigenesis. Many other cancer-specific as well as pan-
cancer gene expression signatures for the prediction of radiation response have since been 
developed, ranging in number of genes from tens to thousands. The RadiationGeneSigDB 
recently curated both oxic and hypoxic gene expression signatures for radiation response, 
comparing predictive performance and identifying similarities in gene expression 
biomarkers [46]. 
 
2.2 Redox Metabolism 
2.2.1 Redox cofactors 
2.2.1.1 NAD+, NADH 
Nicotinamide adenine dinucleotide (NAD) is an omnipresent molecule which acts 
as both an electron-carrying cofactor for oxidation–reduction reactions, as well as a 
substrate for many metabolic and signaling processes [47]. NAD metabolism has been 
implicated in several important biological processes, including energy production, cell 
signaling, and redox homeostasis. Many pathways in the NAD metabolic network are 
disrupted in cancer, including the production of NAD intermediates and consumption of 
NAD by signaling processes necessary for tumor cell survival [48-50]. 
Nicotinic acid mononucleotide (NAMN), a precursor of NAD+, can be formed from 
either quinolinic acid (originating from tryptophan) in the de novo NAD+ synthesis 
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pathway, or from nicotinic acid in the Preiss-Handler pathway (Figure 2-2) [51, 52]. 
NAMN is then converted to nicotinate adenine dinucleotide by nicotinamide 
mononucleotide adenylyl transferase (NMNAT), and then converted into NAD+ by 
NAD+ synthase. By utilizing salvage pathways, NAD+ can also be produced using 
available precursors such as nicotinamide and nicotinamide riboside. The rate-limiting 
enzyme in these salvage pathways is nicotinamide phosphoribosyltransferase (NAMPT), 
which converts nicotinamide to nicotinamide mononucleotide [53]. 
 
Figure 2-2. Many processes in the NAD+ metabolic network are disrupted in cancer, 
including the production of NAD+ intermediates and consumption of NAD+ by 
signaling processes necessary for tumor cell survival. 
Glucose oxidation supplies a significant amount of energy for the transfer of 
electrons from NAD+ to NADH (Figure 2-3). Glycolysis via glyceraldehyde 3-phosphate 
dehydrogenase, oxidative decarboxylation of pyruvate via the pyruvate dehydrogenase 
complex, and the citric acid cycle via isocitrate dehydrogenase isoform 3 (IDH3), the α-
ketoglutarate dehydrogenase complex, and malate dehydrogenase produce a combined 10 
NADH per glucose molecule. In addition, beta oxidation of fatty acid molecules provides 
energy for NAD+ reduction via 3-hydroxyacyl-CoA dehydrogenase. Other enzymes that 
are involved in the reduction of NAD+ to NADH include glutamate dehydrogenase 
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(GLUD), malic enzyme (ME), and methylenetetrahydrofolate dehydrogenase 2-like 
protein (MTHFD2L). Whereas some enzymes are specific to the NAD+ cofactor (including 
ME2), others can nonspecifically reduce both NAD+ and NADP+ (including GLUD1/2) 
with varying catalytic efficiencies. Cytosolic and mitochondrial NADH can be exchanged 
via the malate-aspartate and glycerol-3-phosphate shuttles [51]. The oxidized form of 
NAD+ is maintained at much higher levels than reduced NADH (NAD+/NADH ∼ 3 to 
>100, depending on subcellular compartment as well as free vs. protein-bound states) [54, 
55]. 
 
Figure 2-3. Major inputs and outputs to/from the cellular pools of 
NAD+, NADH, NADP+, and NADPH, including pathways and therapies pertinent to 
the cellular response to radiation therapy. 
2.2.1.2 NADP+, NADPH 
NADPH is a ubiquitous metabolite implicated in over 900 reactions in human 
metabolism [7]. While NADH and NADPH are interchangeable as cofactors for a subset 
of these reactions, they mainly have distinct differences in function. The largely anabolic 
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couple [NADPH]/[NADP+] (∼100:1) is maintained out of equilibrium in cellular 
environments with [NADH]/[NAD+] (1:10–1:1000), which is primarily used in catabolic 
processes [54]. NADPH/NADP+ has a half-cell potential on the order of −400 mV and 
plays an essential role in limiting oxidative stress caused by reactive oxygen species (ROS); 
NADPH is a shared substrate for glutathione reductase and thioredoxin reductase, linking 
antioxidant defense and thiol-based signaling [56]. NADPH is also utilized as an electron 
donor in the synthesis of fatty acid, cholesterol, and nucleotide metabolites [57, 58]. 
 NADP+ is synthesized from NAD+ through NAD kinase (Figure 2-3) [59]. Multiple 
metabolic reactions are implicated in the reduction of NADP+ to NADPH (Figure 2-4). The 
pentose phosphate pathway contains two NADPH-producing reactions in series: G6PD, 
which is thought to carry the largest amount of NADPH-producing flux and is essential for 
cell survival, and PGD, which has also been implicated in tumor growth and redox 
metabolism [60, 61]. Differing isoforms of both malate enzyme and isocitrate 
dehydrogenase catalyze cytosolic (ME1, IDH1) and mitochondrial (ME2/3, IDH2) 
NADPH production utilizing substrates from the TCA cycle. Glutamine intake and 
conversion to glutamate allows for additional production of mitochondrial NADPH 
through glutamate dehydrogenase (GLUD1/2). Finally, multiple cytosolic (MTHFD1, 
ALDH1L1) and mitochondrial (MTHFD2, ALDH1L2) enzymes are involved in folate-
dependent NADPH production. Because NADPH is involved in such a large number of 
reactions and pathways throughout the cellular metabolic network, it has not been 




Figure 2-4. Major NADPH biogenesis pathways and reactions. Interconnection of 
well-studied biochemical reactions that convert oxidized NADP+ to reduced 
NADPH, labeled with their associated enzymes and grouped into biochemical 
pathways (colored boxes). 
2.2.1.3 GSSG, GSH 
Reduced glutathione (GSH) is a key antioxidant molecule, utilized by glutathione 
peroxidase (GPx) and glutaredoxin (Grx) systems for ROS scavenging. Oxidized 
glutathione (GSSG) is converted to GSH via glutathione reductase (GR) and NADPH. 
Normally the GSH/GSSG ratio exceeds 100:1, but decreases significantly with oxidative 
stress [62]. The glutathione half-cell reduction potential (Ehc) is often used as a 
 15 
measurement of oxidative stress, and can be calculated from intracellular GSH and GSSG 










where Ehco is the standard half-cell potential, R is the universal gas constant, T is the 
temperature, z is the number of electrons involved (2), and F is the Faraday constant [63]. 
Proliferating mammalian cells have glutathione Ehc values ranging from around -210 mV 
to -260 mV, whereas apoptotic cells are more oxidized with Ehc values around -170 mV 
[54]. 
De novo GSH synthesis is accomplished in a two-step processes utilizing enzymes 
glutamate-cysteine ligase (GCL) and GSH synthetase, consuming amino acids cysteine, 
glutamate, and glycine in the process [64]. Maintenance levels of intracellular cysteine are 
needed to prevent GSH efflux, extracellular degradation, and increased oxidative stress 
[65]. 
2.2.2 ROS-scavenging enzymes 
Numerous ROS-scavenging systems are employed in different subcellular 
organelles to regulate ROS levels and oxidative stress. Superoxide dismutases (SOD) are 
enzymes which utilize metal ions to convert superoxide (O2•-) to hydrogen peroxide 
(H2O2); different isoforms are present in the cytosol (Cu/ZnSOD SOD1), mitochondria 
(MnSOD SOD2), and extracellular space (Cu/ZnSOD SOD3) [66]. Catalase (CAT) is a 
major H2O2-scavening enzyme, especially in the peroxisome where catalase has increased 
localization and catalytic activity [67, 68]. Although catalase does not rely on NADPH or 
GSH as electron donors, it does require reduced NADPH to prevent oxidation of its active 
site by H2O2 [69]. Glutathione peroxidase (GPx) and glutaredoxin (Grx) both utilize GSH 
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to catalyze the reduction of free H2O2 and glutathionylated protein thiol groups caused by 
H2O2, respectively. Similarly, peroxiredoxin (Prx) and thioredoxin (Trx) both utilize the 
oxidized/reduced thioredoxin couple controlled by thioredoxin reductase (TR) and 
NADPH to reduce free H2O2 and oxidized protein thiol groups, respectively. Table 2-1 
shows the alternative isoforms of these H2O2-scavening enzymes used in the cytosol and 
mitochondrion; having these different isoforms allows for differential regulation in 
response to compartment-specific oxidative stress [70]. 
Table 2-1. Alternative isoforms of cytosolic and mitochondrial GPx, Grx, Prx, and 
TR. 
Enzyme Cytosolic Mitochondrial 
GPx GPX1, GPX2, GPX4 GPX1, GPX4 
Grx GLRX GLRX2 
Prx PRDX1, PRDX2 PRDX3 
TR TXNRD1 TXNRD2, TXNRD3 
 
 
2.2.3 Role of redox metabolism in tumor response to radiation therapy 
 Altered cellular function at any step in the recognition, response, or repair of DNA 
damage has been previously implicated in the sensitivity of cancer cells to ionizing 
radiation [37, 71, 72]. However, because the mechanism of action of radiation therapy 
involves ROS production and resultant DNA damage, redox biology and metabolism are 
believed to play an important role in tumor radiation sensitivity as well. Scavengers of ROS 
including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) 
has been previously shown to modulate intracellular ROS levels in cancer [73-75].  Positive 
correlation between GPx and radiation resistance was previously observed among human 
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cell lines; additionally, elevated expression of manganese superoxide dismutase (MnSOD) 
was observed in radiation-resistant mesothelioma cells [76]. MnSOD overexpression 
resulted in increased radiation resistance of stably transfected CHO cell lines [5]. 
Additionally, increased GPx and CAT activity was observed in radiation-resistant C3H/He 
Him mice compared to radiation-sensitive BALB/c/J Him mice. These findings suggest 
that ROS scavengers may be possible targets for improving radiation sensitivity. 
The activation of both PARP1 and sirtuins by ionizing radiation causes a significant 
depletion of cellular stores of NAD+ [77]. These stores can be replenished by increasing 
flux through the NAD+ salvage pathways. However, consumption of ATP by NMNAT, 
one of the critical enzymes in NAD+ salvage, causes significant depletion of ATP stores. 
In the presence of a low level of DNA damage, PARP activation may promote cell survival; 
on the other hand, the presence of widespread DNA damage causes PARP hyperactivation, 
severe NAD+/ATP depletion, and programmed necrosis [78]. Radiation-resistant tumors 
are capable of maintaining adequate NAD+ production while overcoming the damaging 
effects of radiation on DNA damage and ROS production [79]. Thus, it is expected that 
selectively targeting NAD+ metabolism will sensitize tumor cells to ionizing radiation. 
While NADPH metabolism is central to the ROS response and protection against 
oxidative stress, few enzymes involved in NADPH metabolism have been implicated in 
radiation response. IDH1 R132 mutations which cause oxidation of NADPH and 
production of the oncometabolite 2-hydroxyglutarate (2-HG) are common in low-grade 
gliomas and glioblastomas; these mutations have been associated with relatively favorable 
outcomes and improved sensitivity to radiation and chemotherapy, possibly due to NADPH 
depletion [80, 81]. G6PD overexpression was found to confer resistance to apoptosis 
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mediated by nitric oxide (NO), a reactive nitrogen species (RNS) which causes glutathione 
oxidation and NADPH consumption similar to ROS [82]. Additionally, inhibition of G6PD 
was found to sensitize cancer cells to treatment with cisplatin, a radiation-sensitizing 
chemotherapy [83]. Other studies have shown increased glutamine production in radiation-
resistant cancers and that inhibiting glutamine metabolism improves radiation response, 
possibly implicating glutamate dehydrogenase as an important regulator of radiation 
response [84, 85]. 
 
2.3 Radiation-Sensitizing Chemotherapies 
2.3.1 General principles 
The use of chemotherapy in conjunction with radiation treatment to enhance 
radiation sensitivity began in 1958, when Heidelberger et al. showed increased response in 
preclinical studies of solid tumors when combining radiation treatment with 5-fluorouracil 
[86]. In 1974, Nigro and colleagues led a pioneering study where three out of three patients 
with anal cancer who were treated with a combination of 5-fluorouracil, mitomycin D, and 
radiation therapy achieved complete responses [87]. Today, chemotherapy-radiation 
combination therapies are used for a number of cancer types, including bladder, cervical, 
esophageal, gastric, glioblastoma, head and neck, NSCLC, and rectal cancers [88-95]. 
The mechanism of action of many radiation-sensitizing chemotherapies involves 
the induction of DNA damage or inhibition of DNA damage repair [96]. Examples of 
DNA-targeting radiosensitizers include cisplatin, an alkylating agent which inhibits DNA 
synthesis by forming DNA cross-links, cyclophosphamide, another alkylating agent, and 
doxorubicin, an inhibitor of topoisomerase II and DNA intercalating agent [97-99]. Other 
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types of radiation-sensitizing therapies include those which inhibit pro-survival pathways 
(e.g. EGFR inhibitors), target tumor vasculature (e.g. VEGF inhibitors), or alter cell cycle 
checkpoints (e.g. AZD7762) [100-102]. 
Chemotherapies which modulate redox biology and metabolism are also garnering 
attention for their utility as radiosensitizers [103]. Rischin et al. found that combining 
cisplatin and radiation with tirapazamine, a compound which is metabolized and causes 
ROS formation in anaerobic conditions, resulting in borderline significant failure-free 
survival rates among patients with advanced head and neck cancer [104]. Shaw et al. found 
that combining radiation therapy with RSR13, a hemoglobin-binding inhibitor which 
enhances oxygen delivery to tissues and thereby increases radiation response, resulted in 
significant benefit for patients with brain metastases from breast cancer [105]. While novel 
redox-modulating radiosensitizers are showing promise, many conventionally-used 
chemotherapies have effects on redox metabolism which cause oxidative stress and may 
subsequently sensitize to radiation treatment; however, these alternative redox-based 
mechanisms of radiosensitization are less characterized than their commonly-attributed 
mechanisms of action involving DNA damage [6]. 
2.3.2 Redox metabolism of radiation-sensitizing chemotherapies 
2.3.2.1 Cisplatin 
Cisplatin’s primary redox-based mechanism of action is its binding to 
mitochondrial DNA (mtDNA), causing impaired synthesis of electron transport chain 
proteins, ETC malfunction, and subsequent increases in superoxide production (Figure 2-5) 
[106-108]. Cisplatin is imported into cells via the copper transporter CTR1 [109]. ATP-
catalyzed efflux of the drug can occur via the breast cancer resistance protein (BRCP) or 
 20 
copper efflux transporters ATP7A and ATP7B [110-112]. After import, cisplatin is 
transported to the mitochondria via the copper chaperone Cox17 [113]. Cytosolic cisplatin 
can be cleared by both glutathionylation as well as interaction with metallothioneins, a 
family of trace metal and free radical scavenging proteins [114, 115]. GSH consumption 
from cisplatin glutathionylation may also contribute to redox-based sensitization of cancer 
cells to ROS-generating ionizing radiation. 
 
Figure 2-5. Overview of cisplatin metabolism, including import/export reactions, 
mechanism of action, and drug clearance. 
2.3.2.2 Cyclophosphamide 
While the primary mechanism of cyclophosphamide involves production of 
phosphoramide mustard and subsequent DNA cross-linking, cyclophosphamide 
metabolism involves the utilization of multiple redox cofactors, including NADH, 
NADPH, and GSH; the consumption of these cofactors may contribute to 
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cyclophosphamide’s radiation-sensitizing effects (Figure 2-6) [116-118]. Following 
import, cyclophosphamide efflux can occur via multidrug resistance protein 1 (MDR1) or 
breast cancer resistance protein (BRCP) [119, 120]. Cyclophosphamide can be metabolized 
into 4-hydroxycyclophosphamide (4OH-CPA) or into dechloroethylcyclophosphamide 
(DCE-CPA) and chloroacetaldehyde (CAA) by NADPH-catalyzed cytochrome P450 
activity. 4OH-CPA and related metabolite aldophosphamide (ALDPh) are metabolized 
using  NAD+ cofactors by alcohol dehydrogenase and aldehyde dehydrogenase, 
respectively [121]. NADPH is also used in ALDPh metabolism by aldo-keto reductase. 
Finally, end products phosphoramide mustard and acrolein are glutathionylated and 
exported [122].  
 
 
Figure 2-6. Overview of cyclophosphamide metabolism, including import/export 




Doxorubicin undergoes a one-electron redox cycling mechanism between quinone 
and semiquinone forms, resulting in both superoxide production and NADPH consumption 
which may contribute to radiation sensitization (Figure 2-7) [123-125]. Import of 
doxorubicin occurs via the organic cation transporter SLC22A16 [126]. Doxorubicin efflux 
can occur by either RLIP76 or ATP-dependent ABC-family transporters [127]. The 
quinone form of doxorubicin can be converted to its semiquinone form through either nitric 
oxidase synthase 3 (NOS3, eNOS) or cytochrome P450 oxidoreductase (POR) [128-130]. 
These reactions differ in the stoichiometry of NADPH consumption as well as the 
production of the RNS nitric oxide (NO); the relative importance of these two reactions to 
doxorubicin metabolism and radiation sensitization has not been determined. Following 
reduction, the semiquinone form spontaneously converts back to the quinone form, 
producing superoxide in the process. Doxorubicin quinone is cleared by carbonyl 
reductase, aldo-keto reductase, and cytochrome P450 reductase, all of which consume 




Figure 2-7. Overview of doxorubicin metabolism, including import/export reactions, 
mechanism of action, and drug clearance. 
2.4 Flux Balance Analysis 
Flux Balance Analysis (FBA) is a constraint-based computational modeling 
approach for predicting steady-state metabolic fluxes at a genome-scale [9]. Reaction 
fluxes are predicted by combining (1) a genome-scale metabolic network reconstruction 
for the organism of interest, including metabolites, reactions, and the genes associated with 
metabolic enzymes; (2) constraints imposed on minimum and maximum reaction fluxes, 
which are often implemented using biological information on the sample of interest; and 
(3) an objective function, which is a reaction flux or function of multiple fluxes to be 




2.4.1 Mathematical representation 
2.4.1.1 Flux Balance Analysis (FBA) 
A metabolic network can be represented by a stoichiometric matrix S of size m x r, 
where m and r are the number of metabolites and reactions in the network, respectively. 
Entry Sij is equal to the stoichiometric coefficient of metabolite i in reaction j (Sij < 0 for 
reactants, > 0 for products, and = 0 if metabolite i is not involved in reaction j). The 







where v is a r x 1 vector of reaction fluxes, and m is a m x 1 vector of metabolite 
concentrations. In flux balance analysis, the steady state is assumed (metabolite 
concentrations do not change with time), changing Equation 4 to: 
 𝑆v = 𝟎 (5) 
Each reaction flux vj is also constrained by lower and upper bounds: 
 𝑣𝑚𝑖𝑛,𝑗 ≤ 𝑣𝑗 ≤ 𝑣𝑚𝑎𝑥,𝑗 (6) 
The solutions to Equations 5 and 6 that maximize a particular objective function f(v) are 
chosen. Thus, the FBA problem can be represented as a Linear Programming (LP) problem: 
 max 𝑓(v)
subject to 𝑆v = 𝟎
and 𝑣𝑚𝑖𝑛,𝑗 ≤ 𝑣𝑗 ≤ 𝑣𝑚𝑎𝑥,𝑗
 (7) 
Solving this LP problem provides us with the maximized value fmax of the objective 
function. LP problems can be solved computationally using commercially-available 
optimization software including Gurobi. 
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2.4.1.2 Parsimonious Flux Balance Analysis (pFBA) 
Despite maximizing an objective function, Equation 7 can still result in more than 
one possible solution for the flux vector v which satisfies network stoichiometry and model 
constraints. One approach to obtain a single representative flux vector v is parsimonious 






 s.t. 𝑓(v) = 𝑓𝑚𝑎𝑥 (8) 
where r is the number of reactions in the metabolic network [132]. The biological reasoning 
behind pFBA is that metabolic networks are optimized to maximize their objective while 
utilizing the minimum amount of metabolic resources (including substrates and metabolic 
enzymes) necessary. While having a single representative flux vector facilitates 
downstream analysis of model outputs, this single vector may not be representative of the 
entire solution space characterized by Equation 7. 
2.4.1.3 Flux Variance Analysis (FVA) 
Flux variance analysis (FVA) allows for the calculation of the minimum and 
maximum allowable fluxes through each metabolic reaction vj that still maintain the 
maximum possible objective value as calculated in Equation 7: 
 min/max 𝑣𝑗 s.t. 𝑓(v) = 𝑓𝑚𝑎𝑥 (9) 
This provides an overview of the range of possible flux values that each reaction can obtain, 
which is more representative of the entire solution space than the single flux vector 
obtained from pFBA. While the entire distribution of values for each reaction flux vj is not 
obtained, the average flux through each reaction can be estimated by taking the mean of 
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the minimum and maximum values from Equation 9. To perform FVA, two LP problems 
must be solved per metabolic reactions; for networks with tens-of-thousands of reactions, 
performing FVA across the entire metabolic network takes significantly more 
computational time than FBA. 
2.4.1.4 Random Sampling 
An optimal representation of the possible solution space from Equation 7 is 
obtained from random sampling, where a user-specified number of points are samples 
within the solution space to obtain a distribution of flux values for each metabolic reaction. 
Software such as optGpSampler has been developed for uniform sampling of the solution 
space for constraint-based metabolic models [133]. However, the computation time of 
random sampling increases exponentially with the size of the metabolic network; for 
current metabolic reconstructions with tens-of-thousands of reactions, performing random 
sampling for hundreds of samples and thousands of perturbations per sample (for example, 
with simulated gene knockout screens) is computationally infeasible. 
2.4.2 Genome-scale metabolic reconstructions 
Genome-scale metabolic reconstructions are comprehensive representations of all 
known metabolic reactions, metabolites, and enzyme-encoding genes within the entire 
metabolic network of a particular organism [134, 135]. These reconstructions are 
developed through iterative processes involving the identification of candidate metabolic 
features, refinement based on available biochemical information, conversion into a format 
which can be used in computational models, and evaluation of resulting metabolic 
predictions to ensure accuracy and compatibility with other metabolic features [136]. The 
latest human metabolic reconstruction, Recon3D, incorporates 8,401 metabolites, 13,547 
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reactions, and 3,268 genes [7]. Metabolites and reactions are represented mathematically 
in the stoichiometric matrix, as explained above. Genes are represented in gene-protein-
reaction rules (GPR) which, for each reaction, shows which genes encode the metabolic 
enzymes which catalyze the associated metabolic reaction. Gene names are given as either 
the NCBI gene symbol or gene ID number. GPR’s are written as Boolean functions. For 
example, if the enzymes encoded by either Gene1 or Gene2 can catalyze the reaction on 
their own, the GPR would be “Gene1 OR Gene2”. If both enzymes are needed to catalyze 
the reaction, the GPR would instead be “Gene1 AND Gene2”. When incorporating 
expression data into FBA models, “OR” statements are handled by adding the expression 
values from both genes, and “AND” statements are handled by taking the minimum 
expression value among both genes. Finally, each reaction has an associated enzyme 
commission (EC) number, which provides information about the catalytic activity of the 
particular enzyme [137]. 
2.4.3 FBA objective functions 
An objective function is maximized in Equation 7 to obtain a single (or significantly 
smaller subset) of feasible flux vectors which satisfy network stoichiometry and reaction 
constraints. This objective function is often used to represent a biological “objective” that 
the organism/cell/sample under study is attempting to maximize physiologically [138]. To 
this end, the most commonly used objective function has been maximizing the production 
of biomass, which represents all of the carbohydrate, protein, lipid, nucleotide, and other 
metabolites which a cell or organism needs to survive and grow [139]. The use of the 
biomass objective function as a proxy for optimizing cellular growth has been applied for 
FBA models of both microorganisms as well as cancer cells which demonstrate sustained 
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proliferation; however, its use for most normal human tissues which show minimal 
proliferation is likely unwarranted [140, 141]. Other physiological objective functions 
which have been used previously include the production of metabolic cofactors, including 
ATP, NADH, and NADPH, which are used ubiquitously throughout the metabolic network 
for anabolic and redox reactions [142-144]. 
 Alternative approaches for objective functions have included the incorporation of 
experimental data from the sample of interest into the objective function itself. Lee et al. 
used an objective function which maximized the correlation between experimentally-
measured gene expression data from Saccharomyces cerevisiae and predicted FBA fluxes 
to improve the accuracy of metabolic flux predictions [145]. Montezano et al. developed 
an objective function as the linear combination of reaction fluxes with weights proportional 
to measured proteomics data from Mycobacterium tuberculosis exposed to the antibiotic 
mefloquine [146]. It is yet unclear whether the incorporation of experimentally-measured 
gene/protein expression data as constraints on metabolic fluxes, as modifiers of the 
objective function, or some combination of the two, results in the most accurate metabolic 
predictions. 
2.4.4 Implementation of model constraints using biological data 
FBA models that are personalized to individual cell types or samples of interest are 
most commonly developed by incorporating genome-scale experimental data into the 
minimum and maximum flux constraints for each reaction (Equation 6). Transcriptomic 
data, either from microarrays or RNA-seq, is most often used due to its much wider 
availability for samples of interest compared to genome-scale proteomic or metabolomic 
data [11]. Numerous algorithms for the implementation of transcriptomic data into reaction 
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constraints have been developed, all with associated advantages and disadvantages 
compared to other methods. One of earliest and simplest methods was developed by 
Akesson et al., who set reaction fluxes to zero if the associated gene expression was not 
detected from the utilized microarray platform [147]. Similarly, the GIMME algorithm 
developed by Becker et al. implemented a user-defined gene expression threshold to 
determine whether individual metabolic reactions were to be set as active (reaction allowed 
to carry flux) or inactive (flux set to zero) [148]. iMAT, developed by Shlomi et al., utilizes 
a slightly different approach by discretizing gene expression into high, medium, and low 
expression; reaction fluxes associated with high gene expression are maximized, whereas 
fluxes associated with low gene expression are minimized [149]. All of the aforementioned 
algorithms rely on arbitrary threshold of gene expression data which, although simple to 
understand and implement, does not accurately reflect biological regulation of metabolic 
reactions. 
E-Flux, developed by Colijn et al., constraints the upper flux bound of each reaction 
relative to the expression of the associated gene instead of implementing binary on/off 
states; however, a threshold is still utilized to determine whether loose or tight constraints 
are used for reactions with gene expression higher or lower than the threshold, respectively 
[150]. PROM, developed by Chandrasekaran et al., constrains reaction flux bounds by 
calculating the likelihood that the gene is active relative to the expression of the gene’s 
transcription factor, and sets upper flux bounds in proportion to this calculated probability 
[151]. To avoid setting arbitrary thresholds, MADE, developed by Jensen et al., compares 
multiple gene expression datasets and assesses statistically significant differences to set 
on/off states of reactions for different conditions [152]. These newer methods provide more 
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sophisticated approaches towards integrating gene expression data into reaction upper 
bounds; however, they still rely on either thresholding of expression values or comparison 
to other datasets to set model constraints. 
 Other biological data types other than gene expression have been explored for 
utilization to set metabolic reaction constraints. INIT, developed by Agren et al., uses 
qualitative confidence scores derived from proteomic data from the Human Protein Atlas 
to maximize flux through high-expression reactions and minimize flux through reactions 
with absent expression [153]. Approaches such as those from Hoppe et al. and Yizhak et 
al. implement metabolomic data from E. coli to apply additional constraints on plausible 
metabolic concentration ranges or kinetically-derived flux estimates [154, 155]. Finally, 
dynamic flux balance analysis (dFBA), developed by Mahadevan et al., utilizes time-
resolved biochemical parameters to predict changes in metabolic fluxes and concentrations 
over time [156]. Because of the constraint-based nature of FBA models, additional 
constraints based on multiple biological data types will further constrain flux solution 
spaces and will ultimately yield more accurate predictions of metabolic phenotypes in 
samples of interest. 
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CHAPTER 3. FBA MODELS OF NAD(P)H-DRIVEN ß-
LAPACHONE SENSITIZATION 
3.1 Introduction 
A feature of NAD(P)H utilization is the phenomenon of redox cycling, in which two 
coupled reduction and oxidation reactions can perpetuate a sustained directional cyclic flux 
of a quinone substrate between quinone and semiquinone (reduced) forms due to an ample 
source of electrons. Noted as early as 1968 in Escherichia coli metabolism of streptonigrin 
[157], NADPH-dependent redox cycling has been attributed to acetaminophen 
hepatotoxicity and cardiac lethality of anthracyclines via cytochrome P450 reductase 
[158]. Systems biology modeling of this latter mechanism identified the role of NADPH 
availability in modulating the doxorubicin concentration-dependent switch in ROS 
formation [125]. Model-predicted control via glucose-6-phosphate dehydrogenase (G6PD) 
was experimentally tested through inhibition of the enzyme and confirmed to alter cell line-
specific changes in drug sensitivity. 
A distinct but related mechanism of drug redox cycling is observed through 
NAD(P)H: quinine oxidoreductase 1 (NQO1) bioactivatable compounds. Drugs such as β-
lapachone and deoxynyboquinone rely upon two-electron transfer via NQO1 to catalyze 
interconversion between quinone, hydroquinone, and semiquinone forms, expending one 
NAD(P)H molecule per quinone oxidation to generate two molecules of superoxide [159]; 
they are the only known quinones to cycle through this mechanism. Tumor cells, which  
 
* As published in (1) Lewis et al., Antioxid Redox Signal, 2018; (2) Lewis et al., Semin Radiat Oncol, 2019 
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typically express higher ratios of NQO1 to catalase (CAT) than nonmalignant tissue, are 
known to redox cycle in a futile manner to generate 120 moles of superoxide in 2 min for 
every mole of β-lapachone [160]. Cellular superoxide dismutase (SOD) enzymes convert 
superoxide to the relatively more stable hydrogen peroxide (H2O2). Elevated 
H2O2 (>300 μM) leads to extensive base damage, single-strand DNA lesions, and 
eventually double-strand lesions of DNA. Furthermore, the high rate of NAD(P)H 
consumption contributes to depletion of the nicotinamide pool by subsequent poly(ADP-
ribose)polymerase-1 (PARP1) hyperactivation, with cell death proceeding through 
caspase-independent programmed necrosis [161-163]. 
NADPH is also oxidized to NADP+ by ribonucleotide reductase to maintain dNTP 
pools for DNA repair and cell survival following ionizing radiation [164]. A synergistic 
effect is reported when combining sublethal doses of β-lapachone with radiation therapy 
in NQO1+ human prostate and head and neck cancers [165-167], as well as in non-small 
cell lung cancers. Increased consumption of NAD+ and ATP, enhanced DNA double-strand 
breaks, and prolongation of γ-H2AX were attributed, in the combined therapy, to result in 
head and neck squamous cell carcinoma (HNSCC) tumor regression. The competition for 
NADPH as a substrate for futile redox cycling, reduction of antioxidant defense systems 
(thioredoxin and glutaredoxin), PARP activity, and as a cofactor for dNTP synthesis upon 
radiation and chemotherapeutic insult in high NQO1/CAT tumor cells results in selective 
cytotoxicity. 
Recent bioinformatic analyses have indicated that genetic or pharmacological 
suppression of intracellular [NADPH] through the NAMPT or glutamine biosynthesis 
pathway can confer enhanced sensitivity to β-lapachone by reduced antioxidant defenses 
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and increased ROS, thereby lowering the in vivo dose needed for selective tumor 
cytotoxicity [168-170]. This result suggests that strategically targeting NADPH-
biosynthesis pathways concomitant with NQO1-bioactivated futile redox cycling for 
therapeutic design may be advantageous. Flux balance analysis (FBA) is an optimal tool 
to systematically analyze the genes which contribute to whole-cell NAD(P)H supply and 
demand across the entire metabolome, and how this may impact the response to redox-
cycling therapies. To evaluate the role of global NAD(P)H production on ß-lapachone 
sensitization, as well as to improve upon existing FBA models, we have developed a human 
genome-scale metabolic model that incorporates quantitative transcriptomic, kinetic, 
thermodynamic, and metabolite concentration constraints. These constraints have the 
potential to greatly improve the accuracy and cell-type specificity of predicted flux 
distributions associated with redox metabolism. The goal of our model development was 
to compare intrinsic metabolic changes in matched head and neck cancer cell lines that 
may yield phenotypic differences in sensitivity to NAD(P)H: quinone oxidoreductase 1 
(NQO1)-dependent drugs such as the chemotherapeutic compound β-lapachone that relies 
on redox cycling, ROS production, and nicotinamide depletion for its cytotoxic effects. 
 
3.2 Methods 
3.2.1 Computational methods 
3.2.1.1 Redox-based changes to Recon 2 network 
Recon 2.04 was used as the core metabolic network to build our SCC-61 and rSCC-61 
models [134, 135]. To address missing and inaccurate redox-based reaction information 
within the Recon 2 metabolic network, we have made the following changes (for the 
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reactions below, c = cytoplasm, e = extracellular, n = nucleus, and r = endoplasmic 
reticulum): 
1. We split reaction FTHFDH (NADPH-producing reaction originally catalyzed by 
ALDH1L1 and ALDH1L2) into two separate cytosolic and mitochondrial 
reactions. The cytosolic reaction is catalyzed by ALDH1L1, and the mitochondrial 
reaction is catalyzed by ALDH1L2. 
Originally: 
a. 10-CHO-THF[c]  THF[c], GPR = ALDH1L1 or ALDH1L2, EC = 
1.5.1.6 
 Updated: 
a. 10-CHO-THF[c]  THF[c], GPR = ALDH1L1, EC = 1.5.1.6 
b. 10-CHO-THF[m]  THF[m], GPR = ALDH1L2, EC = 1.5.1.6 
2. We removed gene MTHFR from reaction MTHFD (NADPH-producing reaction 
originally catalyzed by MTHFR and MTHFD1). MTHFR catalyzes the reaction 
converting 5,10-CH2-THF to 5-MTHF, which is already included in the Recon 2 
network. 
Originally: 
a. 5,10-CH2-THF[c]  5,10-CH=THF[c], GPR = MTHFR or MTHFD1, EC 
= 1.5.1.5 
 Updated: 
a. 5,10-CH2-THF[c]  5,10-CH=THF[c], GPR = MTHFD1, EC = 1.5.1.5 




a. NADPH[c] + 2 O2[c]  2 O2•[e] + NADP+[c] + H+[c], GPR = NOX1 or 
CYBB or NOX3 or NOX5, EC = 1.6.3.1 
b. NADPH[n] + 2 O2[n]  2 O2•[c] + NADP+[n] + H+[n], GPR = NOX4, EC 
= 1.6.3.1 
c. NADPH[r] + 2 O2[r]  2 O2•[c] + NADP+[r] + H+[r], GPR = NOX4, EC 
= 1.6.3.1 
Note: The superoxide dismutase-catalyzed reaction is already in Recon 2, 
allowing for the production of hydrogen peroxide from superoxide. 
3.2.1.2 Objective function 
Because FBA models produce a steady-state solution, there cannot be net 
consumption or production of any metabolites in the model. However, adding an artificial 
demand reaction allows for net metabolite consumption or production through existing 
model reactions. In order to maximize the flux through existing Recon 2 reactions that 
convert NADP+ into NADPH within the cytoplasm and mitochondria, a new reaction is 
added with the following stoichiometry: 
 NADPH[c] + NADPH[m] → NADP+[c] + NADP+[m] + H+[c] + H+[m] (10) 
where c = cytoplasm and m = mitochondria. Maximizing this reaction as the objective 
function in turn maximizes the net conversion of NADP+ + H+ into NADPH through all 
other existing model reactions. This allows for the calculation of net NADP+ → NADPH 
flux (equal to the flux through the maximized objective function), as well as the flux 
through all Recon 2 reactions that convert NADP+ into NADPH. 
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 Similarly, the following objective function is used for analyzing the net conversion 
of NAD+ to NADH within the cytoplasm and mitochondria: 
 NADH[c] + NADH[m] → NAD+[c] + NAD+[m] + H+[c] + H+[m] (11) 
However, the sole maximization of NADP+ → NADPH flux (or NAD+ → NADH 
flux) may result in biologically non-viable solutions since it does not take into 
consideration the production of energy sources such as ATP that are necessary for cell 
survival. To ensure that biologically viable outcomes are obtained, we first maximize 
cellular ATP production through the following objective function: 
 ATP[c] + ATP[m] + H2O[c] + H2O[m]
→ ADP[c] + ADP[m] + Pi[c] + Pi[m] + H
+[c] + H+[m] 
(12) 
where c = cytoplasm and m = mitochondria. After calculating the maximum cellular ATP 
production, we set the lower bound of this reaction to 50% of the maximum value. This 
creates an ATP demand where only solutions that result in at least 50% of maximal ATP 
production are considered. While imposing this ATP demand, we then maximize cellular 
conversion of NADP+ to NADPH (NAD+ to NADH) or through the objective function 
given above. 
3.2.1.3 Thermodynamic constraints 
In order to include thermodynamic constraints within the FBA model, all reversible 
reactions (reactions that can carry a net flux in either the forward or reverse direction) 
within the model had to be broken down into two separate reactions - one which only runs 
in the original forward direction, and one which only runs in the original reverse direction. 
All reactions within the model now only have a forward direction. This allows us to set all 
vmin,j values to zero. 
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Two additional sets of equations were added to include thermodynamic constraints 
within the FBA model. The first is of the form: 
 𝑣𝑗 ≤ 𝑏𝑗𝑣𝑚𝑎𝑥,𝑗 (13) 
where bj is a Boolean variable representing the thermodynamic status of reaction j. If 
reaction j is thermodynamically feasible, then bj = 1, and vj ≤ vmax,j (Equation 13 with vmin,j 
= 0). If reaction j cannot carry a net flux due to thermodynamic constraints, then bj = 0, and 
vj ≤ 0 (since vmin,j = 0, this means that vj must equal zero). 
 To determine the value of bj, another set of equations is included of the form: 
 𝐾𝑏𝑗 ≤ 𝐾 − ∆𝐺𝑗 (14) 
where ΔGj is the change in Gibbs free energy of reaction j, and K is an arbitrarily large 
constant that must be set greater than the largest |ΔGj| value in the model. A chemical 
reaction j can carry a net flux if ΔGj < 0. If ΔGj < 0, then K - ΔGj > K, and Equation 14 will 
hold whether bj = 0 or bj = 1. Any thermodynamically-feasible reaction that may contribute 
to the maximization of our objective function will choose to have bj = 1 if possible, in order 
to carry a nonzero flux. However, if ΔGj > 0, K - ΔGj < K, and Equation 14 will only hold 
if bj = 0. Therefore, this reaction cannot carry a nonzero flux. 
The ΔGj of non-transport reactions can be calculated as: 
 
∆𝐺𝑗 = ∆𝐺𝑗




where ΔGjO is the standard change in Gibbs free energy of the reaction, R is the gas 
constant, T is the temperature, Sij is the stoichiometric coefficient of metabolite i in reaction 
j, and xi is the concentration of metabolite i. For reactions involving transport of metabolites 











where ci is the charge of metabolite i, Strans,ij is the transport stoichiometric coefficient of 
metabolite i in reaction j (representing how many molecules of the metabolite is being 
transported between compartments), F is the Faraday constant, and V is the potential of the 
membrane separating the transport metabolites. Vm is estimated using the Goldman-










𝑃Na+[Na+]in + 𝑃K+[K+]in + 𝑃Cl−[Cl−]out
) (17) 
where PNa+, PK+, and PCl- are the relative permeabilities of Na+, K+, and Cl- across the 
membrane (assigned to 1, 5, and 80, respectively). 
Estimated ΔGjO values for many reactions in the Recon 2 model were available from 
the Virtual Metabolic Human database [135]. For any reaction where ΔGjO was not 
available, the value ΔGjO = -999999 was used so that reactions with no available 
thermodynamic data were not made thermodynamically infeasible. 
Gurobi 6.5 optimization software was used to solve the Mixed-Integer Linear 
Programming problem represented by Equations 7, 13, and 14. 
3.2.1.4 Proteomic and kinetic constraints 
For reactions in the Recon 2 model with an associated enzyme commission [134] 
number and gene-reaction rule, the upper bound on the reaction flux was set to be: 
 𝑣max,𝑗 = 𝑘cat,𝑗[E]𝑗 (18) 
where kcat is the turnover number (1/hr) and [E]j is the total abundance (mmol/gDW) of the 
enzyme catalyzing reaction j. This is equivalent to the formula for vmax in Michaelis-
Menten kinetics. Reactions that are missing either an EC number or gene-reaction rule 
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(either because the reaction is not enzyme-catalyzed or due to missing information) were 
unconstrained in an upper bound by assigning an artificially high vmax,j = 999999. 
3.2.1.5 Proteomic and transcriptomic data 
To estimate protein expression values for SCC-61 and rSCC-61 cell lines, gene expression 
data for these cells [171] was compared to gene expression data for CAL-27 cells measured 
using the same gene expression microarray [172]. Data from three samples each of SCC-
61, rSCC-61, and CAL-27 were log2 transformed and normalized using z-score 
normalization. ComBat was then used to remove batch effects between the SCC-61/rSCC-
61 data and CAL-27 data [173]. For each Illumina probe, the mean expression value for 
each cell line was calculated. The fold change comparing SCC-61 to CAL-27, as well as 
comparing rSCC-61 to CAL-27, was calculated for each probe. The fold changes for all 
Illumina probes for a particular gene were averaged. Protein expression values in ppm units 
were calculated for SCC-61 and rSCC-61 by multiplying CAL-27 expression values from 
the ProteomicsDB database by the SCC-61/CAL-27 and rSCC-61/CAL-27 fold changes, 
respectively [174]. The rSCC-61 and SCC-61 protein concentration values estimated in 
this manner were then compared with stable isotope labeling of amino acids in cell culture 
(SILAC) proteomic data acquired by mass spectrometry [175]. The experimentally 
obtained values provide independent confirmation of the relative rSCC-61/SCC-61 values 
on 8.7% coverage of the proteome needed for the FBA models. 
 Missing protein expression values were imputed by performing k-nearest neighbors 
between data from all available tissues and cell lines from the GeneCards database, as well 
as CAL-27, SCC-61, and rSCC-61 cell lines [176]. A custom k-nearest neighbors script 
was written to assign greater weight to neighboring genes that have more available data 
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that can be compared between samples. The distance metric dij between genes i and j is 





𝛼  (19) 
where dEuclidean,ij is the Euclidean distance between two genes (only for tissues where both 
genes have values available), nij is the number of tissues where both genes have values 
available, and α is a constant with value ≥ 1. The larger the value of α, the greater weight 
that is given to neighboring genes that have more available data comparable between 
tissues (weightij ~ 1/dij). The k-nearest neighbors script also employs a parameter 
“minsamples”, which is the minimum number of tissues nij that gene neighbors must both 
have in order to be valid neighbors. Multiple rounds of k-nearest neighbors is run until no 
more missing values are imputed. Afterwards, values that are still missing are imputed by 
the mean value of all genes for a particular tissue. Parameter values used in this paper are: 
k = 100, minsamples = 3, α = 1.5. 









where Na is Avogadro’s number, naa is the average number of amino acids per protein, maa 
is the average molecular mass of an amino acid, gDa is the number of grams per Dalton, 
and pdw is the fraction of the cell’s dry weight that is protein. Parameter values used in this 
paper are naa = 300, maa = 100, and fdw = 0.5. 
 Proteomics data for every gene was used to calculate enzyme concentration values 
[E]j using each reaction’s gene-reaction rule, which is an and/or statement stating which 
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genes must be expressed in order for the enzyme catalyzing the particular reaction to be 
produced. For every tissue and cell type analyzed, gene names were replaced with their 
respective proteomics value (units of mmol/gDW), “X or Y” statements were replaced with 
X+Y, and “X and Y” statements were replaced with min(X,Y). 
3.2.1.6 Kinetic data 
Turnover number data for enzymes within the Recon 2 model were obtained from 
the BRENDA database API [137]. Figure 3-1 provides an outline of the steps used to get 
turnover numbers for all reactions with EC numbers available, starting from most accurate 
to least accurate. When multiple kcat values were available for the correct enzyme and 
substrate, the mean of these values was used. In order to ensure the physiological accuracy 
of kinetic parameters used in the model, only BRENDA kcat values measured at a pH 





Figure 3-1. Pipeline for determining turnover number (kcat) values for every Recon 2 
reaction with an available enzyme commission (EC) number. The number and 
percentage of needed kcat values filled at every step is given. All data is extracted 
from the BRENDA database (25). Subsystem refers to the metabolic subsystem 
assigned to every reaction within the Recon 2 model. 
3.2.1.7 Metabolite concentration data 
Table 3-1 provides the fixed metabolite concentrations used in the model. 
Metabolite concentration ranges from Park et al. [177] were incorporated, giving 
preference to values available in mammalian iBMK cells over yeast cells, and yeast cells 
over E. coli cells (Table 3-2). Human metabolite concentration ranges from The Human 
Metabolome Database (HMDB) for α-ketoglutarate and pyruvate were used instead of 
mammalian iBMK cell values, in order to make the IDH1 and ME1 Recon 2 reactions 
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thermodynamically feasible [178]. Table 3-3 shows the extracellular metabolite 
concentrations used to model Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 
(DMEM/F-12) media (ThermoFisher Scientific; 11320033).  Table 3-4  shows the 
experimentally measured cell-type-specific metabolite values and ranges used in SCC-61 
and rSCC-61 models [179]. All other metabolite concentrations in the model were allowed 
to range from e−15 to e−2 M. 
 























Table 3-4. Experimentally-measured metabolite concentration values and ranges in 
SCC-61 and rSCC-61 cells. 
 
3.2.1.8 Random sampling 
Reaction flux distributions for SCC-61 and rSCC-61 cell types were obtained by 
performing random sampling of the solution space for Equation 7 with all 
thermodynamically-infeasible reactions removed from the model. optReduceModel and 
optGpSampler were used to perform random sampling, and only solutions that achieved at 
least 95% of the maximum objective function value were kept [133]. 
3.2.1.9 Modeling gene knockdown 
siRNA gene knockdown was modeled by decreasing the protein expression of 
individual genes by 75% (predicted percent knockdown using N-TER Nanoparticle siRNA 
Transfection System provided by the manufacturer is ≥ 70%). These decreased protein 
expression values were used to calculate enzyme concentration values [E]j using each 





3.2.2 Experimental methods 
3.2.2.1 siRNA screen 
SCC-61 and rSCC-61 cells were maintained in DMEM/F12 medium that was 
supplemented with 10% fetal bovine serum (Sigma-Aldrich, F4135) at 37C and 5% CO2. 
For RNAi experiments, cells were plated on 96-well plates at seeding densities of 4 x 103 
cells per well. White opaque-bottom 96-well plates were used for the cell viability and 
NADPH luminescent assays. 24 hours after plating, cells were transfected using the N-
TER Nanoparticle siRNA Transfection System (Sigma-Aldrich, N2913) and the MISSION 
siRNA Oxidoreductase Gene Panel (Sigma-Aldrich, SI12100).  Drosophila sequences 
were used for transfection controls as provided by the manufacturer. Three siRNA 
sequences for each of 338 gene targets in the library were pooled, and wells were each 
treated with a final siRNA concentration of 40nM. All transfections and controls were 
performed in triplicate. Serum-containing transfection medium was used. 
3.2.2.2 Cell viability assay 
4 hours after transfection, β-lapachone diluted in serum-containing media was added 
to each well at a final concentration of 3μM (ID50 of rSCC-61 cells). After 24 hours of β-
lapachone exposure, the CellTiter-Glo Luminescent Cell Viability Assay was performed 
(Promega, G7572) according to manufacturer. Luminescence readings were performed 
using a Bio-Tek Synergy 4 multimode reader. 
3.2.2.3 NADPH assay 
Plates with transfected cells were split into control and treatment plates. 24 hours 
after transfection, β-lapachone diluted in serum-containing media was added to the 
treatment plates at a final concentration of 3 μM. An equal volume of media was added to 
 50 
the control plates. After 2 hours of β-lapachone exposure, the NADP/NADPH-Glo Assay 
(Promega, G9081) was performed on both control and treatment plates according to 




3.3.1 Construction of genome-scale metabolic models for HNSCC cell lines 
The cell lines under investigation are a parental line (SCC-61) and a radiation-
resistant line selected after successive survival after ionizing radiation (rSCC-61); these 
cell lines have been extensively characterized for metabolic, transcriptomic, proteomic, 
and epigenetic changes [171, 175, 179]. We hypothesized that β-lapachone sensitivity of 
gene silencing in SCC-61 and rSCC-61 cells could be predicted by FBA models of 
NAD(P)H production. To test this hypothesis, a key component of our model framework 
is the use of a novel objective function that optimized the yield of NAD(P)+ → NAD(P)H 
conversion while maintaining sufficient ATP production to obtain biologically viable 
results; this is a departure from prior FBA models of cancers that solely optimize biomass 
or ATP production. 
Our model comprises three main components (Figure 3-2). The first component is 
the core metabolic network, which is based on the Recon 2 genome-scale human metabolic 
network with 5063 metabolites and 7440 reactions [135]. The core network represents the 
collection of all known human metabolites and associated reactions and is the starting point 
to create cell-type-specific models. We have made additional changes to the Recon 2 
metabolic network to address missing or inaccurate redox-based reaction information. The 
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second component of the model is the incorporation of an upper bound vmax to every 
reaction flux within the network. This upper bound was set as the product of the turnover 
number kcat (units of s−1) and abundance [E] (units of mmol/gDW) of the enzyme that 
catalyzes each particular reaction; this product is equivalent to the Michaelis–Menten 
constant Vmax. If a reaction within the model is not enzyme-catalyzed, an arbitrarily large 
upper bound is given. Turnover numbers for every enzyme in the Recon 2 model were 
obtained from the BRENDA database [137] (Figure 3-1), and enzyme abundance values 
for cell types of interest were obtained using proteomic and transcriptomic data from 
multiple sources. The last component of the model is the incorporation of thermodynamic 
constraints on each reaction [12]. If the ΔG of any reaction could not achieve a value <0, 
then thermodynamically it cannot carry a net flux, and therefore the upper flux bound 
vmax was set to zero. Standard reaction free energies used to calculate ΔG were obtained 
from the Virtual Metabolic Human database [135]. Metabolite concentrations used include 
experimentally verified cellular metabolite concentration ranges, components of cell 
culture media to simulate the extracellular environment, and measured concentration 
values specific to the cell types of interest. The incorporation of enzyme abundances and 
metabolite concentrations allows for the creation of cell-type-specific models, and 
incorporation of enzyme turnover numbers and reaction standard free energies further 
improves the biological accuracy of model predictions. 
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Figure 3-2. Incorporation of disparate sources of biological information into the 
mathematical modeling framework. 
Models specific to SCC-61 and rSCC-61 cell types were constructed to better 
understand their differences in NAD(P)H production. Because proteome-wide enzyme 
abundance values for these two cell types were not available, these values were estimated 
from SCC-61 and rSCC-61 gene expression data by extrapolating onto proteomic values 
measured in CAL-27 head and neck cancer cells; missing values where no proteomic data 
was available were imputed. This methodology conserves most of the correlation between 
experimental gene expression data (used to estimate enzyme abundance) and the small 
amount of experimental proteomic data available for SCC-61 and rSCC-61 cells (Figure 
3-3, Figure 3-4). 
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Figure 3-3. Correlation between experimental proteomic and experimental gene 
expression values (as ratios of rSCC-61 to SCC-61) corresponding to the same NCBI 
gene ID. 
 
Figure 3-4. Correlation between experimental proteomic and model proteomic 
values. Estimation of model proteomic values from experimental gene expression 
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data conserves most of the original correlation between experimental proteomic and 
gene expression values shown in Figure 3-3. 
To determine whether the incorporation of thermodynamic constraints is necessary 
to achieve accurate model predictions, the net conversion of NADP+ to NADPH was 
compared in both cell types, with and without standard free energy values (ΔGo) and 
experimentally measured metabolite values (Q) included in the model (Figure 3-5). Only 
when both data sets were included was the conversion of NADP+ to NADPH greater in 
rSCC-61 cells than in SCC-61 cells. In this case, the ratio of net conversions (rSCC-
61/SCC-61 = 1.40) was very close to the experimentally measured ratio of 
NADPH/NADP+ concentration between rSCC-61 cells and SCC-61 cells (rSCC-61/SCC-
61 = 1.56) [179]. 
 
Figure 3-5. Net conversion of NADP+ to NADPH, expressed as a ratio of rSCC-
61/SCC-61. Values obtained from the model with and without utilizing metabolite 
concentration data (Q) and reaction standard free energy values (ΔGO) are shown. 
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The dotted line corresponds to the experimentally measured ratio of 
NADPH/NADP+ concentration between rSCC-61 and SCC-61 cells. 
3.3.2 Predicted NADPH production across the HNSCC metabolome 
The flux distributions of major NADPH-producing reactions shown in Figure 
1 were calculated in both SCC-61 and rSCC-61 cell types (Figure 3-6). Flux values span 
multiple orders of magnitude and most predicted values are within one order of magnitude 
of experimentally measured flux values determined using 13C-tracers in other cell types 
[177]. Even though the upper flux bound on the glutamate dehydrogenase GLUD1/GLUD2 
reaction is higher in SCC-61 cells than rSCC-61 cells (due to greater gene expression), the 
observed flux values through this reaction in rSCC-61 cells are significantly greater. While 
rSCC-61 cells exhibit a flux distribution constrained relatively close to the upper flux 
bound, SCC-61 cell flux deviates greatly from the GLUD1/GLUD2 upper bound. This 
result highlights the importance of developing genome-scale models for accurate 
prediction of metabolic phenotypes instead of simply comparing individual gene or protein 
expression values. While a large difference in flux through the GLUD1/GLUD2 reaction 
was found between SCC-61 and rSCC-61 cell types, most reactions did not display 
substantial differences in flux distribution. One exception is nicotinamide nucleotide 
transhydrogenase (NNT), which shows significantly greater flux in rSCC-61 cells than 
SCC-61 and was previously found to be a potential prognostic marker in HNSCC [180]. 
However, because NNT flux values are several orders of magnitude lower than flux values 
through other NADPH-producing reactions, differences in NNT flux between SCC-61 and 
rSCC-61 cell types may not be biologically significant. Note that no nonzero solutions for 
the malic enzyme ME2/ME3 reaction were obtained in SCC-61 cells; this artifact is likely 
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due to the unrestricted flux of malate and pyruvate across the mitochondrial membrane to 
the cytoplasm, along with the ability of ME1 to catalyze the same reaction as ME2/ME3 
in the cytoplasm. 
 
Figure 3-6. Box plot showing the flux distributions in both SCC-61 and rSCC-61 
cells of major NADPH biogenesis reactions. Note that no nonzero solutions for the 
ME2/ME3 reaction were obtained in SCC-61 cells (see text). Boxes represent the 
following percentiles: 2.5th, 25th, 50th, 75th, and 97.5th. Dots represent the upper 
flux bound for each reaction (vmax = kcat[E]). 
To determine whether the calculated flux through NADPH-producing reactions 
correlates with the importance of the corresponding gene's expression toward total cellular 
NADPH production, the maximum net NADP+ → NADPH flux in both SCC-61 and rSCC-
61 cell types was calculated after 75% simulated gene knockdown (Figure 3-7). 
Surprisingly, even though the GLUD1/GLUD2 reaction had the largest calculated flux 
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values among all reactions in both cell types, knockdown of these genes caused very little 
change in total cellular NADPH production. However, some gene perturbations had a 
substantial impact on NADPH production, differentially impacting rSCC-61 cells 
(isocitrate dehydrogenase IDH1, G6PD, ME2) or SCC-61 cells (IDH2). These differences 
between reaction flux distributions and impact of gene knockdown suggest that the 
NADPH-producing reactions with the largest flux are not necessarily the most important 
toward global NADPH production. Instead, metabolic flux can be diverted to other parts 
of the metabolic network to maintain NADPH production in these cases. 
 
 
Figure 3-7. Effect of 75% simulated gene knockdown on net conversion of NADP+ to 
NADPH in both SCC-61 and rSCC-61 cells, expressed as a percentage of net 
conversion before knockdown. 
3.3.3 Simulated silencing of IDH1 highlights NADPH flux re-routing 
As shown in Figure 3-7, simulated knockdown of a gene involved in NADPH 
production does not necessarily impact the total cellular production of NADPH. Instead, 
the cell can reroute flux toward other pathways to achieve the goal of maximizing NADPH 
production. To further investigate this rerouting of flux, the flux distributions of SCC-61 
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and rSCC-61 cells after simulated 75% knockdown of five canonical NADPH-producing 
genes from Figure 3-6, as well as methylenetetrahydrofolate reductase (MTHFR), were 
calculated (Figure 3-8, Figure 3-9, Figure 3-10). The condition generating the most 
interesting insight in flux redistribution was the simulated silencing of IDH1, which 
increased flux through GLUD1/GLUD2 toward its vmax value in the SCC-61 line and 
decreased flux through GLUD1/GLUD2 in the rSCC-61 cell line. A likely explanation of 
this differential effect is that both IDH1 and GLUD1/GLUD2 reactions produce α-
ketoglutarate. Because the objective function is to maximize conversion of NADP+ to 
NADPH, the preferred direction of both of these reactions is to produce α-ketoglutarate 
and NADPH. Due to other model constraints on α-ketoglutarate consumption, there is a 
limit to how much combined flux can occur through IDH1 and GLUD1/GLUD2. 
Therefore, reduction in protein levels of IDH1 affords the opportunity of cells to maintain 
NADPH production by rerouting flux through GLUD1/GLUD2. However, whereas SCC-
61 cells normally operate far from the maximum GLUD1/GLUD2 flux bound and can 
therefore increase this flux, rSCC-61 cells cannot increase GLUD1/GLUD2 flux due to 
other constraints on the genome-wide metabolic network. A similar result is obtained with 
simulated G6PD silencing, accounting for the greater impact of G6PD knockdown on 
NADPH production in rSCC-61 cells than SCC-61 cells (Figure 3-9, Figure 3-10). 
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Figure 3-8. Alternative NADPH production pathways after knockdown of 
IDH1. Flux distributions of simulated wild-type and 75% IDH1 knockdown SCC-61 
and rSCC-61 cells. Boxes represent the following percentiles: 2.5th, 25th, 50th, 75th, 
and 97.5th. Dots represent the upper flux bound for each reaction (vmax = kcat[E]), 




Figure 3-9. Alternative NADPH production pathways after 75% knockdown of 
major NADPH-biogenesis genes, as well as MTHFR, in SCC-61 cells. 
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Figure 3-10. Alternative NADPH production pathways after 75% knockdown of 
major NADPH-biogenesis genes, as well as MTHFR, in rSCC-61 cells. 
3.3.4 Upregulation of NADH-producing fluxes in rSCC-61 
Using an objective function of maximizing NADH production, parsimonious flux 
balance analysis was used to obtain a single representative flux vector in both SCC-61 and 
rSCC-61 cell lines that maximizes both the production of NAD+, as well as reduction of 
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NAD+ to NADH. The rSCC-61 model showed greater total NADH production than the 
SCC-61 model, with rSCC-61/SCC-61 = 1.24 (Figure 3-11). Both models displayed 
significant fluxes through the NAD+ salvage, purine salvage, and pentose phosphate 
pathways. The pentose phosphate pathway produces ribose 5-phosphate (R5P), which is 
converted into adenosine monophosphate and phosphoribosyl pyrophosphate by 
phosphoribosyl pyrophosphate synthase (PRPS). Phosphoribosyl pyrophosphate is 
converted to nicotinamide mononucleotide and NAD+ by NAMPT and NMNAT, 
respectively, in the NAD+ salvage pathway, supplying both cell lines with sufficient 
amounts of NAD+. Adenosine monophosphate is converted to other purines and members 
of the purine salvage pathway, eventually being excreted as uric acid. Through this 
pathway, NAD+ produced from the NAD+ salvage pathway can be reduced to NADH by 
both inosine monophosphate dehydrogenase and xanthine oxidase. Additionally, ribose 1-
phosphate (R1P) produced from xanthosine can be reconverted into R5P, entering back 
into the cycle. Thus, the interconnection of the pentose phosphate pathway, NAD+ salvage 
pathway, and purine salvage pathway plays an important role in both NAD+ synthesis and 
reduction to NADH in both cell lines. 
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Figure 3-11. Parsimonious flux balance analysis results in SCC-61 and rSCC-61 cell 
lines. Cytosolic NADH production was maximized to determine the most pertinent 
metabolic pathways and reactions toward both NAD+ production and reduction of 
NAD+ to NADH. Red numbers indicate the ratio of predicted flux values for each 
reaction between rSCC-61/SCC-61 cell lines. 
To find selective targets of NAD+ and NADH production in radiation-resistant 
tumors, the metabolic reactions that had significantly greater flux in the radiation-resistant 
rSCC-61 cell line compared to the radiation-sensitive SCC-61 cell line were determined, 
such that the rSCC-61/SCC-61 flux ratio was larger than the ratio of total NADH 
production (rSCC-61/SCC-61 = 1.24). Both phosphopentomutase (PPM) and PRPS had 
flux ratios of 1.36, and NAMPT had a flux ratio of 1.31. Previous studies have shown that 
inhibition of NAMPT decreases NAD+/NADH levels, increases levels of ROS, and 
sensitizes cancer cells to β-lapachone treatment [170, 181]. These computational and 
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experimental findings suggest that combining NAMPT inhibitors with β-lapachone and/or 
ionizing radiation may be an effective treatment strategy for radiation-resistant tumors. 
 
3.3.5 ß-lapachone sensitivity and effects on NADPH production 
Through its redox cycling mechanism with NQO1, β-lapachone treatment results 
in a net conversion of NADPH to NADP+, thus lowering the 
NADPH/NADP+ concentration ratio. Subsequent hyperactivation of PARP1 by DNA 
damage and elevated pools of NAD+ confers loss of NAD+ in exposed cells. With cell line-
specific models of NADPH production established for SCC-61 and rSCC-61 that account 
for experimentally observed differences in NADPH/NADP+, we next asked if these 
phenotypes correspond to differences in each line's ability to redox cycle β-lapachone. To 
determine what effect siRNA knockdown of canonical NADPH-producing genes as well 
as MTHFR has on changes in NADPH/NADP+ due to redox cycling, we measured relative 
changes in [NADPH] and [NADP+] in each knockdown in the presence of 3 μM β-
lapachone for 2 h. To quantify the effect of β-lapachone on NADPH/NADP+, a β-lapachone 
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(21) 
This effect parameter ranges in value [0,1], where a value of 0 signifies that β-
lapachone has no effect on the NADPH/NADP+ratio, and a value of 1 signifies that β-
lapachone completely eliminates cellular stores of NADPH. A β-lapachone effect ratio is 
used to compare the β-lapachone effects between rSCC-61 and SCC-61 cells: 
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β-Lapachone Effect Ratio =
β-Lapachone Effect on rSCC-61
β-Lapachone Effect on SCC-61
 (22) 
As expected, the effect ratio for Drosophila siRNA control cells is >1 since β-
lapachone is known to have a greater effect on rSCC-61 cells than SCC-61 cells (Figure 
3-12). ME1, IDH1, and MTHFR knockdowns display substantial increases in effect ratio 
over control cells, indicating that these knockdowns have a greater negative impact on 
NADPH/NADP+ ratio in rSCC-61 cells than SCC-61 cells. The G6PD siRNA resulted in 
a minimal change from control for both cell lines. This finding is consistent with reports 
of quinone-based chemotherapeutic tolerance for G6PD-deficient individuals [182, 183]. 
 
Figure 3-12. β-Lapachone effect ratio in wild-type and siRNA gene knockdown 
cells. Equations 21 and 22 are used to calculate β-lapachone effect ratio. 
NADPH/NADP+ ratios were measured both with and without 2 h of exposure of 







3.3.6 Cell line-specific changes in ß-lapachone sensitivity 
Because NQO1-driven quinone redox cycling is a major driver of PARP1 
hyperactivation and programmed necrosis, we hypothesized that large changes in the 
abundance of major NADPH-producing enzymes would directly impact cell viability in 
the presence of β-lapachone. The rSCC-61 cells have NQO1 mRNA that is over twofold 
higher than SCC-61 cells. Correspondingly, the measured β-lapachone IC50 of rSCC-61 
cells by 7-day clonogenic assay is 3 μM, while SCC-61 cells show no sensitivity to the 
drug. Twenty-four-hour cell viability measurements also indicated sensitivity to 3 μM β-
lapachone that is abrogated in the presence of 50 μM dicoumarol, suggesting that the 
differences in viability are due to NQO1-mediated redox cycling (Figure 3-13, Figure 
3-14). To investigate whether our genome-wide estimates of NADPH production can be 
used to predict modulation of β-lapachone sensitivity in SCC-61 and rSCC-61 cells, model 
simulations were run in conjunction with an experimental siRNA screen of 338 
oxidoreductase genes, 229 of which are found in Recon 2 (Figure 3-15). RNA interference 
was simulated by individually knocking down gene expression of all 229 genes by 75% 
and determining the fraction of total cellular NADPH production after knockdown 
compared with before. Model knockdown of 80 genes caused a greater decrease in NADPH 
production in rSCC-61 cells than SCC-61 cells, compared with 56 gene knockdowns 
causing a greater decrease in SCC-61 cells than rSCC-61 cells (Figure 3-16). Experimental 
knockdown of 59 genes decreased cell viability in rSCC-61 cells, while knockdown of only 
10 genes in SCC-61 cells decreased viability in the presence of β-lapachone (Figure 3-17). 
In addition, experimental knockdown of 181 genes had a more negative impact on cell 
viability upon β-lapachone exposure in rSCC-61 cells than SCC-61 cells, compared with 
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48 gene knockdowns having a more negative impact in SCC-61 cells than rSCC-61 cells. 
This corroboration between model and experimental results suggests that the SCC-61 
metabolic network's response to β-lapachone is more robust than in rSCC-61 cells, likely 
due to SCC-61's ability to reroute NADPH-producing flux through alternative metabolic 
pathways. 
 
Figure 3-13. Cell viability of SCC-61 and rSCC-61 cells at varying levels of ß-
lapachone concentration, expressed as a fraction of cell viability at 0 μM ß-




Figure 3-14. Cell viability of SCC-61 and rSCC-61 cells at varying levels of ß-
lapachone concentration, with and without treatment with 50 μM dicoumarol, 
expressed as a fraction of cell viability at 0 μM ß-lapachone. Error bars represent ± 




Figure 3-15. Heat map showing cell viability of all 338 gene knockdowns after 24 h 
of treatment with 3 μM β-lapachone in three replicate experiments. Cell viability 
values are normalized to those from Drosophila control siRNA-transfected cells, and 
the log2 of normalized values was taken (values >0 signify increased cell viability 
after knockdown, values <0 signify decreased cell viability after knockdown). Genes 




Figure 3-16. Model-predicted effect of gene knockdown on net conversion of 
NADP+ to NADPH, expressed as a fraction of net conversion before 
knockdown. (Left) SCC-61 and rSCC-61 results separately. (Right) The ratio of 
rSCC-61/SCC-61 (values <1 signify gene knockdowns that lower NADPH 
production more in rSCC-61 cells, values >1 signify gene knockdowns that lower 
NADPH production more in SCC-61 cells). 
 
Figure 3-17. Experimental effect of gene knockdown on cell viability after β-
lapachone treatment; the average value of three replicate experiments was taken, 
and the result expressed as a fraction of Drosophila control siRNA-transfected 
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cells. (Left) SCC-61 and rSCC-61 results separately; the dotted line represents 
division between genes that decrease versus increase cell viability after 
knockdown. (Right) The ratio of rSCC-61/SCC-61 (values <1 signify gene 
knockdowns that lower cell viability more, or raise cell viability less, in rSCC-61 
cells; values >1 signify gene knockdowns that lower cell viability more, or raise cell 
viability less, in SCC-61 cells). 
Six of the eighteen genes from Figure 2-4 were included in the siRNA panel; among 
these six genes, five displayed the same rSCC-61/SCC-61 relationship (>1 or <1) when 
comparing model NADPH production and experimental cell viability (Table 3-5). 
Aldehyde dehydrogenase ALDH1L1 and ALDH1L2, which had the third and second 
largest rSCC/SCC cell viability ratio among all 229 genes, also had the eighth and 12th 
largest rSCC/SCC NADPH production ratio. This result demonstrates the model's 
capability to predict β-lapachone sensitivity from cellular NADPH production for 
canonical NADPH-producing genes. 
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Table 3-5. Comparison of model and experimental results for canonical NADPH-
producing genes (left) and discovered HNSCC-specific genes of interest (right). 
 
In addition, there was strong agreement between model and experimental results 
for genes not identified as major contributors to NADPH production, but nonetheless 
implicitly involved in metabolic differences between the two cell lines. The emergence of 
CYP4F3 as a gene affecting both model NADPH production and experimental β-lapachone 
sensitivity may stem from the tissue-specific expression of this monooxygenase in the 
trachea and esophagus as well as its reliance on NADPH as a cofactor for arachidonic acid 
utilization [184]. The strong effect of NADH-cytochrome b5 reductase (CYB5R1) levels 
on 24-h drug response (smallest experimentally determined rSCC-61/SCC-61 cell viability 
ratio) further confirms that rerouting of NADPH flux to enhance fatty acid synthesis serves 
as a critical metabolic difference between the cell lines as reported by Mims et al. [179], 
with knockdown in rSCC-61 cells increasing drug sensitivity (0.60 ± 0.28 cell viability 
ratio compared with control siRNA) while knockdown in SCC-61 cells protecting against 
chemotherapy (1.77 ± 0.42 cell viability ratio compared with control siRNA). 
Surprisingly, silencing of CAT showed this differential trend as well to a lesser 
degree. CAT is typically associated with low expression in tumor cells that are β-lapachone 
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sensitive [160, 169], and the ratio of NQO1/CAT is critical for tumor-specific selectivity; 
thus, we expected that reduction of CAT would enhance redox cycling and reduce cell 
viability in both cell lines. Slightly reduced cell viability was observed in the CAT-silenced 
rSCC-61 cells along with slightly enhanced viability in the CAT-silenced SCC-61 cells, 
resulting in a pronounced rSCC-61/SCC-61 ratio of 0.53 and placing this perturbation in 
the top 10% of differentially affected genes. To explore this observation further, we 
evaluated the flux distributions of CAT and SOD1 to determine if concomitant changes in 
superoxide disproportionation could be the source of cell line-specific responses. We found 
no correlation in either cell line model between SOD1 and CAT flux values (SCC-
61: R2 = 0.09, rSCC-61: R2 = 0.02); however, we did note that SOD1 flux values in the 
rSCC-61 model were constrained within a narrow range at a much higher flux than in SCC-
61 cells (0.73 ± 0.08 mmol/gDW/h vs. 0.13 ±0.11 mmol/gDW/h). Thus, rSCC-61 cells 
may be selected to a regime in which there is little to no margin for adjusting 
H2O2 production when H2O2 clearance becomes limited. GSR is another redox enzyme 
predicted to yield differential β-lapachone sensitivity by cell line-specific models and 
validated by experimental results. GSR provides a key couple between 
NAPDH/NADP+ and GSH/GSSG in the cytosol to sustain ROS clearance through the 
glutathione/glutaredoxin antioxidant pathway. Glutathione S-transferase conjugates GSH 
adducts to β-lapachone hydroquinone for drug efflux from cells [185]; our results are 
consistent with GSR modulation limiting reduced glutathione for this process and thus 
sustaining intracellular drug levels for enhanced redox cycling. 
Carbonyl reductase (CBR1), highly expressed in the oral mucosa [186], also 
demonstrated pronounced differences between the cell lines. Because CBR1 is a two-
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electron reductase capable of reducing quinones [187], the increased sensitivity of rSCC-
61 cells to β-lapachone with reduced CBR1 levels suggests a competing role of CBR1 in 
the β-lapachone redox cycling mechanism. Finally, not all perturbations resulted in more 
β-lapachone sensitivity and greater reduction of viability in the rSCC-61 cells. For 
example, ALDH3A1 is implicated in the enzymatic detoxification of aldehydes 
specifically in the gastrointestinal tract. Consistent with other ALDHs examined in this 
study (ALDH1L1 and ALDH1L2), silencing of this NAD(P)+-consuming enzyme resulted 
in an rSCC-61/SCC-61 ratio >1. 
 
3.4 Discussion 
Because of NADPH involvement throughout the human metabolic network, genome-
scale metabolic modeling is an ideal tool to investigate NADPH production between 
radiation-sensitive and radiation-resistant HNSCC phenotypes. Genome-wide metabolic 
models for NCI-60 cancer cell lines are being rapidly developed [188-190]; however, 
models for head and neck cancer cell lines that are not represented in the NCI-60 list are 
lacking. To establish HNSCC-specific models, we have developed a human genome-scale 
metabolic modeling platform that incorporates quantitative transcriptomic, kinetic, 
thermodynamic, and metabolite concentration data to create cell-type-specific models of 
radiation-sensitive (SCC-61) and radiation-resistant (rSCC-61) HNSCC cell lines (Figure 
3-2). While model predictions are in close proximity to experimental measurements when 
both concentration and thermodynamic data are used, unsatisfactory predictions result 
when one or both data sources are not included, demonstrating the necessity of integrating 
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disparate biological data types into the metabolic model to achieve valid results (Figure 
3-5). 
 A common practice used in FBA models is treating gene expression data as binary 
(reaction on or off) to achieve cell-type-specific results. Proteomic data better represent 
gradations in enzyme levels than gene expression data, and setting reaction upper bounds 
relative to quantitative proteomic values is more accurate biologically than completely 
removing reactions from the model that fall under some arbitrary threshold. For our model 
construction, we leveraged the transcriptional similarities and differences between the 
matched SCC-61/rSCC-61 cell lines and the CAL-27 head and neck cancer cell line to 
estimate proteomic values for SCC-61 and rSCC-61 cells. This approach maintains known 
proteomic–transcriptomic correlations where this information was available and provides 
accurate predictions of NADPH production. 
 β-Lapachone is a chemotherapeutic drug that has tremendous promise in increasing 
the radiation sensitivity of cancer cells through an NADPH-consuming futile redox cycle 
and depletion of cellular NADPH stores. Since antioxidative and DNA repair mechanisms 
in radiation-resistant tumors rely on sufficient NADPH supply, combining radiation 
therapy with β-lapachone treatment may be an effective strategy for cancer patients who 
previously have not responded to radiation. Because of the interconnection between β-
lapachone's mechanism of action and cellular NADPH levels, our hypothesis was that the 
relative β-lapachone sensitivity tested with the siRNA screen of oxidoreductase genes on 
radiation-susceptible and radiation-resistant cells could be predicted by the impact of gene 
knockdown on total cellular NADPH. To test this hypothesis, we combined our novel 
genome-scale metabolic modeling platform with the cellular objective function of 
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maximizing conversion from NADP+ to NADPH while maintaining sufficient ATP 
production to obtain biologically viable results; this differs from the classical cancer 
objective functions of maximizing biomass or ATP production. We justify our choice of a 
novel objective function by noting the generation of the rSCC-61 cell line: SCC-61 cells 
were subjected in vitro to repeated rounds of ionizing radiation (2 Gy for a cumulative total 
of 16 Gy) to select radiation-resistant cells; thus, the cells optimized to repair double-
stranded DNA breaks through the use of NADPH were more likely to survive. The 
interconnectedness of NADH, NAD+, NADPH, and NADP+ in maintenance of the global 
nicotinamide pool warrants future exploration in the use of alternative objective functions, 
such as optimization of NAD+ in the radioresistant phenotype. For example, in all 
NQO1+cancer cells examined to date (pancreatic, breast, prostate, NSCLC, and others), 
NAD+ loss correlates well with loss of survival monitored by short-term or long-term 
assays. Because the two cell lines are so extensively characterized for epigenetic, 
transcriptomic, proteomic, and metabolomic changes occurring with gain of a radiation 
resistance phenotype, they serve as a useful system for testing the underlying hypothesis 
that cumulative alterations across the genome that yield changes in NADPH production to 
facilitate radiation-induced DNA damage repair will also enhance NADPH-dependent 
redox cycling for increased β-lapachone sensitivity. Synergy between ionizing radiation 
therapy and β-lapachone treatment has been established in head and neck cancer [167]; our 
flux balance models suggest specific mechanisms that result in this effect. 
 We first found through our modeling that different NADPH-producing reactions 
contribute to the total cellular NADPH pool on varying flux scales (Figure 3-6). Unlike a 
prior FBA model that strongly implicated the 10-formyl-tetrahydrofolate pathway and 
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malic enzyme in NADPH production for HEK293 cells [144], reactions in the α-
ketoglutarate production and pentose phosphate pathways appear to contribute more to the 
NADPH pool for head and neck cancer cells. In addition, whereas most reaction flux 
distributions did not differ much between SCC-61 and rSCC-61 cells, flux values through 
the GLUD1/GLUD2 reaction were greatly increased in rSCC-61 cells compared with SCC-
61. Even though some reactions produce more NADPH than others, the amount of NADPH 
production did not appear to correlate with the effect of simulated gene knockdown on total 
cellular NADPH (Figure 3-7). For example, knockdown of GLUD1 or GLUD2 in the 
models had very little effect on total NADPH production in SCC-61 and rSCC-61 cells. In 
contrast, knockdown of IDH1, G6PD, and ME2 differentially impacted NADPH 
production in rSCC-61 cells, and knockdown of IDH2 differentially impacted SCC-61 
cells. Collectively, these results suggest that the metabolic network can reroute NADPH-
producing flux to other pathways in a cell-type-specific manner to achieve the goal of 
maximizing NADPH production. This was verified with the differential effect of IDH1 
knockdown on rerouting flux through GLUD1/GLUD2 between SCC-61 and rSCC-61 
cells (Figure 3-8). 
 Although our modeling approach represents a vast improvement over past human 
genome-scale metabolic models, it still lacks some detail regarding redox-based reactions. 
Given the dramatic changes in flux distributions upon simulated IDH silencing, inclusion 
of oncometabolite-generating reactions, such as recently reported for IDH mutations in 
HNSCC [191], would be informative for prediction of quinone drug redox cycling. Another 
limiting factor in genome-scale metabolic modeling is the lack of proteomic, kinetic, 
thermodynamic, and concentration parameters for all reactions and metabolites within 
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human metabolism. The FBA modeling platform is constraint based, meaning that more 
accurate predictions are obtained through the incorporation of more constraints on cellular 
function. With greater availability of biological parameters to include within genome-scale 
models, more constraints can be imposed on cellular function to improve the predictive 
power of genome-scale models. This necessitates collaborative efforts to document 
experimentally verified parameter values on a genome scale. Furthermore, a limitation of 
FBA modeling is the steady-state assumption required for calculation of metabolic flux 
values. Many of the oxidoreductase enzymes under discussion in this study are regulated 
by the redox-sensing transcription factor, Nrf2. In particular, NQO1 contains an 
antioxidant response element sequence in the promoter region and, due to its high 
induction, is often used as a positive control for Nrf2-regulated gene activation [192]. A 
feature of β-lapachone cytotoxicity is that the generation of intracellular ROS by futile 
quinone cycling can trigger Nrf2, thereby increasing NQO1 levels and augmenting the 
initial drug mechanism of action. We did not observe changes in NQO1 levels in either cell 
line during a period of 8 h post-β-lapachone exposure; however, other enzyme expression 
changes during this time frame may alter metabolic flux values from our baseline analysis. 
Nonetheless, the snapshot of genome-wide metabolism determined by our systems 
approach highlights the importance of basal NADPH flux distributions in the predictive 
value for NQO1 bioactivated chemotherapeutic compounds. 
  This systems biology analysis on a matched model of HNSCC radiation response 
provides insight on how small variations in cell line transcriptomics and proteomics can 
cumulatively yield dramatic changes in metabolism and large phenotypic changes to a 
therapeutic treatment. Our modeling efforts demonstrate that depending on the distribution 
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of flux, perturbations in metabolic enzymes can have opposite effects on the 
NADPH/NADP+ redox couple, the degree of futile redox cycling of a chemotherapeutic, 
and ultimately the sensitivity of cell viability to the drug. This modeling approach allows 
for continued investigations on synergy of redox-based chemotherapies and radiation 
therapy.  
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CHAPTER 4. FBA MODELS OF REDOX METABOLISM IN 
TCGA TUMORS 
4.1 Introduction 
To investigate the underlying pathophysiological mechanisms of radiation resistance 
and discover targets for improving sensitivity to radiation therapy, previous studies have 
compared differences in tumor biology between radiation-sensitive and radiation-resistant 
patients. Correlative studies using single omics modalities such as genomics or 
transcriptomics have facilitated the discovery of predictive biomarkers and gene expression 
signatures for radiation sensitivity [3, 46, 171, 193-195]. However, these previous findings 
fall short by failing to integrate multiple biological data types, analyze differential 
expression in the context of genome-scale biochemical and regulatory networks, or provide 
mechanistic insights into how these prospective biomarkers impact tumor function and can 
be exploited to improve radiation sensitivity. 
Ionizing radiation therapy results in the generation of reactive oxygen species (ROS) 
such as superoxide (O2-) and hydrogen peroxide (H2O2), which oxidize the cellular 
environment and damage cellular structures including DNA [196-198]. A reduced 
intracellular environment with elevated levels of NADPH, NADH, and GSH is favored by 
tumor cells for resistance to ROS-mediated damage caused by ionizing radiation. For 
example, NADPH is used by glutathione reductase and thioredoxin reductase to reduce 
GSH and thioredoxin, respectively, which comprise two of the most important antioxidant 
systems [199]. Glutathione peroxidase and peroxiredoxins utilize GSH and reduced 
thioredoxin, respectively, to lower intracellular ROS levels [200]. Additionally, NADPH 
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and NADH are cofactors for dihydrofolate reductase and dihydroorotate dehydrogenase, 
respectively, which are enzymes involved in nucleotide production; thus, increased levels 
of these cofactors in turn increase the supply of deoxynucleotides for DNA damage repair 
in response to ionizing radiation [57, 201]. GSH is also directly involved in DNA damage 
repair by reduction of nucleotide bases [202, 203]. Because redox metabolism is critical to 
the response of tumors to ionizing radiation, identifying targets for inhibiting production 
of these redox cofactors may provide a valuable strategy for sensitizing tumors to radiation 
therapy. 
 Redox metabolites such as NADPH are ubiquitous throughout the human metabolic 
network. In the most recent reconstruction of the human metabolic network, it is estimated 
that 957 metabolic reactions directly involve NADP+ and/or NADPH as cofactors 
[7].  Additionally, the fluxes through metabolic pathways connecting and feeding into these 
reactions dictate the observed activity of NADPH-consuming and -generating reactions, 
making it necessary to study the entire metabolic network to obtain an accurate 
understanding of redox metabolism. Because using experimental methods to study all 
13,000+ metabolic reactions, their interconnections, and responses to perturbations is 
currently infeasible, computational methods of modeling human metabolism are needed. 
Flux balance analysis (FBA) is a computational approach for developing genome-scale 
human metabolic models and predicting steady state reaction fluxes for individual samples 
of interest [9]. By combining the stoichiometric representation of the human metabolic 
network, constraints on the fluxes through metabolic reactions, and an objective function 
to maximize a particular metabolic phenotype, predictions of maximum reaction fluxes or 
metabolite production rates under physiological constraints can be obtained. These 
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predictions can be compared between samples of interest to investigate metabolic 
differences contributing to pathophysiological processes. 
Recently, FBA models personalized to individual cell types or tumors have been 
developed through the integration of transcriptomic data; however, there remain significant 
methodological shortcomings in the construction of these models, which have hindered 
their ability to yield accurate and quantitative metabolic predictions [11]. Commonly-used 
FBA algorithms such as GIMME, iMAT, MADE, and CORDA utilize gene expression 
information to determine which metabolic reactions are “on” (reactions are kept in the 
model) or “off” (reactions are removed from the model) based on the expression of the 
associated metabolic enzyme [148, 149, 152, 204]. However, many of these methods rely 
on arbitrary thresholding of gene expression values to determine on and off states, and the 
complete removal of reactions with low associated gene expression is not physiologically 
accurate. Other methods such as E-Flux constrain the maximum flux through a particular 
reaction in proportion to the associated gene expression, but arbitrary reference values are 
still used to set loose versus tight constraints on predicted fluxes [150]. Additionally, most 
FBA models fail to incorporate any kinetic or thermodynamic constraints, which greatly 
affect metabolic fluxes and the directionalities of individual reactions [12]. These 
shortcomings in model construction have ultimately limited the clinical utility of FBA 
models for accurately predicting metabolic phenotypes and directly improving the 
diagnosis and treatment of disease [205]. 
We have previously developed FBA models of radiation-sensitive and radiation-
resistant head and neck squamous cell carcinoma cell lines through the integration of 
transcriptomic, kinetic, and thermodynamic information into quantitative constraints on the 
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maximum flux and directionality of metabolic reactions [206]. These models accurately 
predicted response to treatment with the NADPH-dependent redox-cycling 
chemotherapeutic β-lapachone and facilitated the discovery of novel oxidoreductase genes 
that differentially affected β-lapachone response between radiation-sensitive and -resistant 
cancer cells. Additionally, we identified that radiation-resistant cancer cells were capable 
of increasing fluxes through NAD salvage and purine salvage pathways to increase 
production of NADH; predicted NAD-generating fluxes were greatly increased through 
NAMPT, an enzyme whose activity has previously been associated with radiation 
resistance and poor survival in cancer patients [79, 207]. Here, we extend this approach by 
developing an automated bioinformatics pipeline for integrating multi-omic information 
into personalized FBA models of 716 radiation-sensitive and 199 radiation-resistant patient 
tumors across multiple cancer types from The Cancer Genome Atlas (TCGA) [2]. These 
models are used to investigate differences in redox metabolism between radiation-sensitive 
and -resistant tumors, identify patient clinical factors that are associated with particular 




4.2.1 Computational methods 
4.2.1.1 Objective functions 
Table 4-1 lists the objective functions used in FBA and FVA. To maximize the 
production of a metabolite in all cellular compartments, separate objective functions for 
each compartment with the same weight were simultaneously maximized. To ensure that 
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biologically viable solutions were obtained, all models were checked to ensure that they 
were capable of producing physiological ATP levels typical of mammalian cells (1.0625 
mmol gDW-1 hr-1) while maximizing the imposed objective functions [208]. 
 
Table 4-1. Objective functions used in FBA and FVA. 
Title Objective Function 
NADP+  NADPH 1 nadph[all]  1 nadp[all] + 1 h[all] 
NADP+  NADPH, Cytosolic 1 nadph[c]  1 nadp[c] + 1 h[c] 
NADP+  NADPH, Mitochondrial 1 nadph[m]  1 nadp[m] + 1 h[m] 
NAD+  NADH 1 nadh[all]  1 nad[all] + 1 h[all] 
GSSG  GSH 
2 gthrd[all] + 1 nadp[all]  1 gthox[all] + 1 nadph[all] 
+ 1 h[all] 
H2O2   Ø  1 h2o2[all] 
 dNTP 1 datp[all] + 1 dctp[all] + 1 dgtp[all] + 1 dttp[all]  Ø 
 Palmitate 1 hdca[all]  Ø 
Note: “[all]” signifies that the objective function was maximized in all cellular 
compartments with equal weights. “Ø” signifies no metabolites on the left or right side of 
the equation. 
4.2.1.2 Metabolic network 
Recon 3D version 3.01 was used as the core metabolic network [7]. While the “full” 
version (Recon3D_301.mat) produced erroneous energy-generating cycles (e.g. producing 
ATP without uptake of any metabolic precursors), the “model” version 
(Recon3DModel_301.mat) was found not to be the largest subset of reactions without 
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erroneous energy-generating cycles (additional reactions from the “full” version could be 
added). To this end, following the procedure outlined in Fritzemeier et al., reactions from 
the “full” version were sequentially added back into the “model” version as long as they 
did not result in erroneous energy-generating cycles [209]. 
To address missing and inaccurate redox-based reaction information within Recon3D, 
the following changes were made: 
1. The reaction “FTHFDH” was split into two separate cytosolic and mitochondrial 
reactions. The cytosolic reaction is catalyzed by ALDH1L1, and the mitochondrial 
reaction is catalyzed by ALDH1L2. 
Originally: 
a. 1 10fthf[c] +1  h2o[c] + 1 nadp[c]  1 co2[c] + 1 h[c] + 1 nadph[c] + 1 
thf[c], GPR: 10840.1 or 160428.1, EC: 1.5.1.6 
 Updated: 
a. 1 10fthf[c] + 1 h2o[c] + 1 nadp[c]  1 co2[c] + 1 h[c] + 1 nadph[c] + 1 
thf[c], GPR: 10840.1, EC: 1.5.1.6 
b. 1 10fthf[m] + 1 h2o[m] + 1 nadp[m]  1 co2[m] + 1 h[m] + 1 nadph[m] + 
1 thf[m], GPR: 160428.1, EC: 1.5.1.6 
2. MTHFR was removed from the GPR associated with reaction “MTHFD”. MTHFR 
catalyzes the reaction converting 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, which is already included in Recon3D. 
Originally: 
a. 1 mlthf[c] + 1 nadp[c]  1 methf[c] + 1 nadph[c], GPR: 4522.1 or 
4524.1, EC: 1.5.1.5 
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 Updated: 
a. 1 mlthf[c] + 1 nadp[c]  1 methf[c] + 1 nadph[c], GPR: 4522.1, EC: 
1.5.1.5 
3. Reactions catalyzed by isoforms of NADPH oxidase were added. 
Originally: None 
Updated: 
a. 1 nadph[c] + 2 o2[c]  2 o2s[e] + 1 nadp[c] + 1 h[c], GPR: 27035.1 or 
1536.1 or 50508.1 or 79400.1, EC: 1.6.3.1 
b. 1 nadph[n] + 2 o2[n]  2 o2s[c] + 1 nadp[n] + 1 h[n], GPR: 50507.1, EC: 
1.6.3.1 
c. 1 nadph[r] + 2 o2[r]  2 o2s[c] + 1 nadp[r] + 1 h[r], GPR: 50507.1, EC: 
1.6.3.1 
4. PRDX1 and PRDX2 were removed from the GPR associated with reaction 
“GTHP”. Glutathione peroxidase involves the reduction of hydrogen peroxide by 
glutathione, which does not involve peroxiredoxins. Peroxiredoxin reactions are 
added to Recon3D (see below) 
Originally: 
a. 1 h2o2[c] + 2 gthrd[c]  2 h2o[c] + 1 gthox[c], GPR: 7001.3 or 5052.3 or 
2877.1 or 2876.2 or 5052.2 or 2876.1 or 5052.1 or 7001.1 or 2879.1 or 
7001.2, EC: 1.11.1.9 
 Updated: 
a. 1 h2o2[c] + 2 gthrd[c]  2 h2o[c] + 1 gthox[c], GPR: 2877.1 or 2876.2 or 
2876.1 or 2879.1, EC: 1.11.1.9 
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5. Similarly to (4), PRDX3 was removed from the GPR associated with reaction 
“GTHPm”. 
Originally: 
a. 1 h2o2[m] + 2 gthrd[m]  2 h2o[m] + 1 gthox[m], GPR: 10935.1 or 
10935.2 or 2879.1 or 2876.1, EC: 1.11.1.9 
 Updated: 
a. 1 h2o2[m] + 2 gthrd[m]  2 h2o[m] + 1 gthox[m], GPR: 2879.1 or 2876.1, 
EC: 1.11.1.9 
6. PRDX6 was removed from the GPR’s associated with the following reactions: 
HMR_0960, HMR_0963, HMR_0988, HMR_2441, HMR_1048, HMR_1049. 
These are all glutathione peroxidase reactions, which PRDX6 is not involved in. 
7. Reactions catalyzed by isoforms of peroxiredoxin were added: 
Originally: None 
Updated: 
a. 1 h2o2[c] + 1 trdrd[c]  2 h2o[c] + 1 trdox[c], GPR: 5052.1 or 5052.2 or 
5052.3 or 7001.1 or 7001.2 or 7001.3, EC: 1.11.1.15 
b. 1 h2o2[m] + 1 trdrd[m]  2 h2o[m] + 1 trdox[m], GPR: 10935.1 or 
10935.2, EC: 1.11.1.15 
8. The oxidation and glutathionylation of protein thiol groups, as well as their 




a. 1 h2o2[c] + 1 Pr-SH[c] + 1 gthrd[c]  2 h2o[c] + 1 Pr-SSG[c], GPR: None, 
EC: None 
b. 1 h2o2[m] + 1 Pr-SH[m] + 1 gthrd[m]  2 h2o[m] + 1 Pr-SSG[m], GPR: 
None, EC: None 
c. 1 Pr-SSG[c] + 1 gthrd[c]  1 Pr-SH[c] + 1 gthox[c], GPR: 2745.1, EC: 
1.20.4.1 
d. 1 Pr-SSG[m] + 1 gthrd[m]  1 Pr-SH[m] + 1 gthox[m], GPR: 2745.1, EC: 
1.20.4.1 
e. 1 h2o2[c] + 1 Pr-SH[c]  2 h2o[c] + 1 Pr-SS[c], GPR: None, EC: None 
f. 1 h2o2[m] + 1 Pr-SH[m]  2 h2o[m] + 1 Pr-SS[m], GPR: None, EC: None 
g. 1 Pr-SS[c] + 1 trdrd[c]  1 Pr-SH[c] + 1 trdox[c], GPR: None, EC: None 
h. 1 Pr-SS[m] + 1 trdrd[m]  1 Pr-SH[m] + 1 trdox[m], GPR: None, EC: 
None 
9. The reliance of catalase enzyme on NADPH to prevent oxidation of its active site 
by H2O2 was incorporated [69]. Kirkman et al. measured rates of H2O2 formation 
and corresponding rates of NADPH oxidation in mixtures of catalase and varying 
concentrations of glucose oxidase [210]. If the rate of H2O2 formation by glucose 
oxidase is assumed to equal the rate of H2O2 clearance by catalase, then the slope 
of NADPH oxidation vs. H2O2 formation gives the amount of NADPH oxidized by 
catalase per molecule of H2O2 cleared. Figure 4-1 shows that for every 1 molecule 
of H2O2 cleared by catalase, 0.0641 molecules of NADPH are oxidized; thus, the 
chemical equation for catalase activity is: 
 2 H2O2 + 0.1282 NADPH → 2 H2O + 1 O2 + 0.1282 NADP
+ + 0.1282 H+ (23) 
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This change was made for catalase reactions in the cytosol, mitochondria, 
peroxisome, and endoplasmic reticulum. 
 
Figure 4-1. Regression of NADPH oxidation by catalase enzyme vs. H2O2 formation 
by varying concentrations of glucose oxidase. Data from [210]. 
10. The neomorphic 2-hydroxyglutarate-producing reaction catalyzed by mutant IDH1 
was added. Reactions for 2-hydroxyglutarate export were also added. 
Originally: None 
Updated: 
a. 1 akg[c] + 1 nadph[c]  1 M00653[c] + 1 nadp[c], GPR: 3417.1, EC: 
1.1.1.42 
b. 1 M00653[c]  1 M00653[e], GPR: None, EC: None 
c. 1 M00653[e]  ,  GPR: None, EC: None 
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Because transcriptomic and proteomic data were available at the individual gene 
level but not at the individual isoform level, all isoforms for each individual gene within 
Recon3D were combined. 
 
Other changes made to Recon3D include: 
• Removing the following duplicate reactions (where another reaction exists where 
the stoichiometric vector is an exact multiple of these duplicate reactions): 
“HMR_7257”, “PEHSFABPe”, “G6PDH2c”, “GNDc”, “PGLc”, “RPEc” 
• Removing EC numbers from all transport reactions, since many of these were 
incorrect. 
• Removing the following genes and any associations with them within Recon3D 
reactions, since information about these genes could not be found: 
NCBI Gene ID’s: 0, 100507855, 8041 
• Removing reactions within the following subsystems, as this was necessary to 
prevent de novo production of essential amino acids: 
“Protein assembly”, “Protein degradation”, “Protein modification”, “Protein 
formation” 
• Removing reactions in the “Bile acid synthesis” subsystem, as these are not 
expected to be active in most tumors 
• Removing NQO1 futile cycle reactions, as these un-constrained reactions resulted 
in erroneous predictions of NADPH production: “NADPQNOXR”, 
“NADQNOXR”, “HMR_9538”, “HMR_9722” 
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• Removing oxalosuccinic acid-producing IDH1 reactions, as these overlapped with 
α-ketoglutarate-producing IDH1 reactions: “r0423”, “r0424”, “r0425”, “r0422” 
4.2.1.3 Model flux constraints 
Flux bounds for reactions within Recon3D with both associated GPR rules and EC 
numbers were constrained using the following Michaelis-Menten upper flux bound 
equation: 
 𝑣𝑚𝑎𝑥 = 𝑘𝑐𝑎𝑡[𝐸] (24) 
where kcat and [E] are the turnover number (units of hr-1) and abundance (units of mmol 
gDW-1) of the associated enzyme catalyzing that reaction, respectively. By using the 
abundances of enzymes within individual tumors, these models were able to make 
metabolic predictions that are specific to the individual sample of interest. Additionally, 
these Michaelis-Menten constraints allow models to make flux predictions that are 
quantitative and physiologically-accurate. 
Equation 24 was used to set upper flux bounds vmax,j for all reactions with associated 
GPR rules and EC numbers, as well as lower flux bounds vmin,j for such reactions that are 
reversible (where vmin,j < 0). See sections “Enzyme Abundance Calculation” and “Turnover 
Number Calculation” for more information. 
4.2.1.4 Enzyme abundance calculation 
RNA-Seq gene expression data from TCGA patient tumors was obtained from 
Rahman et al.’s alternative preprocessing method (Gene Expression Omnibus GSE62944) 
[211]. Data from this preprocessing method showed fewer missing values, more consistent 
expression between replicates, and improved prediction of biological pathway activity 
compared to the original TCGA pipeline. 
 92 
Enzyme abundances within individual samples were predicted from sample gene 
expression data using the pipeline in Figure 4-2. Although this approach does not perfectly 
predict experimentally-measured protein abundances or activities, it allows for the 
generation of FBA predictions that are more quantitative and physiologically-accurate than 
other methods that rely solely on thresholding of gene expression data. The approach 
described below relies only on the gene expression data from the individual sample of 
interest and not data from other samples included within the dataset, improving the 
reproducibility of this method as well as allowing for new samples to be analyzed post-
hoc. 
 
Figure 4-2. Pipeline for the estimation of enzyme abundance values from gene 
expression data for individual TCGA patient tumors. Percentages represent the 
percentage of enzyme abundances of associated genes in Recon3D that have been 
cumulatively determined at each step in the pipeline for all TCGA samples. 
The individual steps in the pipeline are explained herein: 
1. Schwanhäusser et al. - By measuring the transcription, translation, and degradation 
rates of individual genes and proteins in NIH3T3 cells, Schwanhäusser et al. 
developed an ODE model relating mRNA and protein abundances per cell that 
encompasses 955/3268 (29.2%) genes in Recon3D [212]. Their model also took 
into account proteins with half-lives longer than the length of the cell cycle, and 
how this would impact measurements of protein abundance. The authors 
demonstrated that these rate constants and model could be applied to accurately 
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predict protein abundances in other samples including cancer cell lines. Using this 
model, gene expression values (transcripts per kilobase-million (TPM)-normalized) 
were converted to protein abundance values (parts per million (PPM)-normalized) 
for the 955 Recon3D genes included. 
2. Linear regression - For each sample, a linear regression of predicted protein 
abundance using the Schwanhäusser et al. method versus the measured gene 
expression values of corresponding genes is performed (example is shown in Figure 
4-3). This regression model is used to predict the abundance of proteins where an 
associated gene expression value is available but not corresponding parameter 
values in the Schwanhäusser et al. method. 
 
Figure 4-3. Example of linear regression step in the pipeline for enzyme abundance 
values, where predicted protein abundances using the Schwanhäusser et al. method 
are regressed versus the measured gene expression values of corresponding genes in 
an individual TCGA sample. 
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3. PaxDB - If no gene expression value is available for a particular sample, the 
harmonic mean of abundance values for the associated protein across all Homo 
sapiens samples within the PaxDB database is taken [213]. If the associated protein 
is not available in the PaxDB database, the harmonic mean of abundance values for 
all proteins across all Homo sapiens samples is taken. Imposing the same values for 
all samples with missing gene expression values acts to prevent differences in FBA 
model predictions between samples due to missing data. The harmonic mean of 
PaxDB values is taken since (1) the arithmetic mean tends to overestimate 
representative values of positively-skewed distributions (as seen with protein 
abundance values); and (2) the smaller protein abundance estimate of the harmonic 
mean well characterizes the fact that missing measured RNA-Seq values are usually 
at least in part due to low actual mRNA expression. 
 
For genes with associated enzymes in multiple cellular compartments (e.g. catalase, 
which localizes to the cytosol, mitochondria, peroxisome, and endoplasmic reticulum), the 
predicted protein expression value was divided into each cellular compartment with 
weights proportional to the COMPARTMENTS value for the cellular compartment in 
which the metabolic reaction takes place [214]. These COMPARTMENTS values provide 
a score representing the confidence that a particular protein is found within a particular 
cellular compartment, using both experimental and computational evidence. 
Validation of this pipeline was performed to ensure (1) that the predicted enzyme 
abundance values correlated at least as well with experimental protein expression data from 
TCGA than gene expression data; and (2) that the predicted enzyme abundance values were 
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at physiological orders of magnitude. Normalized RPPA experimental protein expression 
values from TCGA samples were available for 30 genes/proteins in Recon3D [2]. The 
correlation between experimental enzyme abundance and predicted enzyme abundance 
values (R2PredictedAbundance) was greater than the correlation between experimental enzyme 
abundance and gene expression values (R2Gene) for 18/30 genes (60%; Figure 4-4, Figure 
4-5). Additionally, the largest change in correlation for genes where R2PredictedAbundance < 
R2Gene was less than 0.004, indicating that the R2PredictedAbundance was not significantly lower 
than the R2Gene for any of the 30 genes. 
 
Figure 4-4. Example comparison of (left) gene expression and (right) predicted 
enzyme abundance values to experimental enzyme abundances from TCGA samples 





Figure 4-5. Improvement of correlation to experimental enzyme abundances of 
predicted abundance values (R2PredictedAbundance) compared to original gene expression 
data (R2gene) for all 30 genes/proteins with available experimental values for TCGA 
samples. Blue dashed line: mean value of R2PredictedAbundance-R2gene across all 30 
genes/proteins. 
Because experimental non-normalized protein abundance values were not available 
for TCGA samples for validation, experimentally-measured protein abundances in the 
NCI-60 panel of cancer cell lines were used to analyze the improvement in correlation to 
experimental data and physiological accuracy of predicted abundances on a genome scale 
(Figure 4-6, Figure 4-7). The mean values of predicted enzyme abundances across TCGA 
samples showed significantly greater correlation to experimental NCI-60 abundance values 
(R2 = 0.450) compared to TCGA gene expression values (R2 = 0.314). Additionally, the 
order of magnitude of predicted abundance values matched well with experimental values 
for individual genes/proteins over the majority of orders of magnitude. The match to 
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experimental values was greatest for enzyme abundances that were calculated at the first 
step of the pipeline (Schwanhäusser et al. method; R2 = 0.586) compared to abundances 
calculated at later steps (R2 = 0.286), indicating the necessity for future transcription, 
translation, and degradation rate measurements to be conducted for genes/proteins not 
covered in the Schwanhäusser et al. method. 
 
Figure 4-6. (Left) Correlation between mean gene expression values across TCGA 
samples and mean experimental enzyme abundances across NCI-60 samples for all 
3,268 genes/proteins in Recon3D. Blue line: least squares linear regression line. 
(Right) Correlation between mean predicted enzyme abundances across TCGA 
samples and mean experimental enzyme abundances across NCI-60 samples for all 




Figure 4-7. Breakdown of predicted enzyme abundances into (Left; red dots) those 
values calculated during the first step of the prediction pipeline (Schwanhäusser et 
al. method) and (Right; black dots) those values calculated at later steps of the 
pipeline. Green dashed line: 1:1 line. 
4.2.1.5 Turnover number calculation 
Enzyme turnover numbers for associated reactions within Recon3D were 
determined using available experimental data from the BRENDA database API [137]. 
Because the BRENDA database does not contain data for all Recon3D enzymes with the 
exact same enzyme commission (EC) number and substrate measured using human 
enzymes at 37°C and the correct cellular compartment-specific pH, a pipeline was created 
where Recon3D turnover values are filled in at subsequent steps with less accurate but 
more available information within BRENDA (Figure 4-8). For an individual enzyme-
catalyzed reaction within Recon3D, the associated turnover number was determined as 
close to the start of the pipeline as data was available within BRENDA. Values determined 
towards the start of the pipeline are more accurate, but less turnover number data with this 
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greater accuracy is available within BRENDA. In determining turnover number accuracy, 
priority was given in the order of (1) using the correct EC number (versus using data from 
EC numbers that match only the first 3, 2, or 1 digits with that of the Recon3D reaction); 
(2) using the correct substrate as given in the Recon3D reaction (versus using data from 
any available substrate); (3) using turnover number data taken from human enzymes 
(versus using data from any available organism); and (4) using turnover number data taken 
at physiological temperature and pH (versus using data near but not at physiological 
temperature and pH). At a particular step in the pipeline, if multiple turnover number values 
that met the pipeline criteria were available, a weighted average of these values was taken, 
where the weights are equal to the Tanimoto coefficient (a measure of molecular similarity; 
greater coefficient signifies greater similarity between two molecules) between the desired 
substrate in the Recon3D reaction and the substrate in BRENDA for which the associated 
turnover number was determined. No turnover number values in the BRENDA database 
from mutated enzymes were used at any step in the pipeline. 
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Figure 4-8. Pipeline for the estimation of enzyme turnover numbers using data from 
the BRENDA database API. Percentages represent the percentage of turnover 
numbers of associated reactions in Recon3D that have been cumulatively 
determined at each step in the pipeline. 
4.2.1.6 Mutation data 
The effect of single nucleotide polymorphisms (SNP’s) located in Recon3D genes 
on the catalytic activity of the associated metabolic enzyme was estimated using the 
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Envision computational platform developed by Gray et al [137]. Envision leverages large-
scale experimental mutagenesis datasets to predict a score representing the effect of single 
amino acid changes on protein function; a score less than 1 signifies a loss-of-function, 
while a score greater than 1 signifies a gain-of-function. These quantitative scores were 
shown to correlate better with experimentally-measured percent changes in protein activity 
after mutation than previously-developed methods including SNAP2 and EVmutation. For 
each TCGA patient with mutation data available, the turnover number for a particular 
Recon3D reaction was multiplied by the Envision score for any SNP’s located in the 
associated gene. 
4.2.1.7 IDH1 mutations 
Particular mutations in isocitrate dehydrogenase 1 (IDH1), predominantly at amino 
acid R132, result in both the loss of function of its normal NADPH-generating activity, as 
well as the gain of function of a neomorphic NADPH-consuming activity that produces the 
oncometabolite 2-hydroxyglutarate [215]. This change in function was implemented by 
adding the IDH1-catalyzed neomorphic reaction to Recon3D and imposing turnover 
numbers of the normal and neomorphic reactions measured by Avellaneda Matteo et al. 





Table 4-2.  Turnover numbers of normal and neomorphic IDH1 reactions for given 
IDH1 mutations. 
Mutation kcat Normal [s-1] kcat Neomorphic [s-1] 
WT 85 ± 4 0.019 ± 0.001 
R132C 4.4 ± 0.1 1.60 ± 0.07 
R132G 9.3 ± 0.6 1.59 ± 0.09 
R132H 2.4 ± 0.1 4.2 ± 0.3 
 
4.2.1.8 Thermodynamic constraints 
Only metabolic reactions with a negative change in Gibbs free energy (ΔG) can 
carry a non-zero net flux. Implementing thermodynamic constraints prevents fluxes 
through these thermodynamically infeasible reactions; additionally, this limits the 
formation of thermodynamically infeasible loops that carry net fluxes around closed cycles 
in the metabolic network [217]. To implement thermodynamic constraints on the models, 
the minimum and maximum transformed Gibbs free energy of Recon3D reactions were 
obtained from the Virtual Metabolic Human database [218]. For all reactions where both 
the minimum and maximum ΔG values were greater than zero (and for all reversible 
reactions where both the minimum and maximum ΔG values were less than zero in the 
reverse direction), the maximum flux vmax,j through that reaction was set to zero. 
4.2.1.9 Media constraints 
To simulate experimental cell culture conditions, the modeled external 
compartment contained all metabolites found in RPMI-1640 cell culture media (Thermo 
Fisher #11875) as well as fetal bovine serum (FBS) [219]. The external compartment also 
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contained water, hydrogen ions, hydroxide ions, oxygen, and carbon dioxide. Modeled 
cells were allowed to uptake these available metabolites but not any other metabolites 
found in Recon3D. 
4.2.1.10 Code/model availability 
Code for the generation and simulation of personalized FBA models is available at 
https://github.com/kemplab/FBA-pipeline.  Personalized models can be developed for any 
human sample (such as cell lines or patient tumors) with RNA-seq gene expression data 
(and mutation data if available). Jupyter notebooks are available for 1) the processing of 
sample RNA-seq data to estimate enzyme abundance values; 2) the processing of sample 
mutation data to estimate kinetic rate parameters; 3) running FBA or FVA analysis with 
user-specified model constraints, media constraints, objective function, and samples of 
interest. TCGA models developed for this study are available as well. 
 
4.2.2 Experimental methods 
4.2.2.1 Cell culture 
Table 4-3 provides the matched radiation-sensitive and radiation-resistant cell lines 
used for experimental validation of model predictions. All cell lines were maintained in 
RPMI-1640 cell culture media (Thermo Fisher #11875) with 10% fetal bovine serum 
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surviving colonies. 




4.2.2.2 siRNA transfections 
Cells were seeded in 24-well plates at 5 × 104 cells per well for Ehc GSH/GSSG 
measurements, or 96-well plates at 8 × 103 cells per well for glucose oxidase response 
measurements. 24 hours after seeding, cells were transfected using the N-TER 
Nanoparticle siRNA Transfection System (Sigma-Aldrich #N2913) at a final siRNA 
concentration of 50 nM with serum-free medium for 4 hours; afterwards, an equal volume 
of 2x (20%) FBS-containing medium was added to each well. Negative controls consisted 
of transfection with the MISSION siRNA Universal Negative Control (Sigma-Aldrich 
#SIC001, Lot # WDAA 1199). Predesigned siRNA’s targeting individual genes were 
ordered from Sigma-Aldrich; the top 3 rated siRNA’s based on expected efficacy for each 
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gene target were pooled together and transfected concurrently, except for GLUD1, 
GLUD2, and SUCLG2, where only 2, 1, and 1 siRNA’s were available, respectively (Table 
4-4). Figure 4-9 shows the knockdown efficiency of siRNA transfections in each cell line 
with GAPDH siRNA compared to no siRNA (just N-TER) and negative control siRNA. 
Experiments were performed 24hr after transfection.  
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Figure 4-9. Knockdown efficiency of siRNA transfections in each cell line with 
GAPDH (red) siRNA compared to no siRNA (just N-TER) and negative control 
siRNA. Tubulin (green) was used as a loading control. 
4.2.2.3 Ehc GSH/GSSG measurements 
The protocol and reagents used for measurement of glutathione half-cell potential 
were adapted from [221]. KPE buffer was made by combining 16mL of solution A (6.8g 
KH2PO4 in 500mL dH2O) and 84mL of solution B (8.5g K2HPO4 in 500mL dH2O). After 
removal of cell culture media, 150μL of extraction buffer (0.1% Trition-X100 and 0.6% 
sulfosalicylic acid in KPE) to each well of a 24-well plate containing samples of interest. 
Plates were shaken at 800rpm for 10min to promote cell lysis. For each well, 100μL of 
lysate was taken for GSSG measurement, and 20μL was taken for GSSG+GSH 
measurement. 
For GSSG+GSH measurement, 20μL samples were placed in a clear 96-well plate. 
20μL of GSSG and GSH standards at concentrations of 2e-2, 1e-2, 5e-3, 2.5e-3, 1e-3, 5e-
4, 2.5e-4, 1e-4, 5e-5, 2.5e-5, 1e-5, and 0 mg/mL were placed in separate rows of the 96-
well plate. 120μL of 1:1 DTNB:GR solution (DTNB: 2mg 5,5’-dithiobis(2-nitrobenzoic 
acid) in 3mL KPE; GR: 40μL of glutathione reductase enzyme (250 units/mL) in 3mL 
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KPE) was added to each well. 30sec later, 60μL of NADPH solution (2mg of β-NADPH 
in 3mL KPE) was added to each well. Immediately after, absorbance at 412nm in each well 
was measured every 31sec for a period of 5min10sec (11 measurements) using a BioTek 
Synergy 4 plate reader. All sample and standard values were background subtracted. To 
determine the concentration of GSSG+GSH in each sample (mg/mL), the slope of 
absorbance vs. time from each sample was compared to the average slope of the GSSG and 
GSH standard concentrations. 
For GSSG measurement, 100μL samples as well as 100μL of GSSG and GSH 
standards were placed in a 96-well plate. 10μL of 2VP solution (2-vinylpyridine diluted 
1:50 in KPE) was added to each well. 60min later, 10μL of triethanolamine solution 
(triethanolamine diluted 1:10 in KPE) was added to each well. 10min later, 20μL from each 
well was transferred to a new clear 96-well plate. GSSG was then measured analogously 
to GSSG+GSH. GSSG measurements were multiplied by 1.2 to account for the dilution of 
the original 100μL sample with 10μL of 2VP solution and 10μL of triethanolamine 
solution. 
To determine the concentration of GSH (mg/mL) for each sample, the measured 
concentration of GSSG was subtracted from the measured concentration of GSSG+GSH. 
To convert lysate concentrations (mg/mL) to intracellular concentrations (M), the 




𝑀𝑀 × 𝑉𝑐𝑒𝑙𝑙 × 𝑛𝑐𝑒𝑙𝑙𝑠
 (25) 
where MM is the molar mass of either GSH or GSSG (g/mol), Vsample is the volume of 
sample (20μL), Vcell is the estimated volume of each cell (1 pL), and ncells is the number of 
cells per sample (5 × 104). 
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where Ehco is the standard half-cell potential at pH 7.4 (-264 mV), R is the universal gas 
constant (8.314 J/K/mol), T is the temperature (310.15 K), z is the number of electrons (2), 
and F is the Faraday constant (96485 C/mol = 96.485 J/mV/mol).   
4.2.2.4 Glucose Oxidase Response Measurements 
Prior to seeding, cells were stained with CellTracker Red CMTPX Dye 
(ThermoFisher Scientific, C34552) for 30min. 8 × 103 cells per well were seeded in white-
sided clear-bottom 96-well plates. 24hr after transfection and prior to treatment with 
glucose oxidase, CellTracker fluorescence measurements in each well were taken at Ex 
577nm, Em 602nm using a BioTek Synergy 4 plate reader as a proxy for number of cells 
per well. An average of 10 fluorescence measurements was taken, and measurements were 
background subtracted. Samples were then treated with 10 mU/mL glucose oxidase 
enzyme (Millipore Sigma, G7141) diluted in 100μL cell culture medium (RPMI-1640 + 
10% FBS) for 2hr. Afterwards, 100μL of CellTiter-Glo 2.0 Cell Viability Assay (Promega, 
G9241) was added to each well. Plates were shaken at 800rpm for 2min to promote cell 
lysis, and then incubated at room temperature for 10min. Luminescence measurements 
were then taken using a BioTek Synergy 4 plate reader and background subtracted. Cell 
viability normalized by cell count was measured by dividing the luminescence 





4.3.1 Automated bioinformatics pipeline for integrating multi-omic data 
The framework for building FBA models of tumor metabolism was initiated with 
the community-curated Recon3D human metabolic reconstruction (8,401 metabolites, 
13,547 reactions, and 3,268 genes) [7]. The stoichiometric representation of this 
reconstruction, along with minimum and maximum constraints on reaction fluxes, results 
in a solution space for the steady state fluxes throughout the metabolic network. 
Maximizing an objective function narrows the possible solution space and allows for 
assessment of metabolic phenotypes between tumor models. For example, using the 
objective function of maximizing reduction of NADP+ to NADPH provides estimates of 
maximum cellular NADPH production. Additionally, flux variance analysis (FVA) 
predicts minimum and maximum fluxes through individual metabolic reactions while 
satisfying the maximization of the original objective function; e.g. fluxes through NADPH-
generating reactions while maintaining maximum overall NADPH production. Under the 
assumption that tumors favor maximizing the production of reduced redox cofactors such 
as NADPH to decrease ROS-mediated damage induced by ionizing radiation, the 
associated metabolic fluxes resulting from maximizing cofactor reduction provides 
accurate predictions of tumor metabolism in response to radiation therapy. 
To generate FBA models that are personalized to individual radiation-sensitive and 
radiation-resistant TCGA patient tumors, a Michaelis-Menten Vmax constraint was set on 
all 4,367 Recon3D reactions with both a gene-protein-reaction (GPR) rule and enzyme 
commission (EC) number (Figure 4-10). This constraint sets the maximum flux for each 
reaction (Vmax, units of mmol gDW-1 hr-1) equal to the kinetic rate constant of the enzyme 
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catalyzing the reaction (kcat, units of hr-1), multiplied by the estimated protein abundance 
of the enzyme ([E], units of mmol gDW-1). A custom protein prediction pipeline was 
developed to convert RNA-seq gene expression data from individual TCGA samples into 
estimated enzyme abundances with quantitative accuracy (Figure 4-2). This pipeline takes 
advantage of models developed by Schwanhäusser et al. relating the mRNA and protein 
abundances for individual genes/proteins using experimentally-measured transcription, 
translation, and degradation rates [212]. Additionally, a custom kinetic rate pipeline was 
created to extract turnover numbers for Recon3D metabolic reactions from experimentally-
measured values in the BRENDA database (Figure 4-8) [137]. Envision database scores 
were applied to predict the effect of mutations in individual TCGA samples on the catalytic 
rate of corresponding metabolic enzymes [222]. Finally, standard transformed changes in 
Gibbs free energy (ΔG’०) from the Virtual Metabolic Human (VMH) database were used 
to set thermodynamic constraints, where only reactions with a negative ΔG’० can carry non-
zero net fluxes [218].  These proteomic, kinetic, and thermodynamic constraints allow for 
the prediction of quantitative, patient-specific, and physiologically-accurate metabolic 
fluxes on a genome scale. 
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Figure 4-10. Pipeline for integration of multi-omic data into FBA models. Gene 
expression data from individual tumors was used to estimate the abundances of 
metabolic enzymes. Experimental turnover numbers from the BRENDA database 
and mutation data from individual tumors were combined to estimate the kinetic 
rates of metabolic enzymes. Together, these were used to impose a Michaelis-
Menten Vmax constraint (Vmax = kcat[E]) on all reactions with an available GPR rule 
(denoting the Entrez ID’s of all genes encoding the enzyme which catalyzes the 
reaction) and EC number (denoting the metabolic function of the enzyme). 
Additionally, standard transformed Gibbs free energies from the VMH database 
were used to set the directionalities of metabolic reactions. 
RECIST classification of TCGA samples provided an evaluation metric of radiation 
sensitivity based on changes in tumor size in response to radiation therapy (Figure 4-11). 
Patients with a complete or partial response to radiation (greater than 30% decrease in 
tumor size) were classified as radiation-sensitive, and patients with stable or progressive 
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disease (either less than 30% decrease in tumor size, or increase in tumor size) were 
classified as radiation-resistant. If a patient received multiple courses of radiation therapy, 
they were classified based on the response to their first course. Using this classification, 
716 personalized FBA models of radiation-sensitive patients and 199 personalized models 
of radiation-resistant patients were generated. 
 
Figure 4-11. Classification of TCGA patient tumors into radiation-sensitive and 
radiation-resistant groups from recorded decreases/increases in tumor size after 
radiation therapy. 
4.3.2 Compartmental differences in redox metabolic fluxes 
Personalized FBA models of TCGA samples were first used to predict the 
capabilities of tumor cells to increase their cellular stores of reduced redox couples, which 
would in turn increase their antioxidative capacity and reduce ROS-mediated damage from 
ionizing radiation [51, 207]. Radiation-resistant tumor models were capable of producing 
significantly elevated levels of reduced cofactors NADPH, NADH, and glutathione (Figure 
4-12). To validate model predictions, we performed experimental measurements in 
matched pairs of radiation-sensitive and -resistant cell lines across three different cancer 
types (Table 4-3). Two of the three radiation-resistant cell lines had significantly more 
reduced glutathione half-cell potentials than their matched radiation-sensitive cell line; 
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additionally, the BRCA cell line pair with a more reduced Ehc in the radiation-sensitive cell 
line had a much smaller observed difference compared to the other two pairs (Figure 4-13).  
 
Figure 4-12. FBA-predicted production of reduced NADPH, NADH, and glutathione 
(GSH) in TCGA tumors. 
 
 




While the total cellular production of NADPH was elevated in radiation-resistant 
tumor models, production of NADPH in the cytosol was not increased; interestingly, 
mitochondrial NADPH production accounted for the differences seen between radiation-
sensitive and -resistant tumors (Figure 4-14). Mitochondrial stores of NAD(P)H are 
required by enzymes localized to the mitochondria, many of which are involved in 
nucleotide metabolism, including dihydrofolate reductase and dihydroorotate 
dehydrogenase [223, 224]. In agreement with this observation, radiation-resistant tumor 
models were capable of producing increased levels of deoxynucleotides, suggesting 
increased capacity for DNA-damage repair following exposure to ionizing radiation 
(Figure 4-15) [201]. On the other hand, fatty acid production relies heavily on cytosolic 
stores of NAD(P)H; FBA models indicate no significant differences in production of fatty 
acid precursors including palmitate, suggesting a lesser role of cytosolic NADPH in 
differentiating metabolic phenotypes between radiation-sensitive and radiation-resistant 
tumors (Figure 4-15) [58]. 
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Figure 4-14. Comparison of FBA-predicted cytosolic and mitochondrial production 
of reduced NADPH. 
 
 
Figure 4-15. Downstream effects of increased mitochondrial but not cytosolic 
NADPH production in radiation-resistant tumor models. (Left) Overall production 
of deoxynucleotides. (Right) Overall palmitate production. 
Flux variance analysis (FVA) was used to compare the average fluxes through major 
NADPH-generating metabolic reactions between radiation-sensitive and -resistant tumors 
(Figure 4-16). Surprisingly, predicted fluxes through major cytosolic reactions including 
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G6PD and PGD were greater in radiation-sensitive tumors compared to -resistant tumors; 
this observation is in agreement with previously identified flux distributions in matched 
radiation-sensitive and -resistant head and neck cancer cell lines [206]. On the other hand, 
predicted fluxes through major mitochondrial reactions including GLUD1/2, ME2/3, NNT, 
IDH2, and MTHFD2 were greater in radiation-resistant tumors, allowing these tumors to 
maximize mitochondrial NADPH stores. Hierarchical clustering of NADPH-producing 
fluxes yielded pronounced separation of cytosolic and mitochondrial reactions except for 
the folate-associated reactions MTHFD1 and MTHFD2, both of which displayed increased 
fluxes in radiation-resistant tumor models (Figure 4-17). The majority of radiation-resistant 
tumors formed a few distinct clusters characterized by increased fluxes through 
mitochondrial and folate-dependent NADPH-producing reactions. Clustering of samples 
based on radiation response was found to be significantly greater than based on other 
clinical factors including cancer type, as measured by the silhouette coefficient between 
samples (Figure 4-18). Collectively, these results demonstrate that differences in 




Figure 4-16. (Left) Major NADPH-producing reactions with their associated cellular 
compartments and metabolic pathways. (Right) FVA-predicted average fluxes 
through major NADPH-producing reactions. Average fluxes were calculated as the 
mean of minimum and maximum fluxes through each reaction while maintaining 
maximum total NADPH production. IDH1 fluxes were separated based on tumors 
with IDH1 R132 mutations (left) and wild-type IDH1 tumors (right). Reaction 




Figure 4-17. Hierarchical clustering of FVA-predicted fluxes based on TCGA 
patient tumor (rows) and NADPH-producing reaction (columns). Values are the Z-
score of reaction fluxes across all tumors for each individual reaction. 
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Figure 4-18. Silhouette coefficient between samples comparing radiation response 
and other clinical factors as cluster labels. For each factor, a more positive average 
silhouette coefficient signifies that samples cluster strongly together based on their 
factor value, and a more negative average silhouette coefficient signifies that 
samples cluster weakly based on their factor value (and that some other factor is 
likely to be the true separating factor). 
4.3.3 Heterogeneity in personalized metabolic flux profiles 
Although radiation-resistant tumor models displayed overall changes in redox 
metabolism compared to radiation-sensitive models, heterogeneity among the 199 
radiation-resistant tumors may result in divergent metabolic flux profiles and thus 
differences in optimal therapeutic strategies for improving radiation sensitivity [225]. To 
determine if patient clinical factors such as cancer type and stage could be used to 
distinguish radiation-resistant tumor models with differing metabolic phenotypes, the 
correlation between these clinical factors and predicted fluxes through major NADPH-
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generating reactions was determined (Figure 4-19). While cancer type, patient age, and 
tumor grade were highly correlated with predicted fluxes through most reactions, other 
factors were associated with a few select reactions. Smoking history (whether the patient 
was a current smoker, former smoker, or lifelong non-smoker) was highly associated with 
fluxes through G6PD and PGD, in agreement with previous experimental studies showing 
that exposure to cigarette smoke causes an upregulation of G6PD and shifts glucose 
metabolism towards the pentose phosphate pathway for increased NADPH production 
[226, 227]. Additionally, response to cisplatin treatment was highly associated with fluxes 
through mitochondrial reactions IDH2 and NNT; treatment with cisplatin has been 
previously reported to induce a mitochondrial-ROS response, which could lead to the 
upregulation of mitochondrial NADPH-generating enzymes [106, 228]. 
 
Figure 4-19. Correlation between patient clinical factors and predicted fluxes 
through major NADPH-producing reactions among radiation-resistant patients. 
Values are represented as the p-value of either the univariate regression (for 
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numerical factors) or 1-way ANOVA (for categorical factors) between reaction 
fluxes and clinical factor values. Statistically significant (p ≤ 0.05) associations are 
represented with black borders. 
Nonetheless, radiation-resistant patients with similar clinical factors may display 
stark differences in redox metabolism. Figure 4-20 illustrates personalized metabolic flux 
profiles of three radiation-resistant patients with head and neck squamous cell carcinoma, 
a cancer type characterized by high genetic and metabolic heterogeneity [229]. Although 
these three patients all have very similar clinical factors, the predicted fluxes through 
NADPH-generating reactions differ substantially; whereas some tumor models show 
increased NADPH generation through individual reactions (TCGA-T2-A6WZ: G6PD; 
TCGA-CN-6998: ME1), others show increased fluxes through multiple NADPH-
generating reactions (TCGA-HD-8224: ME1, ME2/3, NNT). These findings demonstrate 
the utility of personalized genome-scale metabolic models for identifying targets for 
inhibiting NADPH production and increasing radiation sensitivity in individual patients. 
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Figure 4-20. Personalized NADPH-generating flux profiles of three radiation-
resistant HNSCC patients, with their associated clinical factors. Radar chart values 
are the percentiles of reaction fluxes across all radiation-resistant tumors for each 
individual reaction. Patient profiles (red, filled) are shown overlaid on top of the 
profiles of all other radiation-resistant HNSCC profiles (black, not filled). 
4.3.4 Impact of IDH1 R132 mutations on glioma NADPH production 
Mutations in the NADPH-generating enzyme isocitrate dehydrogenase (IDH1) at 
amino acid position R132 are common in low grade gliomas and secondary high grade 
gliomas, classes of tumors that are commonly resistant to radiation therapy [230, 231]. 
These mutations affect IDH1 activity by both inhibiting the wild type enzyme’s normal 
function of reducing NADP+ to NADPH, and by causing the mutated enzyme to catalyze 
a neomorphic reaction involving the oxidation of NADPH to NADP+ as well as the 
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production of the oncometabolite 2-hydroxyglutarate (Figure 4-21) [215]. Thus, these 
mutations are expected to decrease cellular NADPH production via both a lack of 
production and a neomorphic consumption by IDH1. Previous experimental studies have 
investigated whether the lack of NADPH production or presence of NADPH consumption 
results in a greater depletion of NADPH levels; although most evidence points to the 
neomorphic reaction’s consumption of NADPH as the major cause of NADPH depletion, 
this question has yet to be resolved [81, 232]. 
 
Figure 4-21. Schematic demonstrating the relative magnitudes of normal (NADPH-
producing, isocitrate to α-ketoglutarate) and neomorphic (NADPH-consuming, α-
ketoglutarate to 2-hydroxyglutarate) IDH1 reactions in IDH1 wild-type (top) and 
IDH1 R132 mutation (bottom) tumors. 
Using experimentally-measured kinetic rates of wild-type and R132-mutant IDH1 
enzymes, separate FBA models of 104 IDH1 R132 patients were generated by 
implementing (1) wild-type normal (α-ketoglutarate-producing) and wild-type neomorphic 
(2-hydroxyglutarate-producing) reactions; (2) mutant normal and wild-type neomorphic 
reactions; and (3) mutant normal and mutant neomorphic reactions (Figure 4-22) [216]. 
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Changes in total cellular NADPH production were evaluated between models 1-2 to 
analyze the effect of the lack of NADPH production, and between models 2-3 to analyze 
the effect of the presence of NADPH consumption. Implementation of the mutant 
neomorphic reaction causes a substantially greater decrease in total cellular NADPH 
production compared to implementation of the mutant normal reaction in almost all patient 
tumors; thus, FBA models predict that the presence of NADPH consumption by mutant 
IDH1 is the major cause of NADPH depletion, in agreement with previous experimental 
studies. Because of the greater kinetic rate of the neomorphic NADPH-consuming reaction, 
NADPH production is predicted to cause the greatest impact in patients with IDH1 R132H 
mutations, the most common and well-characterized IDH1 mutation among gliomas, 
compared to R132C and R132G mutations (Figure 4-23) [216, 233]. However, the 
predicted decrease in cellular NADPH production due to mutant normal and neomorphic 
reactions is negligible compared to wild-type tumors, suggesting that IDH1 R132 
mutations do not significantly alter tumor NADPH production. Despite in vitro 
experiments demonstrating that overexpression of R132-mutant IDH1 results in increased 
sensitivity to radiation therapy, many patient tumors with the IDH1 R132 mutation are still 
radiation-resistant (74.0% of patients in TCGA), possibly due to a negligible effect on 
NADPH production by these mutations. 
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Figure 4-22. NADPH production in individual IDH1 R132C/G/H tumor models 
while implementing (1) wild-type normal and wild-type neomorphic reactions (left), 
(2) mutant normal and wild-type neomorphic reactions (middle), and (3) mutant 
normal and mutant neomorphic reactions (right). Values are normalized relative to 





Figure 4-23. Comparison of the effect of implementing mutant normal and mutant 
neomorphic reactions (right column of Figure 4-22) between IDH1 R132C, R132G, 
and R132H tumors. 
4.3.5 Simulated genome-wide knockout screen for identifying redox targets 
FBA models enable the assessment of changes in metabolic phenotypes in response 
to knockout of a particular metabolic enzyme-encoding gene, providing insight into the 
gene’s role in genome-scale metabolism. A simulated genome-wide knockout screen was 
performed to predict the effect of knocking out each individual gene in Recon3D on total 
cellular NADPH production across all radiation-sensitive and radiation-resistant tumor 
models (Figure 4-24). Most gene knockouts did not significantly decrease total NADPH 
production, providing evidence for the ability of metabolic networks to redirect flux 
through alternate, compensatory pathways following perturbation in order to optimize 
NADPH production [206]. Among the top knockouts across all patient tumors were genes 
directly involved in NADPH generation, including G6PD, GLUD1, ME1, and H6PD. 
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Additionally, knockout of genes involved in glycolysis (ALDOA, GAPDH, PKM, 
PGAM1, ENO1, HK1, GPI) resulted in significant NADPH depletion, demonstrating the 
strong interconnection between central carbon metabolism and NADPH generation [234]. 
There was also significant depletion of NADPH for genes involved in folate metabolism 
(DHFR), amino acid metabolism (PYCR2), and portions of pentose phosphate pathway not 
directly involved in NADPH production (PGLS). 
 
Figure 4-24. Effect of simulated knockout of each individual gene in Recon3D on 
total NADPH production in TCGA tumors. Values are the ratio of total NADPH 
production after versus before knockout. Genes are rank ordered based on 
increasing mean KO/WT ratio value (decreasing gene knockout effect) across all 
tumor models. Outset: KO/WT ratio values are averaged across all tumor models. 
Inset: For the top 15 genes, KO/WT ratio values from individual patient tumor 
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models are shown, along with the statistical significance of the comparison between 
radiation-sensitive and -resistant values. 
A statistical comparison on the effect of each gene knockout on NADPH production 
was performed to determine which knockouts have the greatest differential effect in 
radiation-resistant versus radiation-sensitive tumors. (Figure 4-25). 26 gene knockouts 
caused a significantly greater decrease in NADPH production among radiation-resistant 
tumors compared to radiation-sensitive tumors (log2[Average Effect in Resistant Tumors / 
Average Effect in Sensitive Tumors] > 0; FDR-adjusted p-value < 0.05), and 24 gene 
knockouts caused a significantly greater decrease among radiation-sensitive tumors 
(log2[Resistant/Sensitive] < 0; FDR-adjusted p-value < 0.05). In agreement with observed 
differences in NADPH-generating reaction fluxes, knockout of genes directly involved in 
mitochondrial NADPH production (GLUD1/2, IDH2, ME2) and folate metabolism 
(MTHFD1, MTHFR) caused a greater predicted decrease in NADPH production in 
radiation-resistant tumors, while those involved in cytosolic NADPH production (G6PD, 
PGD) and other members of the pentose phosphate pathway (PGLS, RPE, RPIA, 
TALDO1, TKT) caused a greater decrease in radiation-sensitive tumors. Additionally, 
many aldehyde dehydrogenase genes (ALDH1L1, ALDH1L2, ALDH5A1) showed greater 
predicted decrease in NADPH production in radiation-resistant tumors, consistent with 




Figure 4-25. Volcano plot comparing the effect of each simulated gene knockout 
(individual dot) on total NADPH production between radiation-sensitive and 
radiation-resistant tumors. X-axis: log2(Resistant/Sensitive), where “Resistant” 
equals the mean (WT-KO)/WT ratio in radiation-resistant tumors, and “Sensitive” 
equals the mean (WT-KO)/WT ratio in radiation-sensitive tumors; values < 0 (green 
dot on the left of the dotted line) signifies that a knockout has a greater effect on 
total NADPH production in radiation-sensitive tumors, whereas values > 0 (red dot 
on the right of the dotted line) signifies that a knockout has a greater effect on total 
NADPH production in radiation-resistant tumors. Y-axis: statistical significance 
(false discovery rate-adjusted p-values based on the Benjamini-Hochberg 
procedure) of comparison of knockout effects between radiation-sensitive and 
radiation-resistant tumors; values above the dotted line (FDR-adjusted p-value ≤ 
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0.05) are statistically-significant. The size of each dot is proportional to the overall 
effect size (mean (WT-KO)/WT ratio across all tumor models regardless of 
radiation sensitivity). 
A similar analysis was performed to predict gene knockouts with significant effects 
on glutathione reduction (Figure 4-26, Figure 4-27). Although many genes showed 
overlapping effects between their impact on NADPH reduction and glutathione reduction, 
there were some notable differences. For instance, folate metabolism genes MTHFD1 and 
MTHFR were predicted to have greater impacts on glutathione reduction in radiation-
sensitive tumors. Additionally, many pentose phosphate genes including G6PD, PGD, and 
members of the non-oxidative pathway were not predicted to significantly affect 
glutathione reduction. New gene targets arose having significant impacts on glutathione 
reduction, including genes involved in the TCA cycle (DLST, FH, OGDH, SDHA, 
SUCLG2), oxidation-reduction reactions (AKR1A1, GSR, PRDX6), and glycine 
metabolism (AMT, GCSH, GLDC), which have been previously shown to impact 
GSH/GSSG ratios and ROS levels in cancer [235]. 
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Figure 4-26. Effect of simulated knockout of each individual gene in Recon3D on 
total GSH production. Values are the ratio of total GSH production after versus 
before knockout. Genes are rank ordered based on increasing mean KO/WT ratio 
value (decreasing gene knockout effect) across all tumor models. Outset: KO/WT 
ratio values are averaged across all tumor models. Inset: For the top 15 genes, 
KO/WT ratio values from individual patient tumor models are shown, along with 





Figure 4-27. Volcano plot comparing the effect of each simulated gene knockout on 
total reduced glutathione production between radiation-sensitive and radiation-
resistant tumors. Genes tested by experimental siRNA knockdown studies are 
bolded. 
To validate model-predicted targets of glutathione metabolism, the change in 
glutathione half-cell potential (ΔEhc GSH/GSSG) between siRNA knockdowns and 
negative control siRNA-transfected cells was measured in both radiation-sensitive and -
resistant cell lines for 18 different gene targets (Figure 4-28). The difference in ΔEhc 
between -resistant and -sensitive cell lines (ΔEhcResistant - ΔEhcSensitive) is greater than 
0 if the gene knockdown causes greater oxidation in the radiation-resistant cell line, 
corresponding to a model-predicted log2(Resistant/Sensitive) greater than 0. The t-statistic 
of the 1-sample t-test comparing the three experimentally-measured values of ΔEhcRes - 
ΔEhcSens to the null hypothesis population mean of zero (equal effect in radiation-sensitive 
and -resistant cell lines) also has the same sign as model-predicted log2(Resistant/Sensitive) 
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if model and experiment are in agreement. 4/6 model-predicted radiation-resistant targets 
also had more oxidative effects in the radiation-resistant cell lines; the other two targets 
(TPI1 and ALDH1L1) each had one cell line pair with more oxidative effects in the 
radiation-resistant cell line. While some model-predicted radiation-sensitive targets had 
more oxidative effects in the radiation-resistant cell lines, those targets with the largest 
predicted differential effect (PRDX6, SUCLG2, MTHFR, and GSR) all had more oxidative 
effects in the radiation-sensitive cell lines. These results suggest that FBA models of TCGA 
tumors can accurately predict gene targets which differentially affect glutathione 
production in radiation-sensitive and -resistant cancers. 
 
Figure 4-28. (Left) Schematic showing the measurement of ΔEhc in radiation-
sensitive and -resistant cancer cell lines. (Right) Comparison of model-predicted and 
experimentally-measured effects of gene knockdown on reduced glutathione 
production. Top 3 rows: ΔEhcRes - ΔEhcSens in siRNA knockdowns across all three 
cell line pairs. Middle row: t-statistic from 1-sample t-test comparing the three 
experimentally-measured values of ΔEhcRes - ΔEhcSens to the null hypothesis 
population mean of zero (equal effect in radiation-sensitive and -resistant cell lines). 
Bottom row: model-predicted log fold change in gene knockout effect on reduced 
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glutathione production between radiation-resistant and -sensitive TCGA tumor 
models. 
4.3.6 Disparities in redox metabolism and H2O2-scavenging systems 
Reactive oxygen species including H2O2 contribute significantly to the DNA 
damage and cellular death caused by ionizing radiation therapy [197, 198]. As expected, 
FBA models of radiation-resistant tumors were capable of significantly increased H2O2 
clearance compared to radiation-sensitive tumors (Figure 4-29). To validate model 
predictions of response to ROS, cancer cell line pairs were treated with 10 mU/mL of 
glucose oxidase for 2 hours; when added to the extracellular medium with non-limiting 
levels of glucose, this enzyme produces hydrogen peroxide at levels that remain consistent 
for up to 8 hours, as compared to providing a bolus of extracellular hydrogen peroxide 
which can decrease to half its original concentration in as little as 15 minutes [236, 237]. 
Two of the three radiation-resistant cell lines showed a lesser decrease in cell viability 
when treated with 10 mU/mL glucose oxidase compared to their matched -sensitive cell 
lines, while the other pair showed no significant difference (Figure 4-30). The differential 
effect of glucose oxidase within the cell line pairs matches very well with the observed 
differences in glutathione half-cell potential, suggesting that reduced glutathione stores are 
utilized for H2O2 clearance in these cell lines. 
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Figure 4-29. Model-predicted total clearance of H2O2 in TCGA tumors. 
 
Figure 4-30. Experimentally-measured response of radiation-sensitive and -resistant 
cancer cell lines to 10 mU/mL of glucose oxidase, calculated as the relative cell 
viability compared to 0 mU/mL glucose oxidase. 
To determine the most important contributors to the increased H2O2 clearance 
observed in radiation-resistant tumor models, an assessment of the major cellular H2O2-
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clearing systems, including catalase (CAT), glutathione peroxidase (GPx), glutaredoxins 
(Grx), peroxiredoxins (Prx), and thioredoxins (Trx), was performed (Figure 4-31). Many 
of these systems utilize varying isoforms in different cellular compartments, leading to 
compartmental differences in enzyme abundances. Additionally, while the same CAT 
isoform is found in many different cellular compartments, compartmental pH differences 
lead to differences in observed catalytic rates. Finally, cellular stores of NADPH and 
glutathione cofactors that these systems rely on vary significantly between compartments, 
imposing limits on the maximum fluxes through these metabolic enzymes. All of these 
important considerations are taken into account with our bioinformatics and modeling 
pipeline, as opposed to more traditional modeling approaches such as small-scale kinetic 
models and genome-scale models without kinetic constraints. The majority of H2O2-
clearing fluxes predicted from flux variance analysis did not differ significantly between 
radiation-sensitive and -resistant tumors. However, 3 of the mitochondrial H2O2-clearing 
fluxes (CAT, GPx, Grx) showed significantly greater fluxes in radiation-resistant tumors, 
accounting for the increased overall capacity for H2O2 clearance. This is in agreement with 
previous findings of increased capacity for mitochondrial NADPH reduction as opposed to 
cytosolic NADPH reduction in radiation-resistant tumor models (Figure 4-14). 
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Figure 4-31. FVA-predicted average fluxes through major H2O2-clearing reactions. 
Average fluxes were calculated as the mean of minimum and maximum fluxes 
through each reaction while maintaining maximum total H2O2 clearance. Inset: 
Major H2O2-clearing reactions with their associated cellular compartments and 
compartment-specific isoforms. 
A simulated genome-wide knockout screen was then performed to identify additional 
targets affecting overall H2O2 clearance in radiation-resistant tumors (Figure 4-32). 
Interestingly, while few genes directly involved in H2O2 clearance were found to be 
significant targets (except CAT), many of the same targets from the NADPH knockout 
screen were significant targets with similar differential effects between radiation-sensitive 
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and -resistant tumors. Knockout of cytosolic NADPH production genes (G6PD, PGD) and 
other members of the pentose phosphate pathway (PGLS, RPE, RPIA, TALDO1, TKT) 
showed significantly greater effects in radiation-sensitive tumor models, whereas knockout 
of genes involved in mitochondrial NADPH production (GLUD1/2), central carbon 
metabolism (ACO2, ALDOC, GAPDH, PGAM2, PKM), and folate metabolism 
(MTHFD1, MTHFD2, MTHFR) showed greater effects in radiation-resistant tumor 
models. To validate these targets, Bliss independence scores showing the effect of siRNA 
gene knockdown on glucose oxidase response were measured in radiation-sensitive and -
resistant cell lines for 9 different gene targets (Figure 4-33).  The difference in Bliss score 
between -sensitive and -resistant cell lines (BlissSensitive - BlissResistant) is greater than 0 if the 
gene knockdown causes a greater decrease in cell viability with glucose oxidase treatment 
in the radiation-resistant cell line, corresponding to a model-predicted 
log2(Resistant/Sensitive) greater than 0. The t-statistic of the 1-sample t-test comparing the 
three experimentally-measured values of BlissSensitive - BlissResistant to the null hypothesis 
population mean of zero (equal effect in radiation-sensitive and -resistant cell lines) also 
has the same sign as model-predicted log2(Resistant/Sensitive) if model and experiment 
are in agreement. Although all but one (ALDH1L1) gene knockdown resulted in a greater 
response to glucose oxidase in the radiation-resistant cell lines, three of the model-
predicted radiation-resistant targets (GLUD1, MTHFD1, and PGAM2) had the largest 
differential response across all siRNA’s tested. Additionally, each of the four radiation-
sensitive targets (CPT2, G6PD, PGD< and TKT) had a greater response in at least one of 
the radiation-sensitive cell lines. Interestingly, TCGA models accurately predicted that 
MTHFD1 knockdown would have a greater effect on glutathione reduction in radiation-
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sensitive cancers but a greater effect on H2O2 response in radiation-resistant cancers, 
suggesting that FBA models accurately capture other metabolic systems which impact ROS 
clearance besides glutathione-dependent pathways. Overall, the agreement between model 
predictions and experimental validation demonstrates the ability of FBA models to 
correctly identify novel targets of redox metabolism which differentially impact radiation-
resistant cancers. 
 
Figure 4-32. Volcano plot comparing the effect of each gene knockout on total H2O2 
clearance between radiation-sensitive and radiation-resistant tumors. Genes tested 




Figure 4-33. (Left) Schematic showing the measurement of Bliss independence 
scores in radiation-sensitive and -resistant cancer cell lines. (Right) Comparison of 
model-predicted and experimentally-measured effects of gene knockdown on H2O2 
clearance. Top 3 rows: BlissSens - BlissRes in siRNA knockdowns across all three cell line 
pairs. Middle row: t-statistic from 1-sample t-test comparing the three 
experimentally-measured values of BlissSens - BlissRes to the null hypothesis population 
mean of zero (equal effect in radiation-sensitive and -resistant cell lines). Bottom 
row: model-predicted log fold change in gene knockout effect on H2O2 clearance 
between radiation-resistant and -sensitive TCGA tumor models. 
4.4 Discussion 
The role of reactive oxygen species (ROS) formation on oxidative DNA damage and 
ultimately cellular death during ionizing radiation treatment has been well characterized; 
however, the identification of targets within the redox metabolic network which may 
impact antioxidation, ROS response, and sensitivity to radiation therapy is still ongoing 
[238]. Initial studies identified G6PD as an important contributor of cellular stores of 
NADPH, which is used for both biosynthetic/repair processes as well as antioxidation via 
reduction of glutathione and thioredoxin [239, 240]. Enzymes involved in central carbon 
metabolism, including GLUT1, PFK, and PK were later found to significantly impact 
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radiation response and viewed as potential targets for improving radiation sensitivity [16, 
241-244]. Systems biology studies using genome-scale datasets have recently provided 
unbiased approaches towards discovery of metabolic targets implicated in radiation 
response, including FAS, LDH, and PRDX1/2 [175]. However, our bioinformatics and 
metabolic modeling pipeline represents, to our knowledge, the first study to integrate 
multiple -omic datasets into genome-scale mechanistic models to compare redox 
metabolism between radiation-sensitive and radiation-resistant tumors, as well as to 
identify novel biomarkers which could be targeted to improve radiation therapy response. 
Because redox cofactors such as NADPH are involved in nearly one thousand 
reactions throughout the human metabolic network, genome-scale FBA models are well-
suited to study redox metabolism and their interconnections with other metabolic processes 
[7]. Nonetheless, few studies have used FBA models for studying cancer redox 
metabolism. Fan et al. developed an FBA model of immortalized baby mouse kidney 
epithelial cells to identify major contributors to the cellular NADPH pool, finding that 
folate-dependent enzymes MTHFD1 and MTHFD2 contributed to NADPH production as 
much as the more commonly-studied enzyme G6PD [144]. Although experimentally 
measured uptake/excretion fluxes and growth rates were used to constrain their model, 
most reactions were not constrained by cell type-specific information such as 
transcriptomic data, which is commonly used to set bounds on maximum reaction fluxes 
[11]. Additionally, their use of parsimonious flux balance analysis (minimizing total sum 
of fluxes while maintaining experimentally-measured fluxes and growth rates) yields 
single values for each reaction flux which do not capture the biological variability in 
metabolic fluxes as well as flux variance analysis [245]. Benfeitas et al. later developed 
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FBA models of hepatocellular carcinomas (HCC) to characterize heterogeneity in redox 
metabolism between HCC tumors at differing stages of progression and within different 
HCC tumor clusters [246]. Using these models, the authors discovered distinct differences 
in NADPH production and H2O2 clearance between HCC tumors with high G6PD 
expression and those with high ALDH2 expression. However, their use of the MADE 
algorithm for converting transcriptomic data into upper flux bounds results in discrete 
reaction constraints which lack quantitative accuracy compared to using continuous 
enzyme abundance values. Furthermore, kinetic and thermodynamic effects on reaction 
constraints, which have significant impacts on metabolic fluxes, were not present in their 
models [12]. Our approach overcomes these methodological shortcomings by 
incorporating transcriptomic and mutational data from individual patient tumors, as well 
as genome-scale kinetic and thermodynamic parameter values, into quantitative constraints 
on metabolic fluxes, allowing for more accurate predictions of metabolic differences 
between radiation-sensitive and -resistant tumors (Figure 4-10). 
Our previous FBA modeling and experimental analysis of radiation-sensitive and -
resistant head and neck cancer (HNSCC) cell lines suggested that radiation-resistant 
cancers were capable or rerouting flux through alternative metabolic pathways in order to 
achieve maximal production of redox cofactors including NADPH and NADH [206, 207]. 
This flux rerouting was also seen in our FBA models of radiation-resistant TCGA tumors, 
as increased flux through mitochondrial NADPH-producing reactions allowed for 
increased mitochondrial stores of reduced redox cofactors as well as increased fluxes 
through mitochondrial H2O2-clearing reactions (Figure 4-14, Figure 4-31). While 
mitochondrial-specific compartmentalization of signaling and energy metabolism has been 
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previously identified to impact chemotherapy and radiation response, mitochondrial 
compartmentalization of antioxidant stores for protection against ROS-mediated damage 
from ionizing radiation has not been well characterized; nonetheless, mitochondrial 
NADPH-producing enzymes identified from this study, including GLUD1, IDH2, ME2, 
and NNT, have been previously implicated in regulation of oxidative stress and tumor 
proliferation, and their targeting for increasing radiation sensitivity should be explored 
[247-252]. Additionally, simulated gene knockdown screens and validation with 
experimental siRNA knockdown experiments suggested that genes involved in 
mitochondrial (GLUD1/2) and folate-dependent (MTHFD1) NADPH production, as well 
as central carbon metabolism genes (LDHB, PGAM) may be novel targets for inhibiting 
reduced glutathione production and/or H2O2 clearance in radiation-resistant tumors (Figure 
4-28, Figure 4-33). On the other hand, G6PD, the most well-studied NADPH-producing 
reaction, actually exemplified larger fluxes in radiation-resistant tumor models and showed 
lower experimental effects on targeted H2O2 clearance in radiation-resistant cell lines 
compared to the aforementioned gene targets. Interestingly, the G6PD cluster identified by 
Benfeitas et al. in hepatocellular carcinomas (HCC) is highly enriched in genes identified 
from this current study as radiation-sensitive targets (ALDOA, G6PD, PGD, RPE, RPIA), 
whereas the ALDH2 cluster is highly enriched in genes identified as radiation-resistant 
targets (ALDH2, ALDH5A1, ALDH6A1, CAT, MTHFD1, SHMT1) [246]. Despite the 
fact that the authors were not analyzing redox metabolism in the context of radiation 
sensitivity, this correspondence between gene sets from separate analyses may suggest that 
there exist two fundamental tumor subtypes with distinct redox metabolic phenotypes and 
corresponding radiation sensitivities. 
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With FBA models of patient tumors, personalized metabolic flux profiles can be 
generated to identify optimal gene targets for clinical subsets or individual radiation-
resistant patients (Figure 4-20). These personalized metabolic predictions also demonstrate 
the significant amount of heterogeneity in redox metabolism between patient tumors. 
While the majority of initiatives for precision/personalized cancer treatment has focused 
on mutations and expression differences in signaling pathway proteins, a greater focus on 
exploiting metabolic differences between patient tumors is currently being made [253]. For 
example, heterogeneity in glycolytic metabolism is being used to identify diagnostic 
biomarkers and treatment strategies for both pancreatic cancer and acute myeloid leukemia 
patients [254, 255]. Personalized nutrition may also be a viable strategy for manipulating 
tumor metabolism, including redox metabolism, in individual patients; most NADPH-
generation pathways are supplied by glucose and glutamine intake, and folic acid levels 
may impact folate-dependent reactions [256, 257]. Continued development of genome-
scale metabolic models of individual patient tumors will undoubtedly aid in the 
identification of novel metabolic targets or optimal nutrition strategies for individual cancer 
patients. 
Some differences in predictions arose between these FBA-based metabolic models 
and previous computational models of redox metabolism, mainly in the relative flux 
magnitudes of H2O2-clearing enzymes. In their ODE-based models of H2O2 elimination in 
Jurkat T cells, Adimora et al. predicted that catalase was insignificant in its contribution to 
steady-state H2O2 clearance; instead, the major contributors to H2O2 elimination were 
predicted to be glutathione peroxidase, peroxiredoxin, and thioredoxin (involving 
reduction of the protein dithiol pool) [237]. However, the authors only included 
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peroxisomal catalase in their model construction, and mentioned that the low peroxisomal 
content of Jurkat cells as well as low diffusion rate of H2O2 from the cytosol into 
peroxisomes could lead to the small predicted contribution of catalase. There are also 
known differences in enzyme utilization for H2O2 clearance based on the observed H2O2 
concentration; while other enzymes may dominate at lower concentrations, catalase has 
been shown to be the primary scavenging enzyme at higher H2O2 concentrations which can 
be induced by ionizing radiation therapy and cause double-stranded DNA breaks [258-
261]. Prior studies on catalase have focused on the predominant peroxisomal form, as well 
as its cytosolic form which varies between cell types due to differences in membrane 
localization [74, 262-264]. Nonetheless, mitochondrial catalase has been detected and 
shown to mitigate cellular damage caused by mitochondrially-produced ROS [265-267]. 
Our FBA models predicted that while peroxisomal catalase did not show significant flux 
differences between radiation-sensitive and radiation-resistant tumors, mitochondrial 
catalase showed significantly higher fluxes in radiation-resistant tumors. Even though the 
magnitudes of mitochondrial catalase flux predicted from these FBA models may be higher 
than expected due to the use of the COMPARTMENTS database to calculate relative 
catalase distribution as well as the lack of transport constraints on H2O2 diffusion between 
cellular compartments, the observation of higher fluxes in radiation-resistant tumor models 
is consistent with greater mitochondrial NADPH generation which was also observed. 
Despite the recent increase in experimental metabolomics studies towards identifying 
altered metabolic phenotypes in cancer, an integrated assessment of the 13,000+ human 
metabolic reactions and their collective impact on individualized treatment response is 
currently infeasible using solely experimental approaches [268]. Instead, computational 
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approaches which integrate multi-omic measurements and global reconstructions of human 
metabolism into predictive models provide tremendous utility in improving our 
understanding of pathophysiological processes and discovering personalized metabolic 
targets [10]. In this study, we have shown that flux balance analysis models of individual 
patient tumors can identify important differences in redox metabolism between radiation-
sensitive and -resistant tumors. Specifically, radiation-resistant tumors can upregulate 
metabolic flux through mitochondrial NADPH-generating and H2O2-clearing reactions to 
increase cellular antioxidant stores, decrease levels of reactive oxygen species, and resist 
the damaging effects of ionizing radiation treatment. Additionally, these metabolic models 
identified novel targets in the redox metabolic network that significantly impact antioxidant 
production and ROS response, both across the entire radiation-resistant cohort as well as 
in individual patient tumors. These targets represent potential biomarkers for the a priori 
prediction of radiation sensitivity, as well as therapeutic strategies for sensitizing tumors 
to radiation therapy. Ultimately, the development of personalized metabolic models has the 
potential to facilitate the clinical management of cancer patients and improve long-term 
outcomes.  
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CHAPTER 5. MACHINE LEARNING CLASSIFIERS FOR 
PREDICTION OF RADIATION RESPONSE 
5.1 Introduction 
Tumor resistance to radiation therapy has been attributed to multiple 
pathophysiological mechanisms, including alterations in cellular metabolism, signaling, 
and DNA damage repair [15, 16, 269]. Despite recent advancements in our biological 
understanding of radiation resistance, methodologies for the a priori prediction of radiation 
response in individual cancer patients have yet to be implemented clinically. The ability of 
predicting therapeutic response would ensure that cancer patients only receive optimal 
therapies tailored to that individual, thereby improving patient outcomes, preventing 
unnecessary side effects, and decreasing overall healthcare costs. 
Statistical methods for identifying clinical biomarkers for predicting radiation 
therapy response have been used for decades. Early studies focused on correlations 
between radiation response and clinical factors including tumor staging, primary site, and 
Karnofsky performance score [31, 33]. The inclusion of physiological parameters such as 
tumor oxygenation status resulted in improved predictions of radiation sensitivity [35, 36]. 
Predictors using clinical information later switched from classical statistical methods to 
newer machine learning algorithms which enabled improvements in accuracy and 
biomarker detection [270-272]. As methods for transcriptomic analysis improved with 
microarrays and later RNA-seq, gene expression-based classifiers for radiation response 
rose to popularity and have recently been curated by the RadiationGeneSigDB database 
[46, 273-283]. These classifiers span a wide range of feature count (from a handful to 
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many-thousand), statistical or machine learning method used for biomarker detection, and 
original gene expression dataset. However, there is currently a lack of radiation response 
classifiers which integrate multiple -omics modalities. While genomic and transcriptomic 
data is becoming more widely available for large numbers of patient tumors through 
initiatives such as The Cancer Genome Atlas, metabolomic data from these tumors is 
lacking, limiting its use in predictive models for radiation therapy response [2]. 
Genome-scale metabolic modeling approaches such as flux balance analysis (FBA) 
are becoming increasingly popular for predicting metabolic phenotypes in individual 
cancer cell lines or tumors of interest [9, 10, 284]. By combining a curated reconstruction 
of the human metabolic network with constraints on metabolic reaction activities and an 
objective function to maximize a particular metabolic phenotype, predictions of steady-
state reaction fluxes or metabolite production rates under physiological constraints can be 
obtained at a genome scale. We previously developed a novel bioinformatics pipeline for 
integrating genomic, transcriptomic, kinetic, and thermodynamic parameters into 
personalized FBA models of 716 radiation-sensitive and 199 radiation-resistant patient 
tumors across multiple cancer types from TCGA. Using these personalized metabolic 
models, we discovered that radiation-resistant tumors could upregulate levels of reduced 
redox cofactors such as NADPH and glutathione to increase antioxidant stores and 
clearance of reactive oxygen species (ROS) generated from ionizing radiation. We then 
identified novel targets of redox metabolism which could inhibit antioxidant production 
and ROS-clearance in radiation-resistant cancers; these model predictions were validated 
by performing siRNA gene knockdown experiments in a panel of matched radiation-
sensitive and radiation-resistant cancer cell lines. With these models, we also demonstrated 
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the ability to predict metabolic phenotypes in individual patient tumors, which could be 
used to inform personalized diagnostic and therapeutic strategies. Thus, these models 
provide accurate genome-scale metabolic predictions in tumor samples with little available 
experimentally-measured metabolomics information. 
While machine learning methods have been previously combined with genome-scale 
metabolic models to improve prediction of metabolic phenotypes, most studies combining 
these two methodologies have focused on microbiological applications rather than 
applications to cancer metabolism or predicting treatment outcomes [285]. We hypothesize 
that output predictions from personalized genome-scale metabolic models of individual 
patient tumors would not only provide an additional -omics dataset to better understand 
pathophysiological differences between radiation-sensitive and -resistant tumors at a 
systems level, but could also be integrated with clinical, genomic, and transcriptomic data 
to develop accurate machine learning classifiers for the a priori diagnosis of radiation 
sensitivity in cancer patients. To this end, we developed a machine learning pipeline for 
integrating multi-omic data into machine learning classifiers which outperform previous 
predictors of radiation sensitivity. Additionally, we utilized recently-developed FBA 
models of TCGA patient tumors to predict production rates of metabolites across the 
human metabolic network, and incorporated these into machine learning classifiers to 
obtain novel metabolite biomarkers associated with sensitivity or resistance to radiation 
therapy. Finally, we demonstrate the capability to predict optimal multi-omic and non-





5.2.1 Computational methods 
5.2.1.1 TCGA data retrieval and processing 
Clinical data from TCGA patients was obtained from the GDC data portal (clinical 
drug, clinical patient, and clinical radiation files) and the Synapse TCGA_Pancancer 
project (biological sample files) [2, 286]. Drug names were standardized according to the 
standard available from the Gene-Drug Interactions for Survival in Cancer (GDISC) 
database [287]. Categorical clinical features were one-hot encoded before inputting into 
machine learning classifiers. RNA-Seq gene expression data was obtained from Rahman 
et al.’s alternative preprocessing method (Gene Expression Omnibus GSE62944) [211]. 
Data from this preprocessing method showed fewer missing values, more consistent 
expression between replicates, and improved prediction of biological pathway activity 
compared to the original TCGA pipeline. Mutation data using the MuTect variant caller 
was obtained from the GDC data portal [2, 288]. For all data types, only features with at 
least two unique non-missing values were included. 
5.2.1.2 Radiation sensitivity 
TCGA samples were classified into radiation-sensitive and radiation-resistant 
groups according to their reported sensitivity to radiation therapy based upon the RECIST 
classification method. Patients with a complete or partial response to radiation (greater than 
30% decrease in tumor size) were classified as radiation-sensitive, and patients with stable 
or progressive disease (either less than 30% decrease in tumor size, or increase in tumor 
size) were classified and radiation-resistant. If a patient received multiple courses of 
radiation therapy, they were classified based on the response to their first course. 
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5.2.1.3 Data splitting 
The collection of 716 radiation-sensitive and 199 radiation-resistant samples was 
randomly split into training+validation (80%) and testing (20%) groups. Within the 
training+validation group, 5-fold cross validation was performed to identify optimal 
hyperparameter values. The training (80%) group was used for training the model with a 
given set of hyperparameters; within this training group, 87.5% was directly used for 
training, and 12.5% was used to identify the optimal iteration to perform early stopping 
during training. The validation (20%) group was used to assess model performance with 
the given set of hyperparameters. The averaged validation performance across all 5 folds 
was used to determine the optimal set of hyperparameters; once this optimal set was 
determined, the model was retrained on the training+validation group, and the testing group 
was used to assess overall model performance. 20 iterations of randomized 
training+validation/testing splitting were performed to analyze model predictions and 
performance metrics over multiple instances. All data splits were performed using stratified 
shuffle splitting, where the proportion of radiation-sensitive and -resistant samples were 
kept the same between the two groups.  
5.2.1.4 Gradient boosting classifiers 
XGBoost (v0.90) was used to develop gradient boosting machine (GBM) base and 
meta learner classifiers [289]. Nd base classifiers were trained using individual -omic data 
types (e.g. clinical, gene expression, mutation, or FBA-predicted metabolomics), where Nd 
is the number of individual data types. For individual samples, each of the Nd base 
classifiers outputs the predicted probability of radiation resistance (p1, p2, …, pNd) using 
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features from the individual data type. Each base classifier receives the same 
training/validation/testing split of samples. 
Subsequently, for each sample within the 5 validation sets used with the Nd base 
learners, the best individual base learner is determined using the sample’s known radiation 
class and predicted probabilities of radiation resistance from the Nd base learners (e.g. the 
best base learner for a radiation-resistant sample is that which outputs the highest 
probability of radiation resistance for that sample). A meta learner is then trained using 
these samples to predict the best base learner based on sample features from all Nd data 
types. The meta learner outputs the predicted probability that each of the Nd base learners 
is the best for a particular sample (w1, w2, …, wNd). This multi-class classification is 
expedited by only using features from the Nd data types with non-zero SHAP values from 
the Nd individual base learners (see explanation of SHAP values below). Because 
validation samples from the 5-fold cross validation were never directly used in training the 
base learners (only used in assessing the accuracy of base learners and determining optimal 
hyperparameter values), they can be used to train this meta learner without overfitting or 
inflation of model performance metrics. Note that, once the meta learner is trained using 
the predicted probabilities from the base learners, the base learners and meta learner act 
independently of each other when used on new testing samples. 
Each testing sample is run through 1) all Nd base learners to obtain the predicted 
probabilities of radiation resistance using each of the Nd individual data types (p1, p2, …, 
pNd); and 2) the meta learner to obtain the predicted probabilities that each of the Nd base 
classifiers is the best classifier for that sample (w1, w2, …, wNd). To obtain the final 
predicted probability of radiation resistance for the testing sample, the weighted average 
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of the base learner probabilities is taken, with the meta learner probabilities as weights: p 
= w1p1 + w2p2 + … + wNdpNd. If this final probability is greater than 0.5, the testing sample 
is classified as radiation-resistant; otherwise, it is classified as radiation-sensitive. 
5.2.1.5 Bayesian optimization 
To determine the optimal combination of GBM hyperparameters for both the base 
learner and meta learner classifiers, Bayesian optimization was used. This iterative 
approach automates the search for optimal hyperparameter values by calculating an 
acquisition function which provides the expected benefit of sampling a particular point in 
hyperparameter space on the overall search for optimal hyperparameters with minimal 
cross-validation error. At each iteration, the point in hyperparameter space with the largest 
acquisition function value is chosen, 5-fold cross validation is used to determine the 
performance of those particular hyperparameters, and the acquisition function is updated 
to then determine which next point in hyperparameter space will be sampled. Hyperopt 
(v0.1.2) was used to perform Bayesian optimization [290]. Table 5-1 provides the 8 GBM 
hyperparameters chosen for optimization of both base learner and meta learner classifiers, 
with the ranges of values in the hyperparameter search space. 28=256 iterations of Bayesian 






Table 5-1. Hyperparameter ranges for Bayesian optimization with gradient boosting 
classifiers. 
Parameter Name Distribution Lower Bound Upper Bound 
eta log-uniform 0.01 0.5 
gamma log-uniform 0 5 
max_depth uniform 1 11 
subsample uniform 0.5 1 
colsample_bytree uniform 0.5 1 
colsample_bylevel uniform 0.5 1 
reg_lambda log-uniform 1 4 
reg_alpha log-uniform 0 1 
 
5.2.1.6 Model performance metrics 
Weighted log loss was used as the performance metric to be minimized while 
performing 5-fold cross validation and Bayesian optimization to determine optimal 
hyperparameter values for each base learner: 
 
Weighted Log Loss =
1
𝑁𝑠




where yi is the true class label of sample i (yi=0 if sensitive, yi=1 if resistant), pi is the 
predicted probability of sample i being radiation resistant (belonging to class 1), wR is the 
weight given to radiation-resistant samples (wR = # sensitive samples / # resistant samples), 
and NS is the total number of samples. The weight given to radiation-resistant samples 
accommodates for the fact that there are more radiation-sensitive samples than radiation-
resistant samples, and prevents classifiers from focusing on optimizing performance 
exclusively on radiation-sensitive samples rather than all samples equally. 
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Multiclass log loss was used as the performance metric for the meta learner: 
 









where yi,k is 1 if dataset k is the true optimal dataset of sample i and 0 otherwise, pi,k is the 
predicted probability of dataset k being the optimal dataset of sample i, NS is the total 
number of samples, and Nk is the total number of datasets. 
Final model performance was assessed on testing samples across the 20 iterations of 
randomized training+validation/testing splitting. The following performance metrics were 
used: 
1. Weighted log loss (explained above) 
2. Area under the receiver operating characteristic (ROC; plot of true positive rate vs. 
false positive rate) curve (AUROC) 
3. Balanced accuracy, an accuracy metric that corrects for unequal numbers of 
























6. Positive predictive value: 
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7. Negative predictive value: 
 




5.2.1.7 SHAP values 
The importance of individual features towards the prediction of radiation 
sensitivity, both averaged across all samples as well as for individual samples, was 
determined by calculating SHAP values for each classifier. Each SHAP value represents 
the change in the predicted probability of radiation resistance for patient i attributed to 
feature j [291]. Features with positive SHAP values for patient i signify those where the 
particular value of feature j attributed to patient i is such that it increases patient i’s 
predicted probability of radiation resistance; larger absolute SHAP values indicate features 
with larger contributions to the predicted probability (either negatively or positively). Mean 
absolute SHAP values across all samples provide an indication of the overall importance 
of a particular feature in the classifier’s prediction of radiation sensitivity. SHAP values 
were averaged across 20 training+validation/testing splits by a weighted average, with 
weights proportional to the inverse of the weighted log loss performance metric on the 
testing set for that split. Values were normalized by the difference between prior and 
posterior probabilities of radiation resistance for each sample. SHAP v0.29.1 was used to 





5.2.1.8 Comparison of machine learning algorithms 
sklearn.ensemble.RandomForestClassifier() and 
sklearn.linear_model.LogisticRegression() functions with scikit-learn v0.21.2 were used to 
implement random forest and logistic regression with L1 regularization classifiers, 
respectively. Keras v2.3.1 was used to implement the neural network with L1 
regularization classifier. Weighted log loss was used as the loss function for the neural 
network classifier, and early stopping was performed in the same manner as for the GBM 
classifier. Missing values were imputed and scaled using sklearn.impute.SimpleImputer() 
and sklearn.preprocessing.StandardScaler() functions, respectively, before training with 
the random forest, logistic regression, and neural network algorithms. Table 5-2, Table 5-3, 
and Table 5-4 provide the hyperparameters and value ranges used for Bayesian 
optimization with each algorithm. 20 training+validation/testing splits were performed for 
each algorithm except the neural network, where during 7/20 splits some samples were 
explicability dropped during training/testing, preventing the performance from these splits 
to be compared with other algorithms. 
Table 5-2. Hyperparameter ranges for Bayesian optimization with the random 
forest classifier. 
Parameter Name Distribution Lower Bound Upper Bound 
n_estimators log-uniform 1 1000 
criterion choice entropy, gini 
max_depth uniform 1 11 
min_samples_split uniform 0 1 
min_samples_leaf uniform 0 0.5 
max_features choice log2, sqrt 
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Table 5-3. Hyperparameter ranges for Bayesian optimization with the logistic 
regression classifier with L1 regularization. 
Parameter Name Distribution Lower Bound Upper Bound 
C log-uniform 0.001 1000 
 
Table 5-4. Hyperparameter ranges for Bayesian optimization with the neural 
network classifier with L1 regularization. 
Parameter Name Distribution Lower Bound Upper Bound 
Number of layers uniform 1 5 
Neurons per layer choice 8, 16, 32, 64, 128, 256, 512, 1024 
activation_function choice elu, relu, sigmoid 
optimizer Choice adam, rmsprop, sgd 
l1 log-uniform 0.000001 0.1 
dropout uniform 0 0.5 
 
5.2.1.9 Comparison of gene expression datasets 
11 oxic radiation response gene expression signatures from RadiationGeneSigDB 
were compared to the top genes from the gene expression classifier (782 genes with 
cumulative SHAP value sum of 95%). Gene names from RadiationGeneSigDB signatures 
were converted to Entrez gene ID’s and gene symbols. Those genes where a matching 
Entrez gene ID or gene symbol could not be found were removed. Additionally, those 




To compare performance of gene expression signatures on radiation sensitivity 
prediction using TCGA data, GBM classification models predicting radiation-sensitive vs. 
radiation-resistant classes of TCGA samples were trained using expression data from the 
subset of genes for each signature. The performance of these models was assessed via both 
weighted log loss and AUROC. To compare performance of gene expression signatures on 
radiation sensitivity prediction using CCLE data, GBM regression models predicting 
radiation response (reported as area under the curve of survival vs. radiation dose; [293]) 
of CCLE cell lines were trained using expression data from the subset of genes for each 
signature. The performance of these models was assessed via both mean absolute error 
(MAE) and mean squared error (MSE).  
5.2.1.10 Flux Balance Analysis (FBA) 
Generation of personalized FBA models of individual TCGA samples was 
performed as described above. To predict the maximum production of particular 
metabolites in TCGA models, the following objective function was used: 
 1 met[all] →   (34) 
where “met” is the metabolite to be maximized, and “[all]” represents the maximization of 
the objective function across all cellular compartments where the metabolite is 
located.  The modeled external compartment contained all metabolites found in DMEM/F-
12 cell culture media (Thermo Fisher #11320) as well as fetal bovine serum (FBS) to match 




5.2.1.11 Code availability 
Code for the generation of machine learning classifiers for radiation response using 
multi-omic TCGA data is available at https://github.com/kemplab/ML-radiation.  Jupyter 
notebooks are available for 1) training/testing of base learner classifiers; 2) training/testing 
of meta learner classifiers; 3) analysis of classifier predictions and feature importances.  
 
5.2.2 Experimental methods 
5.2.2.1 Cell culture 
Table 5-5 provides the matched radiation-sensitive and radiation-resistant cell lines 
used for experimental validation of metabolites levels predicted from FBA. All cell lines 
were maintained in DMEM/F-12 cell culture media (Thermo Fisher #11320) with 10% 
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Three biological replicates of each cell line were grown in separate T-25 flasks with 
the cell culture conditions described above. Cell pellets with approximately 1 million cells 
were obtained from trypsinization, centrifugation, and removal of supernatant. Samples 
were reconstituted in 90% MeOH, 10% H2O at a ratio of 200 μL/1 million cells. Aliquots 
of the supernatant were combined to create a pooled sample used for quality control. 
Aliquots of the samples were transferred to LC vials and stored at 4°C. 
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Hydrophilic interaction chromatography-tandem mass spectrometry (HILIC-
MS/MS) untargeted metabolomics was performed. Chromatography parameters were as 
follows: BEH HILIC Column, 150 mm X 2.1 mm, 1.7 μm; mobile phase A: 80% H2O / 
20% ACN, 10mM ammonium formate, 0.1% FA; mobile phase B: 100% ACN, 0.1% FA; 
column temperature: 40°C; 2 μL sample injection. MS parameters were as follows: 
resolution: 240,000; scan range: 70-1050 m/z; polarity: positive/negative; AGC target: 1e5. 
MS2 parameters were as follows: isolation window: 0.8 m/z; detector: Orbitrap; polarity: 
positive/negative; fragmentation method: HCD; collision energy: 15, 30, 45; resolution: 
30,000. 
Compound Discoverer 3.1 was used to perform quality control, metabolite 
identification, and quantification of metabolite levels. Results for positive and negative ion 
modes were combined. Metabolites with no identified name were initially removed from 
the analysis. If duplicate metabolites with the same identification were obtained, then the 
entry with the largest maximum area was used. KEGG ID’s for each metabolite were 
manually identified based on metabolite name, molar mass, and chemical formula. 
Metabolites from experimental metabolomics were matched to those from FBA analysis 
by matching KEGG ID’s. 
For the comparison of model-predicted and experimentally-measured metabolite 
values, all metabolites within the following Recon3D subsystems that were matched with 
experimental metabolites were included in the analysis: 
• Nucleotide Metabolism: “Nucleotide interconversion”, “Nucleotide salvage 
pathway”, “Pentose phosphate pathway”, “Purine catabolism”, “Purine synthesis”, 
“Pyrimidine catabolism”, “Pyrimidine synthesis” 
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• Lipid Metabolism: “Cholesterol metabolism”, “Fatty acid oxidation”, “Fatty acid 
synthesis”, “Glycosphingolipid metabolism”, “Phosphatidylinositol phosphate 
metabolism”, “Sphingolipid metabolism”, “Steroid metabolism” 
• Cysteine/Antioxidant Metabolism: “Glutathione metabolism”, “ROS 
detoxification”, plus metabolite “Lipoamide” 




5.3.1 Dataset-independent ensemble for radiation response classification 
716 radiation-sensitive and 199 radiation-resistant TCGA patient tumors were 
available for classification of radiation sensitivity (Figure 5-1). These samples are divided 
into training+validation and testing sets, where the testing set is used solely to evaluate 
model performance. 5-fold cross validation using training and validation sets is used to 
determine optimal hyperparameter values. Stratified shuffling is performed at each data 
split to ensure equal distribution of radiation-sensitive and -resistant samples at each step. 
20 randomized iterations of training+validation/testing splits are performed to obtain 
unbiased averages of model performance metrics across multiple data splits. When 
multiple datasets are integrated for prediction of radiation response, optimal classifier 
performance was found when implementing a dataset-independent ensemble architecture, 
where each dataset is first trained on an independent “base learner” machine learning 
classifier (Figure 5-2). Afterwards, outputs of each base learner are integrated into a “meta 
learner” that determines which datasets provide the most predictive value for each 
 165 
individual sample. Finally, the base learner and meta learner predictions are used to 
determine the ultimate classification of each sample as either a radiation-sensitive or 
radiation-resistant tumor. 
 
Figure 5-1. Splitting of data into training (both direct training and early stopping), 




Figure 5-2. Dataset-independent ensemble architecture, with base learners for each 
dataset and one meta learner for integration of base learner outputs. 
Each base learner is composed of a gradient boosting machine (GBM) that performs 
two-class classification (either radiation-sensitive or -resistant) using features from an 
individual dataset (Figure 5-3). Besides providing optimal performance accuracy, GBM 
classifiers using decision tree ensembles have many useful characteristics compared to 
other machine learning algorithms, including embedded feature selection, capability of 
handling missing values (which is common in clinical datasets), and efficient management 
of high-dimensional datasets (where the number of features greatly exceeds the number of 
samples) [289, 294, 295]. Bayesian optimization is performed to determine the optimal 
hyperparameter values for the GBM classifier; by calculating an acquisition function that 
determines the most informative point in hyperparameter space to sample at each iteration, 
this approach yields better performance compared to traditional approaches such as grid 
search or random search [290, 296]. At each iteration of Bayesian optimization, 5-fold 
cross validation is used to calculate the performance of the set of hyperparameters, 
measured by the mean weighted log loss plus one standard error; greater weight is given to 
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radiation-resistant samples in the weighted log loss to ensure that the classifier 
performances equally well on both classes despite the lower number of radiation-resistant 
samples. During model training, early stopping is employed to prevent overfitting. After 
the classifier has been trained, it is run on the testing set using the optimal set of 
hyperparameters. 
 
Figure 5-3. GBM base learner performing two-class classification of radiation 
sensitivity or resistance. For each iteration of Bayesian optimization and set of 
hyperparameters, 5-fold cross validation is performed. The set of hyperparameters 
with the lowest mean weighted log loss plus 1 standard deviation is chosen. Early 
stopping is employed during training to prevent model overfitting. 
By comparing each base learner’s prediction to the true class of validation set 
samples, the meta learner is trained to determine which base learner/dataset provides the 
most accurate prediction of radiation sensitivity for each new sample (Figure 5-4). This 
meta learner performs an Nd-class classification, where Nd is the number of independent 
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base learners/datasets, and the output is Nd probabilities that each base learner/dataset 
provides the most accurate prediction (all Nd probabilities sum to 1). The features this meta 
learner is trained on include all features from the Nd datasets which have non-negative 
SHAP values from their respective base learners; features which do not impact the base 
learner predictions are not included, which increases the training speed while maintaining 
accuracy. The implementation of this GBM-based meta learner is otherwise similar to that 
of each base learner, utilizing Bayesian optimization and 5-fold cross validation to 
determine optimal hyperparameter values. After training of base and meta learners, each 
testing set sample is run through all Nd base learners and the meta learner (Figure 5-5). 
Each of the base learners calculates a probability pi (where i∈(1,Nd)) of radiation resistance 
(0 ≤ pi ≤ 1), and the meta learner calculates the weights wi for each pi based on how accurate 
it predicts each base learner to be on this sample. The final probability of radiation 
resistance assigned to the sample is the weighted average p = w1p1 + w2p2 + … + wNdpNd; 
samples with p < 0.5 are classified as radiation-sensitive, while samples with p > 0.5 are 
classified as radiation-resistant. Because the meta learner is utilized independently of base 
learners when running testing set samples, it can be used to determine which datasets 
provide the most utility for a given patient, which can inform strategies for obtaining 
optimal clinical and biological measurements at a personalized level. 
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Figure 5-4. GBM meta learner performing Nd-class classification of the most 
accurate base learner/dataset for each sample, where Nd is the number of 
independent base learners/datasets. The meta learner is trained using features and 
base learner predictions on the validation sets. 
 
Figure 5-5. Prediction of radiation response for each testing set sample. Base 
learners provide the predicted probabilities of radiation resistance (pi), and the meta 
learner provides the weights for each base learner probability (wi) based on its 
predictions of the accuracy of each base learner on the individual sample. The 
ultimate probability of radiation resistance for the sample is the weighted sum p = 
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w1p1 + w2p2 + … + wNdpNd; samples with p < 0.5 are classified as radiation-sensitive, 
while samples with p > 0.5 are classified as radiation-resistant. 
To demonstrate the importance of these different components of the machine 
learning pipeline, the performance of a classifier trained on clinical, gene expression, and 
mutation data from TCGA was compared with versus without these different components. 
Figure 5-6 shows that the dataset-independent ensemble architecture performs better than 
initially combining all three datasets and training on a single GBM classifier; this increase 
in performance holds across multiple different performance metrics, including weighted 
log loss, area under the receiver operating characteristic curve (AUROC), balanced 
accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive 
value (NPV). Performing Bayesian optimization provides an additional increase in 
performance compared to using default hyperparameter values (Figure 5-7). Furthermore, 
the use of GBM’s as the base and meta learners provides greater performance compared to 
other commonly used machine learning algorithms with embedded feature selection, 
including random forests, logistic regression with L1 regularization, and neural networks 
with L1 regularization (Figure 5-8). Although the performance of this pipeline varies 
between patients of different cancer types, there was no significant correlation between 
performance and number of samples per cancer type or proportion of radiation-resistant 
samples per cancer type (Figure 5-9). Model performance was lowest for samples within 
the minority class of heavily-skewed cancer types, such as radiation-resistant samples of 
the largely radiation-sensitive breast cancer (BRCA; Figure 5-10). However, for more 
balanced cancer types such as lung adenocarcinoma (LUAD), there was no observable 
difference in performance between radiation-sensitive and -resistant samples. Overall, this 
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machine learning architecture is a robust platform for integrating multi-omic data and 
providing accurate predictions of radiation sensitivity in individual patient tumors. 
 
Figure 5-6. Performance comparison of classifiers trained on Clinical + Gene 
Expression + Mutation data from TCGA, either by combining datasets together 





Figure 5-7. Performance comparison of classifiers trained on Clinical + Gene 
Expression + Mutation data from TCGA, either without (using default 
hyperparameters) or with Bayesian optimization. 
 
Figure 5-8. Performance comparison of classifiers trained on Clinical + Gene 




Figure 5-9. (Left) Correlation between sample log loss and number of samples 
within each cancer type. (Right) Correlation between sample log loss and proportion 
of radiation-resistant samples within each cancer type. 
 
Figure 5-10. Comparison of log loss between radiation-sensitive and radiation-
resistant (left) breast cancer (BRCA) samples, and (right) lung adenocarcinoma 
(LUAD) samples. 
5.3.2 Gene expression classifier implicates cellular metabolism 
The development of biomarker panels for radiation response has mainly focused on 
using gene expression data from cancer cell lines or tumors as features [46, 273-283]. To 
compare our machine learning pipeline with previous classifiers for radiation response and 
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identify novel gene expression biomarkers, a classifier using RNAseq gene expression data 
from radiation-sensitive and -resistant TCGA tumors was developed. 782 of the 22,819 
genes in the dataset (3.43%) were identified as important in the classification of radiation 
response, as determined by having a cumulative 95% sum of the classifier’s mean absolute 
SHAP values (mean |ΔP| across all tumors; Figure 5-11). Among the 50 genes with the 
largest feature importances, 10 were previously identified as having a role in the tumor 
response to ionizing radiation therapy [297-306]. To determine whether the identified 
group of 782 genes has more predictive value than previously identified gene sets in 
RadiationGeneSigDB, machine learning classifiers were trained using only the genes from 
each respective gene set, and the predictive accuracy of each classifier was compared 
(Figure 5-12). When performing a classification task of differentiating radiation-sensitive 
and -resistant TCGA tumors, our group of 782 genes has the highest accuracy of all gene 
sets; however, this is likely due to our gene list being discovered by using the TCGA 
dataset, whereas other gene lists were discovered from other gene expression datasets. To 
eliminate this potential bias, a separate regression task was performed to predict the area 
under the curve of survival vs. radiation dose for 524 cancer cell lines from the Broad 
Institute Cancer Cell Line Encyclopedia (CCLE) [307]. Our group of 782 genes performed 
among the best gene lists on this separate dataset, and there appeared to be a threshold 
where gene lists of less than 100 genes could not accurately predict radiation response 
among the CCLE cell lines.  
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Figure 5-11. (Left; black overlay) Feature importance scores for individual gene 
expression features. Scores are calculated as the average absolute SHAP value 
(mean |ΔP|), which is the absolute value of the change in predicted probability of 
radiation resistance attributed to that feature, averaged across all tumor samples; 
features with larger scores have greater impacts on the classifier’s prediction of 
radiation sensitivity. Features are ordered by decreasing feature importance score. 
Among the top 50 features, those with previous literature suggesting a role in tumor 
radiation response are annotated. (Right; gray overlay) Cumulative sum of feature 
importance scores. Those features within the 95% cumulative sum of feature 




Figure 5-12. Comparison of predictive value of identified gene expression 
biomarkers (red) to previously identified gene sets in RadiationGeneSigDB (black). 
(Left) Performance on classification task using gene expression features from TCGA 
patient tumors, assessing performance by weighted log loss (top) and area under the 
ROC curve (bottom). (Right) Performance on regression task using gene expression 
features from CCLE cancer cell lines, assessing performance by mean absolute 
error (top) and mean squared error (bottom). 
To determine how these 782 genes are involved in the biological response to 
radiation therapy, the enrichment of gene sets representing the Hallmarks of Cancer was 
determined (Figure 5-13) [308, 309]. The “deregulating cellular energetics” hallmark was 
the only with significantly greater enrichment than random chance, suggesting that cellular 
metabolism may play an important role in radiation response. Even though DNA damage 
is one of the most well-characterized effects of ionizing radiation therapy, the “genome 
instability & mutation” hallmark had a substantially lower enrichment than random chance 
[310]. To determine if the positive/negative enrichment of these hallmarks was shared with 
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other previously-established gene sets for radiation response, hierarchical clustering of the 
hallmark enrichment rank for each gene set was performed (Figure 5-14). There appeared 
to be two major clusters of gene sets: a larger cluster having a very high rank for the 
“genome instability & mutation” hallmark (value close to 1; greater enrichment than 
chance), and a smaller cluster having a very low rank (value close to 10; lower enrichment 
than chance). This dichotomy suggests that although the biological response to ionizing 
radiation therapy certainly involves genomic instability and DNA-damage repair, other 
biological processes such as cellular metabolism, which have garnered less attention in 
relation to radiation response, may play critical roles as well [311-313]. 
 
Figure 5-13. Enrichment of hallmarks of cancer by identified gene expression 
biomarkers. Fold enrichment > 1 indicates hallmarks with greater enrichment than 





Figure 5-14. Hierarchical clustering of hallmark enrichment ranks based on both 
gene set (column) and hallmark (row). Enrichment ranks are the rank of each 
hallmark based on fold enrichment, from high fold enrichments (rank close to 1, 
greater enrichment than chance) to low fold enrichments (rank close to 10, lower 
enrichment than chance). 
The enrichment of cancer expression modules by our group of 782 genes also 
suggests an involvement of cellular metabolism in radiation response (Figure 5-15) [314]. 
Module #354, which involves amino acid and sulfur metabolism, showed a much greater 
enrichment than all other modules; the sulfur-containing amino acid cysteine is heavily 
involved in redox metabolism by the presence of its thiol group, and is a precursor for the 
production of glutathione, an important antioxidant [315, 316]. 42 other expression 
modules showed significant enrichment and involved disparate metabolic processes 
 179 
including central carbon metabolism, lipid and fatty acid metabolism, and oxidoreductase 
activity. To gain better insight into which specific metabolic pathways may show increased 
or decreased activity in radiation-resistant tumors, the enrichment of individual metabolic 
subsystems within the Recon3D human metabolic reconstruction was determined (Figure 
5-16) [7]. For subsystems with significant enrichment, the SHAP values for each individual 
gene were analyzed to determine whether increased expression was associated with 
increased probability of radiation sensitivity or resistance. Several significant metabolic 
subsystems involved the metabolism of sugars including glucose, fructose, mannose, and 
galactose, as well as the production of phospholipids and triglycerides. Additionally, the 
majority of genes involved in these metabolic pathways showed positive correlations 
between expression and radiation resistance, suggesting that these pathways may be 
upregulated in radiation-resistant tumors. Together, analysis of this gene expression 
classifier suggests that radiation-resistant tumors exemplify dysregulation in their cellular 
metabolic networks, and that additional features involving the cellular metabolism of 
radiation-sensitive and -resistant tumors will provide significant benefit in developing 
machine learning classifiers for radiation sensitivity. 
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Figure 5-15. Enrichment of cancer expression modules by identified gene expression 
biomarkers. Modules are ordered by increasing p-value (decreasing statistical 
significance). Modules relevant to cellular metabolism are annotated with their 
number and descriptions. 
 
Figure 5-16. Enrichment of Recon3D metabolic subsystems by identified gene 
expression biomarkers. Subsystems are ordered by increasing p-value (decreasing 
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statistical significance). Genes within each subsystem are annotated above or below 
colored significance bars based on whether their expression is positively correlated 
with predicted sensitivity (green) or resistance (red) to radiation therapy, 
respectively. 
5.3.3 Genome-scale metabolic models accurately predict metabolite production  
Although the gene expression and mutations of metabolic genes are directly 
available from TCGA to use as features, other types of metabolic information on these 
tumors are lacking. However, using outputs from genome-scale metabolic models of these 
TCGA tumors would provide an additional source of metabolic features which could be 
used in the prediction of radiation response. We have previously shown that integration of 
gene expression and mutation information from TCGA patient tumors, as well as kinetic 
and thermodynamic parameters from publicly-available repositories, into personalized 
genome-scale FBA models of tumor metabolism can provide accurate predictions of 
differences in redox metabolism between radiation-sensitive and radiation-resistant 
tumors. This was accomplished by using objective functions which captured the reduction 
of redox cofactors and clearance of reactive oxygen species, which is necessary by 
radiation-resistant tumors to withstand oxidative stress caused by ionizing radiation 
therapy [196]. It is hypothesized that an objective function maximizing the production of 
a particular metabolite will provide accurate predictions of relative metabolite production 
between radiation-sensitive and radiation-resistant tumors if this metabolite is particularly 
beneficial to either class of tumors and thus the metabolic network of these tumors is 
optimized to produce elevated levels of this metabolite. These metabolites with large 
differential production between radiation-sensitive and -resistant tumors (and that would 
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be accurately predicted by FBA models) would be useful towards prediction of radiation 
sensitivity and thus selected by feature selection, whereas metabolites with similar 
production rates among the two classes (which may not be well captured by the objective 
function and thus not accurately predicted by FBA models) would not be useful and would 
be removed by feature selection. 
To predict the production of individual metabolites within TCGA tumors for use in 
machine learning classifiers, a metabolome-wide objective function screen was performed, 
where the maximization of each metabolite was individually used as an objective function, 
and the resulting objective value was used as a prediction for maximum metabolite 
production (Figure 5-17). All 871 metabolites in Recon3D that (1) had KEGG database 
ID’s, (2) were not present in the extracellular media, and (3) were capable of being 
produced by all FBA tumor models, were included in screen. Figure 5-17 shows the ratio 
of average predicted production of each metabolite in radiation-resistant versus radiation-
sensitive tumors. There were a few major classes of metabolites which showed at least 2-
times greater predicted production in radiation-resistant tumors. Sulfur-containing 
metabolites including lipoamide, a known antioxidant, and L-cystathionine, an 
intermediate in the synthesis of cysteine and glutathione, were among the metabolites with 
greatest differential production in radiation-resistant tumor models [317-320]. 
Additionally, the production of lipid and fatty acid metabolites including glycerol, γ-
linolenic acid, and butyric acid was also predicted to be significantly higher in radiation-
resistant tumors; these metabolites are involved in antioxidation, lipid peroxidation, and 
phospholipid production, all of which are implicated in the response to ionizing radiation 
[175, 179, 321-323]. These findings are consistent with the significant enrichment of genes 
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involved in sulfur metabolism, lipid metabolism, and oxidoreductase activity from the gene 
expression classifier for radiation response. Interestingly, the inflammation-mediating 
eicosanoids PGJ2, PGD2, and TXA2 showed increased predicted production in radiation-
resistant tumors. Finally, while fewer metabolites were predicted to have at least 2-times 
greater production in radiation-sensitive tumors, many nucleotide metabolites, including 
thymine and deoxyribose, were among this group. 
 
Figure 5-17. (Left) Schematic showing the integration of multi-omic data from 
TCGA and publicly-available repositories, as well as objective functions maximizing 
the production of individual metabolites, to predict relative metabolite production 
rates in TCGA patient tumors. (Right) Model-predicted production of 871 
metabolites between radiation-sensitive and radiation-resistant tumors. Values are 
the log2 ratio of average production of the metabolite in radiation-resistant tumors 
divided by average production in radiation-sensitive tumors; log2(Predicted 
Resistant/Sensitive) < 0 signifies that a metabolite has greater maximum production 
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in radiation-sensitive tumors, log2(Predicted Resistant/Sensitive) > 0 signifies that a 
metabolite has greater maximum production in radiation-resistant tumors. 
Metabolites are rank ordered based on increasing ratio value. Colors indicate 
metabolite classes (cyan: sulfur-containing metabolites; green: eicosanoids; orange: 
lipids and fatty acids; purple: nucleotides). 
To determine whether radiation-resistant cancers do show increased or decreased 
levels of these FBA-predicted classes of metabolites, an analysis of metabolomics data 
from the NCI-60 cancer cell line panel was performed (Figure 5-18) [324]. Among 139 
metabolites screened, cholesterol was found to have the most positive correlation between 
metabolite concentration and cell line surviving fraction at 2 Gy radiation (SF2) within the 
NCI-60 panel. Cholesterol, closely related to many lipid metabolites predicted to have 
increased production in radiation-resistant tumors, was previously shown to be upregulated 
in response to ionizing radiation and may protect against lipid peroxidation [325, 326]. 
Glycerol and glyceric acid, other metabolites involved in lipid metabolism which were 
discovered from the FBA objective function screen, as well as glutathione, an important 
sulfur-containing antioxidant, also showed largely positive correlations with radiation 
response. Many uracil-containing metabolites as well as oritidine 5’-phosphate, a precursor 
to uridine monophosphate, were among the metabolites with largely negative correlations 
with radiation response, in agreement with FBA predictions of nucleotide production. 
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Figure 5-18. (Left) Correlation between metabolite concentration and surviving 
fraction at 2 Gy radiation (SF2) among 139 experimentally-measured metabolites in 
the NCI-60 panel of cancer cell lines. Metabolites are ranked by the correlation 
coefficient between concentration and SF2. Metabolite classes are colored as in (B). 
(Right) Example regression between concentration and SF2 for cholesterol. 
Although the NCI-60 screen provided evidence of increased/decreased production of 
general classes of metabolites over a wide range of radiation-resistant cancers, not enough 
metabolites were available to compare model-predicted and experimentally-measured 
levels of individual metabolites. To this end, untargeted metabolomics was performed on 
four matched pairs of radiation-sensitive and radiation-resistant cell lines from four 
different cancer types (Figure 5-19) [175, 220, 327, 328]. For nucleotide, lipid, immune 
system-mediating, and cysteine/antioxidant metabolites that were identified in both the 
experimental metabolomics screen and the FBA-based objective function screen, the fold 
change in measured concentrations between matched radiation-resistant and -sensitive cell 
lines, as well as the average fold change across all four matched pairs, was compared to 
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the ratio of average predicted production in radiation-resistant versus radiation-sensitive 
FBA tumor models (Figure 5-19, Figure 5-20, Figure 5-21, Figure 5-22, Figure 5-23). FBA 
models correctly predicted that most nucleotide metabolites, including derivatives of 
adenine, guanine, thymine, and inosine, were downregulated in radiation-resistant cancers; 
additionally, cytidine derivatives were correctly predicted to be upregulated in radiation-
resistant cancers, unlike most other nucleotides. Interestingly, there were a large number 
of lipid metabolites with greater experimentally-measured levels among the radiation-
sensitive cell lines, as well as a large amount of heterogeneity between cell lines of different 
cancer types. Only two lipid metabolites (CDP-choline and succinate) had incorrect 
predictions in terms of matching signs of log2 ratio values with average experimentally-
measured levels, and not having at least one cell line pair with a statistically-significant 
difference in the same direction as the FBA-predicted metabolite differences; this suggests 
that FBA models are able to capture the observed diversity in lipid levels. Although model-
predictions of absolute oxidized (GSSG) and reduced (GSH) glutathione production did 
not match well with experimentally-measured values, previous model predictions of 
increased reduction potential of GSSG to GSH in radiation-resistant tumors agrees with 
experimental findings of greater GSH/GSSG ratios in radiation-resistant cell lines (Figure 
4-13). Finally, model-predicted production of the antioxidant lipoamide, as well as immune 
mediators anandamide and 2-arachidonylglycerol, matched very well with experimental 
measurements, which were upregulated in nearly all radiation-resistant cell lines. Overall, 
these findings demonstrate that FBA-based genome-scale metabolic models provide 
accurate predictions of relative metabolite production between radiation-sensitive and -
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resistant cancers, allowing for their use in machine learning classifiers for radiation 
sensitivity. 
 
Figure 5-19. (Left) Schematic showing the comparison of model-predicted 
metabolite production in radiation-sensitive and -resistant TCGA tumors, with 
experimentally-measured metabolite concentrations in matched radiation-sensitive 
and -resistant cell lines from four different cancer types. (Right) Comparison of 
model-predicted and experimentally-measured (“FBA”) metabolite levels, expressed 
as the log2 of the ratio of metabolite levels in radiation-resistant versus radiation-
sensitive tumor models or cell lines. Experimentally-measured values are shown for 
each individual cell line pair, as well as averaged across all 4 cell line pairs (“MEAN 
EXP”). Statistically-significant differences in experimentally-measured metabolite 
levels within each cell line pair are represented by green (Sensitive > Resistant) or 
red (Resistant > Sensitive) box outlines. Metabolites are grouped by metabolite 





Figure 5-20. Experimentally-measured levels of nucleotide metabolites in radiation-
sensitive and -resistant cell lines across four cancer types from untargeted 
metabolomics. (Left) Replicate metabolite concentrations from all four cell line 
pairs, with values expressed as the log10 of the normalized area from LC-MS/MS. 
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Statistical significance of the difference between radiation-sensitive and -resistant 
cell line values is shown. 
 
Figure 5-21. Experimentally-measured levels of lipid metabolites in radiation-
sensitive and -resistant cell lines across four cancer types from untargeted 
metabolomics. (Left) Replicate metabolite concentrations from all four cell line 
pairs, with values expressed as the log10 of the normalized area from LC-MS/MS. 
Statistical significance of the difference between radiation-sensitive and -resistant 




Figure 5-22. Experimentally-measured levels of cysteine/antioxidant metabolites in 
radiation-sensitive and -resistant cell lines across four cancer types from untargeted 
metabolomics. (Left) Replicate metabolite concentrations from all four cell line 
pairs, with values expressed as the log10 of the normalized area from LC-MS/MS. 
Statistical significance of the difference between radiation-sensitive and -resistant 
cell line values is shown. 
 
Figure 5-23. Experimentally-measured levels of immune system-mediating 
metabolites in radiation-sensitive and -resistant cell lines across four cancer types 
from untargeted metabolomics. (Left) Replicate metabolite concentrations from all 
four cell line pairs, with values expressed as the log10 of the normalized area from 
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LC-MS/MS. Statistical significance of the difference between radiation-sensitive and 
-resistant cell line values is shown. 
5.3.4 Multi-omic classifier identifies clinical subpopulations of cancer patients 
Using the dataset-independent ensemble architecture, a machine learning classifier 
integrating clinical, gene expression, mutation, and FBA-predicted metabolite production 
rates was developed. With an AUROC of 0.906 ± 0.004, this classifier has significantly 
greater performance compared to previously-developed machine learning classifiers for 
radiation response [46, 271]. Figure 5-24 shows that using a predicted probability p=0.5 
threshold for classifying radiation-sensitive and -resistant tumors results in a much greater 
specificity than sensitivity, indicating that the classifier provides more accurate predictions 
for radiation-sensitive samples compared to radiation-resistant ones. Although this may be 
desired to give greater certainty for patients who are classified as radiation-resistant (small 
number of false positives), the classification threshold can be changed to provide a better 
balance between sensitivity and specificity. 
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Figure 5-24. Receiver operating characteristic (ROC) curve, averaged across 20 
training+validation/testing splits. Blue line represents the mean value across all 
splits, with the light blue error band representing +/- 1 standard deviation. The 
points on the ROC curve signifying both the p=0.5 threshold and optimal threshold 
(that which maximizes Youden’s index) for differentiating radiation-sensitive and -
resistant samples are shown, with associated sensitivity and specificity values. 
725 of the 52,223 features from the four datasets (1.39%) were among the 
cumulative 95% sum of the classifier’s mean absolute SHAP values (Figure 5-25). While 
the majority of these 725 features were gene expression (48.3%) and metabolite (32.6%) 
features, the clinical features contributed more than half of the total SHAP values (60.1%; 
Figure 5-26). Tumor histology had the largest overall impact on radiation response 
predictions; although there are known differences in radiation sensitivity between different 
cancer types, the differences in radiation response between histologic variants of the same 
cancer type is much less characterized [31, 329, 330]. Interestingly, the patient’s response 
to different chemotherapies also had a significant impact; many of these chemotherapies 
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are radiation sensitizing and have known impacts on redox metabolism, including cisplatin, 
fluorouracil, cyclophosphamide, and carboplatin [121, 331-334]. Mutations with large 
feature importance scores included those directly involved in redox and lipid metabolism; 
IDH1 R132H (major SNP in the IDH1 gene) results in lower NADPH levels and the 
production of the oncometabolite 2-hydroxyglutarate, while BRAF V600E (major SNP in 
the BRAF gene) results in the upregulation of HMG-CoA lyase and subsequent conversion 
of HMG-CoA to the ketone body acetoacetate [215, 335]. 
 
Figure 5-25. (Left; black overlay) Feature importance scores for individual features, 
calculated as the average absolute SHAP value (mean |ΔP|) across all tumor 
samples. Features are ordered by decreasing feature importance score. (Right; gray 
overlay) Cumulative sum of feature importance scores. Those features within the 





Figure 5-26. List of top 50 features with largest feature importance scores, colored 
based on their original dataset. (Inset, Left) Number of features contributing to the 
725 total important features from each individual dataset. (Inset, Right) Relative 
contribution of features from each dataset to the sum of absolute SHAP values, 
averaged across all samples. 
Averaged across all patients, clinical features supplied the majority of cumulative 
SHAP values and were most useful for prediction of radiation sensitivity. However, 
individual samples varied significantly in the contribution of clinical, gene expression, 
mutation, and metabolite features towards sensitivity classification (Figure 5-27). Using 
unsupervised clustering, three clusters of patients with varying contributions of clinical 
features were found (Figure 5-27, Figure 5-28). “High Clinical” patients are categorized 
by very large clinical feature contributions, meaning that performing multi-omic analysis 
of tumor biopsies from these patients to obtain gene expression, mutation, and metabolic 
features would not significantly improve the ability to classify these patients. On the other 
hand, “Low Clinical” patients have much lower clinical feature contributions; multi-omic 
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features provide the majority of cumulative SHAP values, with metabolic features alone 
providing nearly as much utility as clinical features for these patients (Figure 5-29). For 
this group of patients, while clinical features such as chemotherapeutic response have 
negligible utility, multi-omic measurements from tumor biopsies would be necessary to 
accurately predict response to radiation therapy. To determine what factors differentiate 
these three patient clusters, chi-squared tests comparing the expected and observed 
frequencies of patients with different values of each clinical factor were performed (Figure 
5-30). Significant heterogeneity in clinical clusters was seen between patients of different 
cancer types; while some cancers including prostate (PRAD) and bladder (BLCA) cancer 
were categorized mainly by “Low Clinical” patients, others including breast (BRCA) and 
cervical (CESC) cancer consisted mostly of “High Clinical” patients (Figure 5-31). 
Histological subtypes of the same cancer type also showed significant heterogeneity, again 
demonstrating the importance of tumor histological characterization on radiation 
sensitivity prediction. 
 
Figure 5-27. (Left) Relative contribution of features from each dataset to the sum of 
absolute SHAP values for each individual sample. (Right) Clustering of samples into 
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“Low”, “Medium”, and “High” clinical groups based on the relative contribution of 
features from the clinical dataset toward the sum of absolute SHAP values. The 
optimal number of clusters was calculated based on maximizing the gap statistic 
from k-means clustering (Figure 5-28). 
 
Figure 5-28. Gap statistic associated with k-means clustering of clinical dataset 
contributions for each sample from the multi-omic classifier, as a function of 
number of clusters (k). The optimal number of clusters is that which yields the 




Figure 5-29. List of top 50 features with largest feature importance scores among 
samples within the “Low Clinical” cluster. (Inset) Relative contribution of features 
from each dataset to the sum of absolute SHAP values, averaged across all samples 
within the “Low Clinical” cluster. 
 
 
Figure 5-30. Statistical significance of patient clustering into “Low/Medium/High” 
clinical groups based on different clinical factors, as calculated by the chi-squared 
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test with Yates’ correction. Only statistically significant (p ≤ 0.05) clinical factors 
are shown. 
 
Figure 5-31. (Left) Heterogeneity of samples from different cancer types in terms of 
clinical dataset contribution and distribution into “Low/Medium/High” clinical 
groups. (Right) Heterogeneity of samples from different histological subtypes of 
breast cancer (BRCA) in terms of clinical dataset contribution and distribution into 
“Low/Medium/High” clinical groups. 
The meta learner of the ensemble architecture outputs the probability that each 
dataset provides the most utility in classification, used as weights for the predicted 
probability of radiation resistance from each dataset-independent base learner. These 
weights provide accurate predictions of cumulative SHAP values of the clinical dataset 
relative to other datasets, and can differentiate between patients within the “Low Clinical” 
cluster and “Medium/High Clinical” clusters (Figure 5-32). Because the meta learner can 
be run independently of base learners on testing samples, it can be used to predict a priori 
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whether patient clinical information is sufficient to accurately predict radiation sensitivity, 
or whether multi-omic features from tumor biopsy samples are needed. 
 
Figure 5-32. Using the meta learner weight for the clinical dataset (probability that 
the clinical dataset is the optimal dataset for each individual sample) to determine a 
priori clustering into the “Low Clinical” or “Medium/High Clinical” groups. Dotted 
line signifies the optimal threshold separating “Low Clinical” or “Medium/High 
Clinical” groups, which maximizes the accuracy of predicting clinical cluster based 
on meta learner weight. 
5.3.5 Metabolic features highlight network-level involvement 
Analysis of gene expression and multi-omic classifiers for radiation sensitivity 
suggests that cellular metabolism is integral to the tumor response to ionizing radiation, 
and that metabolic features can contribute significantly to the prediction of radiation 
response in individual patient tumors. The 236 FBA-based metabolic features with 
significant feature importance scores from the multi-omic classifier were examined to 
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identify individual metabolic biomarkers for radiation sensitivity. Metabolite set 
enrichment analysis indicates significant enrichment of several metabolic pathways 
involved in central carbon metabolism, lipid metabolism, and nucleotide metabolism 
(Figure 5-33). Interestingly, many metabolites are involved in transport between various 
cellular compartments as well as the extracellular space, suggesting that these biomarker 
metabolites could be measured in interstitial fluid or blood as well as within the tumor 
itself. To identify individual metabolites with the largest impact on radiation response, the 
spearman correlation between predicted metabolite production rate and SHAP value 
(change in probability of radiation resistance due to that metabolite) across all patients was 
calculated for each metabolite (Figure 5-34). These correlation values signify whether 
increased tumor metabolite levels are predicted to increase (positive correlation) or 
decrease (negative correlation) the probability of radiation resistance, and to what extent. 
 
Figure 5-33. Metabolite-set enrichment analysis of the 236 significant metabolic 
features from the multi-omic classifier into Recon3D metabolic subsystems. The 
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statistical significance and number of metabolites in each subsystem are shown. 
Only statistically significant (p ≤ 0.05) subsystems are shown. 
 
Figure 5-34. Regression between metabolic feature SHAP value and predicted 
metabolite production for a representative metabolite (butyric acid), showing values 
for each individual patient tumor, as well as the Spearman correlation coefficient. 
Figure 5-35 highlights many of the significant metabolic features, their predicted 
impact on radiation response, and their interconnections with central carbon metabolism. 
Significant metabolites in the glycolysis and TCA pathways (fructose 1,6-bisphosphate, 3-
phosphoglyceric acid, succinyl-CoA, and succinate) were all positively correlated with 
radiation resistance, while genes promoting gluconeogenesis (PCK2 and LDHA) were 
associated with radiation sensitivity. Fructose 2,6-bisphosphate, an allosteric regulator of 
PFK-1 that activates glucose breakdown, had one of the most positive correlation values 
with radiation resistance. Interestingly, many metabolites in early mannose metabolism had 
positive correlations values. Experimental studies have shown that radiation induces the 
upregulation of mannose-6-phosphate receptors as well as production of high mannose-
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type N-glycans; however, the function of mannose in radiation response has yet to be 
determined [336, 337]. 
 
Figure 5-35. Overview of significant metabolic biomarkers and their 
interconnections within the human metabolic network. Different metabolic 
pathways are shown with colored backgrounds. Significant metabolic features are 
denoted by colored boxes, where the color indicates the Spearman correlation 
coefficient between the SHAP value for that feature and predicted metabolite 
production rate (see Figure 5-34); metabolites with positive correlations (red) are 
predicted to have higher production in radiation-resistant tumors, whereas 
metabolites with negative correlations (green) are predicted to have greater 
production in radiation-sensitive tumors. Significant gene expression and mutation 
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features are denoted by colored reaction arrows, either in red (higher gene 
expression or mutation rate in radiation-resistant tumors) or in green (higher gene 
expression or mutation rate in radiation-sensitive tumors). 
Greater fluxes through central carbon metabolism in radiation-resistant tumor 
models resulted in increased production of both glycerol 3-phosphate and free fatty acids. 
This allowed for enhanced production of lipid and phospholipid metabolites, including 
phosphatidylinositol, phosphatidylethanolamine, and triglycerides. The majority of 
significant metabolites involved in fatty acid and cholesterol metabolism also had positive 
correlations with radiation resistance (Figure 5-36). Many of these metabolites have 
previously-identified roles as antioxidants with effects on lipid peroxidation, including 
capric acid, butyric acid, eicosatrienoic acid, docosapentaenoic acid, γ-linolenic acid, and 
myristic acid [338-343]. There was a dichotomy between sphingolipid metabolites that had 
either strongly positive or strongly negative correlations with radiation resistance; this 
agrees with previous studies showing that while the production of ceramides in response 
to DNA damage promotes apoptosis, other pro-survival sphingolipids can promote 
therapeutic resistance (Figure 5-37) [344, 345]. 
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Figure 5-36. Spearman correlation coefficients of significant metabolic biomarkers 
involved in fatty acid and cholesterol metabolism. 
 
Figure 5-37. Spearman correlation coefficients of significant metabolic biomarkers 
involved in sphingolipid metabolism. 
While metabolic fluxes through lipid and fatty acid-generating pathways are 
enhanced in radiation-resistant tumor models, model-predicted production of metabolites 
involved in nucleotide and energy metabolism, also closely connected to central carbon 
metabolism, was highly correlated with radiation sensitivity (Figure 5-38). Despite the 
expectation that radiation-resistant tumors would upregulate nucleotide synthesis for 
enhanced DNA damage repair, many of these nucleotide metabolites showed 
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downregulation experimentally in radiation-resistant cell lines (Figure 5-19). Previous 
studies found enzyme upregulation and increased production of pyrimidine nucleotides in 
radiation-resistant cancers, which was observed experimentally with cytidine and 
deoxycytidine in Figure 5-19 [346]. However, machine learning classifiers did not identify 
pyrimidines as having significant impact on predicting radiation response; instead, purine 
metabolites, which showed decreased production in radiation-resistant cancers from both 
FBA models and experimental metabolomics, did have significant impacts on machine 
learning predictions. The disparate metabolic pathways for generating these two nucleotide 
classes may allow for differences in regulation and function in response to ionizing 
radiation therapy [347, 348]. The observed negative correlation between ATP production 
and radiation resistance is likely due to purine synthesis rather than availability of high-
energy phosphates; FBA models predict significantly greater capacity for conversion of 
ADP to ATP in radiation-resistant tumors, in accordance with previous experimental 
findings (Figure 5-39) [349, 350]. 
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Figure 5-38. Spearman correlation coefficients of significant metabolic biomarkers 
involved in (left) nucleotide metabolism, and (right) energy metabolism. 
 
Figure 5-39. Maximal conversion of ADP to ATP in radiation-sensitive and -
resistant tumors, predicted from FBA metabolic models. 
Many eicosanoid precursors and inflammatory mediators were found to significantly 
impact classification and had positive correlations with radiation resistance (Figure 5-40). 
Increased eicosanoid production in radiation-resistant models was due to both elevated 
levels of arachidonic acid precursors (membrane phospholipids including dihomo-γ-
linolenic acid) and increased expression of eicosanoid-producing enzymes. The majority 
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of significant sulfur-containing metabolites (66.7%) also had positive correlations with 
radiation resistance (Figure 5-41). However, among the 8 sulfur-containing metabolites in 
the top 50 of all features among “Low Clinical” samples, only half had positive correlation 
values. This suggests that the sulfur-containing functional groups such as thiol groups may 
play other roles in the biological response to ionizing radiation other than providing 
antioxidant function and therapeutic resistance [351]. Together, these findings indicate that 
metabolic features from multiple interconnected pathways including central carbon 
metabolism, lipid metabolism, and nucleotide metabolism are viable biomarkers for the 
prediction of radiation response. 
 
Figure 5-40. Metabolic pathway of eicosanoid production, highlighting significant 




Figure 5-41. Spearman correlation coefficients of significant sulfur-containing 
metabolic biomarkers. Colored dots signify metabolites within the top 50 of all 
features among “Low Clinical” samples in the multi-omic classifier. 
5.3.6 Personalized predictions of non-invasive clinical and metabolic biomarkers 
While the integration of genome-scale mutational, transcriptomic, and 
metabolomic information into multi-omic classifiers may provide optimal performance in 
predicting radiation therapy response, it requires invasive and costly tests to measure these 
biomarkers from tumor biopsies. To determine the efficacy of a non-invasive predictor of 
radiation sensitivity, a machine learning classifier was developed which integrates clinical 
data derived from non-invasive means (excluding any staging or histological information 
from tumor biopsies) with FBA-predicted production rates of metabolites known to be 
quantifiable in human blood samples (Figure 5-42) [178]. Surprisingly, this non-invasive 
classifier showed similar performance to the multi-omic classifier, with increased 
sensitivity and decreased specificity (Figure 5-43). The higher sensitivity of the non-
invasive classifier minimizes the number of false negatives and ensures that few radiation-
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resistant patients will be missed, making it ideal as a first-line screening test [352]. If a 
patient tests positive, further analysis can be performed to obtain features needed for the 
multi-omic classifier, which has a higher specificity and is ideal as a second-line diagnostic 
test. 
 
Figure 5-42. Inclusion of non-invasive clinical features and blood-based metabolic 




Figure 5-43. Comparison of model AUROC, sensitivity, and specificity between 
multi-omic and non-invasive classifiers. 
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97 of the 363 features from the two datasets (26.7%) were among the cumulative 
95% sum of the classifier’s mean absolute SHAP values (Figure 5-44). Similar to the multi-
omic classifier, the individual patient contribution of clinical features towards cumulative 
SHAP values formed a multi-modal distribution; unsupervised clustering separated these 
patients into “Low Clinical” and “High Clinical” groups (Figure 5-45). While cancer type 
constitutes about one-fourth of the predictive utility among “Low Clinical” patients, all 
other non-invasive clinical factors cumulatively make up only about one-fourth as well 
(Figure 5-46). For these patients, blood metabolite features provide almost one-half of the 
cumulative SHAP values, demonstrating the value of blood-based biomarkers in radiation 
sensitivity prediction. Many of the major metabolite groups from the multi-omic classifier 
also represent the metabolites with largest mean SHAP values in the non-invasive 
classifier, including lipids (e.g. butyric acid), nucleotides (e.g. GDP), and immune system 
mediators (e.g. prostaglandins J2 and D2). 
 
Figure 5-44. (Left; black overlay) Feature importance scores for individual features, 
calculated as the average absolute SHAP value (mean |ΔP|) across all tumor 
samples. Features are ordered by decreasing feature importance score. (Right; gray 
overlay) Cumulative sum of feature importance scores. Those features within the 
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95% cumulative sum of feature importance scores (bolded number) are kept for 
further analysis. 
 
Figure 5-45. (Left) Clustering of samples into “Low” and “High” clinical groups 
based on the relative contribution of features from the clinical dataset toward the 
sum of absolute SHAP values. The optimal number of clusters was calculated based 
on maximizing the gap statistic from k-means clustering (Right). 
 
Figure 5-46. Analysis of clinical and metabolic feature contributions among the 




Figure 5-47 provides a representative example of how clinical and metabolic features 
are cumulatively used by the non-invasive classifier to predict the posterior probability of 
radiation resistance in individual patients. For this patient, blood metabolic features 
constituted 64.5% of the cumulative SHAP values and increased the predicted probability 
of radiation resistance from 48.9% to 73.5%, allowing for the correct classification into the 
radiation-resistant class. This patient had the highest SHAP value among all patients for 
the metabolite 5Z-tetradecenoic acid, suggesting that this particular metabolite is a very 
useful blood-based biomarker for their diagnosis of radiation sensitivity. On the other hand, 
this patient had one of the lowest SHAP values for the metabolite phenylacetylglutamine, 
suggesting a lower relative utility of this biomarker compared to other cancer patients. 
Overall, this methodology allows for the determination of personalized biomarker panels 
with maximal diagnostic utility for individual patients, reducing the number of features 
needed to be measured per patient as well as decreasing associated costs for diagnosis. 
 
Figure 5-47. (Left) Breakdown of feature contributions towards prediction of 
radiation resistance in a representative radiation-resistant patient (TCGA-S9-
A7IY). (Upper) Contribution of each data type towards the progression from prior 
to posterior probability of radiation resistance. (Lower) SHAP values of individual 
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features for this patient. (Right) Plots of feature SHAP value versus predicted 
metabolite production rate for two features, illustrating (upper) a feature whose 
absolute SHAP value for patient TCGA-S9-A7IY is larger than average, and (lower) 
a feature whose absolute SHAP value for patient TCGA-S9-A7IY is smaller than 
average. 
5.4 Discussion 
While interest in the prediction of radiation sensitivity in cancer patients has been 
present for decades, these predictors have yet to be used in the clinical setting [272]. The 
recent progression of high-throughput technologies including whole genome sequencing 
and RNA-seq have facilitated the generation of multi-omic datasets from cancer cell line 
and tumor samples, including the Cancer Cell Line Encyclopedia (CCLE) and The Cancer 
Genome Atlas (TCGA); these datasets provide tens of thousands of biological features for 
exploring the pathophysiological mechanisms of radiation response and the generation of 
predictive models [2, 307]. Development of sophisticated machine learning algorithms has 
simultaneously provided methods for analyzing these high-dimensional biological datasets 
and making reliable predictions from them [271]. Nevertheless, recently-developed 
classifiers for radiation response have failed to integrate multiple -omic modalities or 
utilize other modeling strategies for feature generation and biomarker identification. Here, 
we propose a novel strategy of integrating metabolic features from personalized genome-
scale FBA models with clinical, genomic, and transcriptomic data to predict radiation 
sensitivity in individual TCGA patient tumors. By utilizing a dataset-independent 
ensemble architecture with gradient boosting models and Bayesian optimization, we obtain 
superior accuracy compared to previously-developed classifiers for radiation response. 
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Additionally, by integrating predicted metabolite production rates from FBA models, 
which were experimentally validated through untargeted metabolomics on matched 
radiation-sensitive and -resistant cancer cell lines, metabolic biomarkers were identified 
across the human metabolic network which correlate with radiation resistance. Finally, to 
our knowledge this is the first study to demonstrate the capability of identifying multi-omic 
and non-invasive biomarkers with maximum diagnostic utility for predicting radiation 
response in individual cancer patients. 
Many of the identified metabolic biomarkers from this study agree with previous 
experimental evidence from radiation-resistant cancers and radiation-sensitizing therapies. 
Most of the identified fatty acid and cholesterol metabolite biomarkers had positive 
correlations with radiation resistance (Figure 5-36). Radiation-resistant head and neck 
cancer cells were shown to have enhanced fatty acid production from increased expression 
of fatty acid synthase [179]. Additionally, ionizing radiation was shown to cause increased 
cholesterol production in lung cancer cells [325]. Plasma levels of total and HDL 
cholesterol were found to be increased in radiation-resistant SPRET/EiJ mice compared to 
radiation-sensitive BALB/cByJ mice, implicating cholesterol as a potential non-invasive 
metabolic biomarker (Figure 5-48). Treatment with HMG-CoA reductase inhibitors 
including simvastatin have been shown to sensitize prostate cancer cells to radiation 
therapy, potentially by compromising DNA damage repair [353-357]. Other agreements 
between model predictions and experimental studies include the potential role of immune-
modulating eicosanoids in radiation resistance. Several prostaglandins including PGD2, 
PGF2α, PGI2, and PGJ2, as well as thromboxane A2, had positive correlations with 
radiation resistance (Figure 5-40). Previous experimental studies have associated increased 
 215 
production of prostaglandins PGF2α and PGE2 with radiation resistance, and have found 
that cyclooxygenase inhibitors such as aspirin may enhance response to radiation therapy 
and improve outcomes of cervical, prostate, and rectal cancer patients [358-363]. These 
findings suggest that lipid and eicosanoid metabolites may have utility as both diagnostic 
biomarkers and therapeutic targets for improving radiation sensitivity. 
 
Figure 5-48. Comparison of (left) plasma total cholesterol levels, and (right) plasma 
HDL cholesterol levels, in radiation-sensitive BALB/cByJ mice versus radiation-
resistant SPRET/EiJ mice from the CGDpheno1 and Paigen4 datasets in the Mouse 
Phenome Database. 
Stacked generalization is a form of ensemble learning where the output of multiple 
machine learning classifiers (“base learners”) is used as input for another classifier (“meta 
learner”), which determines the optimal combination of original predictions to use as the 
final class prediction [364]. This machine learning architecture has been shown to improve 
predictive accuracy compared to individual classifiers in multiple medical applications 
[365-369]. However, in most cases there is only one input dataset being supplied to the 
multiple base learners. Here, we instead input different -omics datasets to separate base 
learners, and use the meta learner to determine the relative contribution of the different 
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datasets to the overall class prediction. While it may be anticipated that this architecture 
would decrease performance accuracy since it prevents interactions between features from 
different datasets, we have shown that it improves performance across multiple metrics in 
the prediction of radiation response (Figure 5-6). One possible explanation is that this 
dataset-independent ensemble architecture can better accommodate multiple high-
dimensional datasets (where the number of features is much larger than the number of 
samples) compared to concatenating these datasets into one with even higher 
dimensionality. We propose that this architecture may provide optimal performance in 
other situations where multiple high-dimensional datasets (such as multi-omics datasets) 
are being integrated, which is becoming increasingly common in biomedical applications 
[370]. Another benefit of this ensemble architecture is that the meta learner can be utilized 
independently of the base learners after training to predict which individual datasets will 
provide the most utility for the a priori diagnosis of radiation sensitivity in individual 
patients. For example, the meta learner can accurately differentiate between “Low Clinical” 
patients (with large contributions of gene expression, mutation, and metabolic datasets 
from patient biopsy samples and genome-scale metabolic modeling) and “High Clinical” 
patients (with greater contribution from clinical data from electronic medical records) 
(Figure 5-32). “Low Clinical” and “High Clinical” patients also differed significantly in 
the diagnostic utility of individual features, including chemotherapy response, IDH1 SNP, 
and lipid metabolite levels (Figure 5-29). Thus, the meta learner’s ability to stratify patient 
populations allows for optimal planning and resource allocation for collecting biological 
measurements with diagnostic utility for individual cancer patients. Moreover, the use of 
gradient boosting models as the base and meta learners provides a significant amount of 
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embedded feature selection, demonstrated by the identification of only 725 (1.39%) out of 
52,223 total features as important for class prediction in the multi-omic classifier (Figure 
5-25). This decrease in model complexity not only lowers the cost of measuring biological 
features needed for prediction, but also improves the interpretability of models which 
improves the likelihood of adoption by clinicians [371].  
In addition to demonstrating the utility of multi-omic data for the classification of 
radiation response, we showed that a classifier utilizing non-invasive clinical information 
and blood-based metabolic biomarkers can predict radiation sensitivity with comparable 
accuracy (Figure 5-43). Blood-based diagnostic tools are garnering attention for their use 
in early detection, monitoring, and optimal treatment identification for cancer patients 
[372]. An area where the identification of novel circulating biomarkers could provide 
significant utility is in adaptive radiotherapy, where a cancer patient’s radiation treatment 
is modified over time in response to the observed efficacy of previous treatments [373, 
374]. The integration of machine learning and genome-scale metabolic modeling could be 
used to identify readily accessible blood-based metabolic signatures for both measuring the 
biological response of radiation therapy as well as identifying necessary changes or 
additions of radiation-sensitizing chemotherapies in response to changes in radiation 
sensitivity [375]. Both machine learning and genome-scale metabolic modeling are 
powerful tools for understanding cancer pathophysiology, identification of clinical 
biomarkers, and prediction of patient outcomes. Their synergistic integration will 
inevitably yield additional insights for improving precision medicine and long-term care 
of cancer patients. 
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CHAPTER 6. FBA MODELS OF RADIATION-SENSITIZING 
CHEMOTHERAPEUTICS 
6.1 Introduction 
A large number of chemotherapeutics have been found to increase sensitivity of 
cancer cells to ionizing radiation therapy through one or more of their mechanisms of 
action [376]. Thus, these drugs can be used in combination to enhance tumor cell death, or 
to decrease side effects on normal tissues by using lower radiation doses. Because ionizing 
radiation causes cellular death mainly through direct and indirect ROS-mediated DNA 
damage, many chemotherapies which either induce additional DNA damage or limit DNA 
damage repair mechanisms in response to radiation treatment have been found to have 
radiosensitizing effects, such as 5-fluorouracil and gemcitabine [96, 333]. Many 
chemotherapies that act in part by redox-based mechanisms of action are also radiation 
sensitizers; however, the impact of these drugs on oxidative stress and redox metabolism 
have seldom been associated with their radiation-sensitizing activity [6]. For example, 
while doxorubicin is known to undergo one-electron redox cycling resulting in NADPH 
consumption and superoxide generation, its radiosensitizing activity is mainly attributed to 
its effects on DNA damage caused by topoisomerase II inhibition and DNA intercalation 
[123-125, 377, 378]. Additionally, although cisplatin can cause superoxide generation 
through disruption of oxidative phosphorylation, radiation sensitization has instead been 
previously attributed to inhibition of nonhomologous end joining [106, 379]. Mechanistic 
modeling of redox-directed chemotherapeutic metabolism may provide insights into 
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possible mechanisms of radiation sensitization caused by altered redox biology and 
metabolism. 
Kinetic ordinary differential equation (ODE)-based representations have 
traditionally been used to model the metabolism of redox-directed drugs. Finn et al. 
developed kinetic models of doxorubicin metabolism in acute lymphoblastic leukemia 
(ALL) cell lines with varying drug sensitivities, and showed alterations in cytotoxicity from 
switching between superoxide generation and NADPH depletion [125]. Similar kinetic 
models have been developed for cisplatin and cyclophosphamide metabolism [380, 381]. 
While kinetic models can more accurately capture the dynamic nature of drug metabolism, 
genome-scale metabolic models may present an alternative strategy for capturing the 
interconnections between drug metabolism and the human metabolic network which arise 
from use of common metabolic cofactors such as ATP, NADH, and NADPH; however, 
few genome-scale metabolic models of xenobiotic metabolism have been developed. 
Sahoo et al. incorporated a drug module composed of 210 metabolites and 721 metabolic 
reactions into the Recon2 metabolic reconstruction and defined drug metabolic objective 
functions to simulate the interconnection of many commonly-used medications (including 
statins, acetaminophen, and cyclosporine) with genome-scale metabolism [382]. Other 
studies have used genome-scale metabolic models of cancer cell lines to predict selective 
drug targets by identifying genes essential for cellular biomass production [141, 383]. 
Despite the advantage of genome-scale models in incorporating the thousands of human 
metabolic reactions involved in production or consumption of redox cofactors, FBA 
models of redox-directed chemotherapeutics and their interconnections with the redox 
metabolic network have yet to be developed. 
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 Because chemotherapeutics have multiple complex mechanisms of action, potential 
modelling of these drugs using FBA may be best accomplished by maximizing multiple 
different objective functions that reflect these disparate mechanisms. FBA objective 
functions are often used to reflect the biological “objective” of the organism or cell type 
under study; for example, biomass production (proliferation) is often maximized in models 
of microorganisms and cancer cells [138]. Nonetheless, the choice of the optimal objective 
function for a particular application is often subjective, as a precise biological “objective” 
is unlikely to be captured by a single function. Few studies have investigated the use of 
multiple objective functions for obtaining better correspondence between model 
predictions and experimental validation. Garcia Sanchez et al. used a combination of 
compartment-specific objective functions to reflect differential compartmentalization of 
metabolic optimization observed in Saccharomyces cerevisiae [384]. Budinich et al. 
developed multi-objective flux balance analysis (MO-FBA) to reflect differences in 
objective functions between single microbial strains in an ecosystem with nutrient 
exchange between strains [385]. Despite these examples, there is currently a lack of 
systematic approaches for identifying optimal multi-feature objective functions for FBA 
models. 
 To investigate the role that genome-scale redox metabolism has on redox-driven 
chemotherapeutic activity, the mechanism of action of three commonly used 
chemotherapeutics (cisplatin, cyclophosphamide, and doxorubicin) were incorporated into 
FBA models of TCGA tumors. The metabolism of each of these three drugs involves one 
or multiple redox cofactors, including NADH, NADPH, and GSH (Figure 2-5, Figure 2-6, 
Figure 2-7). An optimal multi-feature objective function for each drug module was 
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identified by developing a novel objective function screening algorithm, comparing model-
predicted objective values between drug-sensitive and drug-resistant TCGA tumors. These 
optimal objective functions were then used to predict chemotherapeutic response and 
radiation-sensitizing effect in radiation-resistant TCGA tumors, in order to determine in 
which patients these chemotherapies could be effectively used either alone or in 
combination with radiation therapy. 
 
6.2 Methods 
6.2.1 Integration of chemotherapeutic metabolism modules into FBA models 
6.2.1.1 Prediction of kinetic rates of transport reactions 
Matsson et al. previously quantified the kinetic rates of transport reactions for a 
range a substrates through a number of solute carrier (SLC) family and ATP-binding 
cassette (ABC) family transporters [386]. For a particular transport reaction in any of the 
drug modules (detailed below), if an exact match between both transporter and substrate 
was made with the Matsson et al. dataset, then that recorded kinetic rate was used. If a 
match was made between transporters but not substrate, a weighted average of the recorded 
kinetic rates for that transporter was used, with weights equal to the Tanimoto coefficient 
between the desired model substrate and Matsson et al. dataset substrate. If a match was 
made between substrates but not transporters, an average of the recorded kinetic rates for 
that substrate for all SLC-family transporters (for import reactions) or ABC-family 
transporters (for export reactions) was used. If there was no available match for transporter 
or substrate, both averages for transporters and weighted averages for substrates were 
performed as detailed above. 
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6.2.1.2 Cisplatin module 
The following metabolites involved in cisplatin metabolism were added: 
1. Cisplatin (“cis[]”): extracellular, cytosolic, mitochondrial 
2. Cisplatin-mitochondrial DNA (“cis-mtDNA[]”): mitochondrial 
3. Cisplatin-GSH (“cisGSH[]”): extracellular, cytosolic 
4. Cisplatin-metallothionein (“cisMT[]”): extracellular, cytosolic 
The following reactions involved in cisplatin metabolism were added: 
• Exchange reactions: 
1. Exchange of cisplatin: 
1 cis[e]  Ø, GPR: None, EC: None 
2. Exchange of cisplatin-GSH: 
1 cisGSH[e]  Ø, GPR: None, EC: None 
3. Exchange of cisplatin-metallothionein: 
1 cisMT[e]  Ø, GPR: None, EC: None 
• Transport reactions: 
1. Transport of cisplatin from extracellular to cytosol: 
1 cis[e]  1 cis[c], GPR: 1317, EC: Transport (see above) 
2. Transport of cisplatin from cytosol to extracellular: 
1 cis[c] + 1 atp[c] + 1 h2o[c]  1 cis[e] + 1 adp[c] + 1 pi[c], GPR: 
9429 or 538 or 540, EC: Transport 
3. Transport of cisplatin-GSH from cytosol to extracellular: 
1 cisGSH[c] + 1 atp[c] + 1 h2o[c]  1 cisGSH[e] + 1 adp[c] + 1 pi[c], 
GPR: 1244, EC: Transport 
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4. Transport of cisplatin-metallothionein from cytosol to extracellular: 
1 cisMT[c]  1 cisMT[e], GPR: None, EC: None 
5. Transport of cisplatin from cytosol to mitochondrion: 
1 cis[c]  1 cis[m], GPR: 10063, EC: 1.9.3.1 
• Cisplatin mechanism 
1. Cisplatin to cisplatin-mtDNA: 
1 cis[m] + 0.5 o2[m]  1 cis-mtDNA[m] + 0.5 o2s[m], GPR: 4535 or 
4536 or 4537 or 4538 or 4539 or 4540 or 4541 or 4519, EC: 1.9.3.1 
• Cisplatin clearance 
1. Cisplatin to cisplatin-GSH: 
1 cis[c] + 1 gthrd[c]  1 cisGSH[c] + 1 h[c], GPR: 2944 or 9446 or 
2950 or 2952, EC: 2.5.1.18 
2. Cisplatin to cisplatin-metallothionein: 
2 cis[c] + 2 gthrd[c]  1 cisMT[c] + 1 gthox[c] + 2 h[c], GPR: 4489 
or 4502 or 4504 or 84560, EC: 1.8.5.1 
• Artificial sinks 
1. Cisplatin-mtDNA sink: 
1 cis-mtDNA[m]  Ø, GPR: None, EC: None 
6.2.1.3 Cyclophosphamide module 
The following metabolites involved in cyclophosphamide metabolism were 
added: 
1. Cyclophosphamide (“cpa[]”): extracellular, cytosolic 
2. Dechloroethylcyclophosphamide (“dce-cpa[]”): extracellular, cytosolic 
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3. Chloroacetaldehyde (“caa[]”): extracellular, cytosolic 
4. 4-Hydroxycyclophosphamide (“4oh-cpa[]”): cytosolic 
5. 4-Ketocyclophosphamide (“4k-cpa[]”): extracellular, cytosolic 
6. Aldophosphamide (“aldph[]”): cytosolic 
7. Alcophosphamide (“alcph[]”): extracellular, cytosolic 
8. Carboxyphosphamide (“cph[]”): extracellular, cytosolic 
9. Phosphoramide mustard (“phmust[]”): cytosolic 
10. Acrolein (“acr[]”): cytosolic 
11. Phosphoramide mustard-GSH (“phmust-GSH[]”): extracellular, cytosolic 
12. Acrolein-GSH (“acr-GSH[]”): extracellular, cytosolic 
The following reactions involved in cyclophosphamide metabolism were added: 
• Exchange reactions: 
1. Exchange of cyclophosphamide: 
1 cpa[e]  Ø, GPR: None, EC: None 
2. Exchange of dechloroethylcyclophosphamide: 
1 dce-cpa[e]  Ø, GPR: None, EC: None 
3. Exchange of chloroacetaldehyde: 
1 caa[e]  Ø, GPR: None, EC: None 
4. Exchange of 4-ketocyclophosphamide: 
1 4k-cpa[e]  Ø, GPR: None, EC: None 
5. Exchange of alcophosphamide: 
1 alcph[e]  Ø, GPR: None, EC: None 
6. Exchange of carboxyphosphamide: 
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1 cph[e]  Ø, GPR: None, EC: None 
7. Exchange of phosphoramide mustard-GSH: 
1 phmust-GSH[e]  Ø, GPR: None, EC: None 
8. Exchange of acrolein-GSH: 
1 acr-GSH[e]  Ø, GPR: None, EC: None 
• Transport reactions: 
1. Transport of cyclophosphamide from extracellular to cytosol: 
1 cpa[e]  1 cpa[c], GPR: None, EC: None 
2. Transport of cyclophosphamide from cytosol to extracellular: 
1 cpa[c] + 1 atp[c] + 1 h2o[c]  1 cpa[e] + 1 adp[c] + 1 pi[c], GPR: 
5243 or 9429, EC: Transport 
3. Transport of dechloroethylcyclophosphamide from cytosol to 
extracellular: 
1 dce-cpa[c]  1 dce-cpa[e], GPR: None, EC: None 
4. Transport of chloroacetaldehyde from cytosol to extracellular: 
1 caa[c]  1 caa[e], GPR: None, EC: None 
5. Transport of 4-ketocyclophosphamide from cytosol to extracellular: 
1 4k-cpa[c]  1 4k-cpa[e], GPR: None, EC: None 
6. Transport of alcophosphamide from cytosol to extracellular: 
1 alcph[c]  1 alcph[e], GPR: None, EC: None 
7. Transport of carboxyphosphamide from cytosol to extracellular: 
1 cph[c]  1 cph[e], GPR: None, EC: None 
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8. Transport of phosphoramide mustard-GSH from cytosol to 
extracellular: 
1 phmust-GSH[c] + 1 atp[c] + 1 h2o[c]  1 phmust-GSH[e] + 1 
adp[c] + 1 pi[c], GPR: 1244, EC: Transport 
9. Transport of acrolein-GSH from cytosol to extracellular: 
1 acr-GSH[c] + 1 atp[c] + 1 h2o[c]  1 acr-GSH[e] + 1 adp[c] + 1 
pi[c], GPR: 1244, EC: Transport 
• Cyclophosphamide mechanism 
1. Cyclophosphamide to 4-hydroxycyclophosphamide: 
1 cpa[c] + 1 o2[c] + 1 nadph[c] + 1 h[c]  1 4oh-cpa[c] + 1 h2o[c] + 
1 nadp[c], GPR: 1555 or 1559 or 1557 or 1576, EC: 1.14.14.1 
2. 4-hydroxycyclophosphamide to aldophosphamide: 
1 4oh-cpa[e]  1 aldph[c], GPR: None, EC: None 
3. Aldophosphamide to phosphoramide mustard: 
1 aldph[c]  1 phmust[c] + 1 acr[c], GPR: None, EC: None 
• Cyclophosphamide clearance 
1. Cyclophosphamide to dechloroethylcyclophosphamide: 
1 cpa[c] + 1 o2[c] + 1 nadph[c] + 1 h[c]  1 dce-cpa[c] + 1 caa[c] + 1 
h2o[c] + 1 nadp[c], GPR: 1576 or 1577, EC: 1.14.14.1 
2. 4-hydroxycyclophosphamide to 4-ketocyclophosphamide: 
1 4oh-cpa[c] + 1 nad[c]  1 4k-cpa[c] + 1 nadh[c] + 1 h[c], GPR: 124 
or 125 or 126 or 127 or 128 or 130 or 131, EC: 1.1.1.1 
3. Aldophosphamide to alcophosphamide: 
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1 aldph[c] + 1 nadph[c] + 1 h[c]  1 alcph[c] + 1 nadp[c], GPR: 
10327 or 231 or 57016, EC: 1.1.1.21 
4. Aldophosphamide to carboxyphosphamide: 
1 aldph[c] + 1 nad[c] + 1 h2o[c]  1 cph[c] + 1 nadh[c] + 1 h[c], 
GPR: 216 or 218 or 7915, EC: 1.2.1.3 
5. Phosphoramide mustard to phosphoramide mustard-GSH: 
1 phmust[c] + 1 gthrd[c]  1 phmust-GSH + 1 h[c], GPR: 2938, EC: 
2.5.1.18 
6. Acrolein to acrolein-GSH: 
1 acr[c] + 1 gthrd[c]  1 acr-GSH + 1 h[c], GPR: 2938, EC: 2.5.1.18 
6.2.1.4 Doxorubicin module 
The following metabolites involved in doxorubicin metabolism were added: 
1. Doxorubicin (“doxQ[]”): extracellular, cytosolic 
2. Doxorubicin semiquinone (“doxSQ[]”): cytosolic 
3. Doxorubicinol (“doxHQ[]”): extracellular, cytosolic 
4. 7-Deoxydoxorubicinone (“doxdeoxy[]”): extracellular, cytosolic 
5. Daunosamine (“daun[]”): extracellular, cytosolic 
The following reactions involved in cyclophosphamide metabolism were added: 
• Exchange reactions: 
1. Exchange of doxorubicin: 
1 doxQ[e]  Ø, GPR: None, EC: None 
2. Exchange of doxorubicinol: 
1 doxHQ[e]  Ø, GPR: None, EC: None 
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3. Exchange of 7-deoxydoxorubicinone: 
1 doxdeoxy[e]  Ø, GPR: None, EC: None 
4. Exchange of daunosamine: 
1 daun[e]  Ø, GPR: None, EC: None 
• Transport reactions: 
1. Transport of doxorubicin from extracellular to cytosol: 
1 doxQ[e]  1 doxQ[c], GPR: 85413, EC: Transport 
2. Transport of doxorubicin from cytosol to extracellular, RALBP1: 
1 doxQ[c]  1 doxQ[e], GPR: 10928, EC: Transport 
3. Transport of doxorubicin from cytosol to extracellular, ABC 
transporters: 
1 doxQ[c] + 1 atp[c] + 1 h2o[c]  1 doxQ[e] + 1 adp[c] + 1 pi[c], 
GPR: 5243 or 4363 or 1244 or 10257 or 9429, EC: Transport 
4. Transport of doxorubicinol from cytosol to extracellular: 
1 doxHQ[c]  1 doxHQ[e], GPR: None, EC: None 
5. Transport of 7-deoxydoxorubicinone from cytosol to extracellular: 
1 doxdeoxy[c]  1 doxdeoxy[e], GPR: None, EC: None 
6. Transport of daunosamine from cytosol to extracellular: 
1 daun[c]  1 daun[e], GPR: None, EC: None 
• Doxorubicin mechanism 
1. Doxorubicin to doxorubicin semiquinone, NOS3: 
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1 doxQ[c] + 2 o2[c] + 1 arg_L[c] + 1.5 nadph[c] + 1.5 h[c]  1 
doxSQ[c] + 2 h2o[c] + 1 no[c] + 1 citr_L[c] + 1.5 nadp[c], GPR: 4846, 
EC: 1.14.13.39 
2. Doxorubicin to doxorubicin semiquinone, POR: 
1 doxQ[c] + 0.5 nadph[c] + 0.5 h[c]  1 doxSQ[c] + 0.5 nadp[c], 
GPR: 5447, EC: 1.6.2.4 
3. Doxorubicin semiquinone to doxorubicin: 
1 doxSQ[c] + 1 o2[c]  1 doxQ[c] + 1 o2s[c] + 1 h[c]: GPR: None, 
EC: None 
• Doxorubicin clearance 
1. Doxorubicin to doxorubicinol: 
1 doxQ[c] + 1 nadph[c] + 1 h[c]  1 doxHQ[c] + 1 nadp[c], GPR: 873 
or 874 or 10327 or 8644, EC: 1.1.1.2 or 1.1.1.184 
2. Doxorubicin to 7-deoxydoxorubicinone: 
1 doxQ[c] + 0.5 nadph[c] + 1.5 h[c]  1 doxHQ[c] + 1 daun[c] + 0.5 
nadp[c], GPR: 5447, EC: 1.6.2.4 
6.2.2 Multi-feature objective function screen 
For each drug module, the following were considered as possible single objective 
functions: (1) maximizing the production of each metabolite involved in the drug 
mechanism (including cofactors such as ATP and NADPH); (2) maximizing the flux 
through each reaction involved in the drug mechanism; and (3) maximizing the conversion 
between cofactor forms involved in the drug mechanism (e.g. conversion of ADP to ATP). 
The performance of each objective function was assessed by calculating the area under the 
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receiver operating characteristic curve (AUROC) for classifying drug-sensitive and drug-
resistant TCGA tumors using the calculated objective value for each sample as threshold 
values; objective functions with the largest AUROC value provide optimal separation 
between drug-sensitive and drug-resistant classes. 
Figure 6-1 provides an overview of the objective function screen to find the optimal 
multi-feature objective function for each drug module. All 2-feature objective functions 
composed of individual features with AUROC > 0.5 were considered. 10 combinations of 
weights for each feature of the 2-tuple were assessed. Weight values for each feature were 
randomly sampled from a uniform distribution centered at the inverse of the average single-
feature objective value across all samples and spanning ± 2 standard deviations; this results 
in all feature objective values being on roughly equal orders of magnitude, allowing for 
accurate comparison of multiple-feature objective functions. After assessing each 2-feature 
objective function, those with AUROC greater than the best single-feature objective 
AUROC at any weight combination were kept for the next round. All the individual 
features among the top 2-feature objective functions were added systematically to the top 
2-feature objective functions to create the 3-feature objective functions that will be 
assessed. This iterative pipeline continues until a round where no n-feature objective 
functions had an AUROC value greater than the top (n-1)-feature objective function. 
Afterwards, the top 10 overall objective functions underwent 100 iterations of Bayesian 
optimization to find the optimal weight combination which maximizes AUROC. The 
objective function and weights with the largest overall AUROC were used for prediction 
of drug metabolism response. 
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Figure 6-1. Overview of the objective function screen pipeline. 
6.2.3 Machine learning regressors for radiation sensitizing effect 
Implementation of machine learning regressors was analogous to that discussed in 
Chapter 5, except that base learners were performing regression tasks with mean squared 













where yitrue is the true value for sample i, yipred is the predicted value for sample i, and Ns is 
the total number of samples. 
6.2.4 Code availability 
Code for the simulation of chemotherapeutic response in FBA models of TCGA 
tumors is available at https://github.com/kemplab/FBA-chemosim.  Jupyter notebooks are 
available for 1) implementation of multi-feature objective function screen; 2) simulation 






6.3.1 Optimal FBA objective functions utilize redox cofactors 
Figure 6-2, Figure 6-3, and Figure 6-4 show the optimal objective functions for 
each drug module from the multi-feature objective function screen. All three optimal 
objective functions were composed of more than one feature. Two of the three optimal 
objective functions contained drug efflux reactions and/or the production of ATP necessary 
for drug efflux, consistent with previously-identified roles of drug efflux pumps including 
ABC transporters in chemotherapeutic resistance [387]. Additionally, two optimal 
objective functions contained drug clearance reactions or the production of metabolic 
cofactors including GSH and NADH which are utilized for drug clearance. Most notably, 
all three optimal objective functions contained metabolic reactions which utilize redox 
cofactors or the direct production of redox cofactors: cisplatin metabolism involves the 
production of the glutathionylated biproduct Cis-GSH, cyclophosphamide metabolism 
involves the direct production of NADH, and doxorubicin metabolism involves the 
NADPH-consuming reactions NOS3 and POR. The reduced forms of all three redox 
cofactors showed upregulated in radiation-resistant TCGA tumor models, suggesting that 
their utilization in chemotherapeutic metabolism may contribute to the drugs’ radiation-
sensitizing effect (Figure 4-12) [207, 388-390]. 
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Figure 6-2. Optimal objective function for cisplatin response, highlighting the 
features involved (bolded metabolites and reaction arrows) and their relative 
weights. Features are colored based on relative weight values (largest value = dark 
red, lowest value = light orange). 
 
 
Figure 6-3. Optimal objective function for cyclophosphamide response, highlighting 
the features involved (bolded metabolites and reaction arrows) and their relative 
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weights. Features are colored based on relative weight values (largest value = dark 
red, lowest value = light orange). 
 
Figure 6-4. Optimal objective function for doxorubicin response, highlighting the 
features involved (bolded metabolites and reaction arrows) and their relative 
weights. Features are colored based on relative weight values (largest value = dark 
red, lowest value = light orange). 
 Figure 6-5 shows the improvement in AUROC of each multi-feature objective 
function compared to the top single-feature objective function for each drug module; the 
DeLong test, a non-parametric approach for comparing the areas under two correlated ROC 
curves, shows that each of these three improvements is statistically significant [391]. For 
each drug module, the optimal objective value threshold for separating model-predicted 
drug-sensitive and -resistant classes was defined as that which maximizes Youden’s J 
statistic: 
 𝐽 = Sensitivity + Specificity − 1 (36) 
This optimal threshold represents the point on the ROC curve which has the smallest 
distance from the top-left corner (where TPR=1 and FPR=0). Figure 6-6 shows the optimal 
objective value thresholds and corresponding Youden’s J statistic for each drug module. 
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Figure 6-5. Comparison of ROC curves and AUROC values between the top single-
feature objective function (light blue) and top multi-feature objective function (dark 
blue) for each drug module. The p-value of the DeLong test comparing the two 
AUROC values is shown. Dark blue dot represents the point on the ROC curve 
which maximizes Youden’s J statistic. 
 
 
Figure 6-6. Separation of model-predicted drug-sensitive and drug-resistant classes 
based on the optimal objective value threshold which maximizes Youden’s J 
statistic. 
6.3.2 FBA models predict chemotherapy response and radiation sensitization 
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Optimal multi-feature objective functions and objective value thresholds for each 
drug module were used to predict chemotherapeutic response in radiation-resistant tumor 
models and determine for which radiation-resistant patients these alternative therapies may 
be beneficial (Figure 6-7). While 53.8% of radiation-resistant patients were predicted to be 
cisplatin-sensitive, only 40.7% were predicted to be cyclophosphamide-sensitive and 
38.7% doxorubicin-sensitive. This larger proportion of radiation-resistant drug-resistant 
patients may be attributed to the similar metabolic effects of these chemotherapies as 
ionizing radiation therapy, in that they deplete cellular stores of reduced redox cofactors 
and promote ROS-mediated DNA damage [377, 392]. 
 
Figure 6-7. Prediction of chemotherapeutic response in radiation-resistant patient 
tumors. Optimal objective value thresholds separating drug-sensitive and -resistant 
classes are shown, with the number and percentage of radiation-resistant tumors 
predicted to be drug-sensitive. 
 While FBA models predicted that a large percentage of radiation-resistant patient 
tumors would not respond to treatment with these chemotherapies alone, it is yet unclear 
whether these chemotherapies could be used to sensitize these radiation-resistant tumors to 
radiation therapy when used in conjunction. The optimal objective function for 
implementation of cisplatin, cyclophosphamide, and doxorubicin metabolism involved the 
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redox cofactors GSH, NADH, and NADPH, respectively; all three of these reduced 
metabolites were previously shown to be upregulated in radiation-resistant tumor models 
for antioxidant protection against ROS-mediated damage from ionizing radiation (Figure 
4-12). To predict the radiation-sensitizing effect of these chemotherapies in radiation-
resistant drug-resistant patient tumors, the decrease in maximal GSH, NADH, and NADPH 
production caused by maintaining each tumor’s cisplatin, cyclophosphamide, or 
doxorubicin objective value was determined (Figure 6-8). A wide spectrum of radiation-
sensitizing effects was observed for each chemotherapy, with some tumor models showing 
significant decreases in reduced cofactor production, while others showing negligible 
effect. 
 
Figure 6-8. Predicted effect of maintaining chemotherapy objective value on 
maximal production of reduced redox cofactors in radiation-resistant drug-resistant 
tumor models. 
6.3.3 Machine learning regressors identify sensitization biomarkers 
To determine which multi-omic features are predictive of radiation-sensitizing 
effect and could be used as diagnostic biomarkers for combination therapy response, 
machine learning regressors utilizing clinical, gene expression, mutation, and metabolic 
features from each radiation-resistant drug-resistant TCGA tumor were built for each of 
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the three chemotherapies. Each machine learning regressor accurately predicts FBA model-
calculated radiation-sensitizing effect of each chemotherapy, with statistically-significant 
Pearson and Spearman correlations between predicted and actual effects (Figure 6-9, 
Figure 6-10). The doxorubicin regressor shows the best performance among the three 
chemotherapies, likely due to the greater number of available radiation-resistant drug-
resistant samples. 
 
Figure 6-9. Comparison of machine learning regressor-predicted (y-axis) and FBA 
model-calculated (x-axis) radiation-sensitizing effects of each chemotherapy. Error 
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bars signify ± 1 standard error for each patient tumor across 20 
training+validation/testing splits. Red dotted line: 1:1 line. 
 
Figure 6-10. Pearson and Spearman correlation values (and associated p-values) for 
the regression of machine learning regression-predicted (y-axis) vs. FBA model-
calculated (x-axis) radiation-sensitizing effects of each chemotherapy. All testing set 
performance values across 20 training+validation/testing splits are shown. 
 SHAP values were calculated for each feature among the three machine learning 
regressors to determine which multi-omic features are most predictive of radiation-
sensitizing effect. Metabolic features contributed more than half of the cumulative feature 
importance scores for both cisplatin and cyclophosphamide regressors (Figure 6-11, Figure 
6-12). Nicotinic acid adenine dinucleotide (NAAD), a 5,5’-dinucleotide metabolite that can 
be converted to NAD+ via glutamine-dependent NAD+ synthetase, was the 2nd-highest 
feature in the cisplatin regressor and highest overall feature in the cyclophosphamide 
regressor [393]. This metabolite is likely utilized in nicotinamide metabolism for 
generation of NAD(P)+, which can be reduced to NAD(P)H and utilized by glutathione 
reductase to elevate levels of GSH for chemotherapy metabolism [394]. Additionally, 
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pantetheine 4’-phosphate, a related metabolite to pantothenic acid (vitamin B5) which is 
involved in lipid and cholesterol metabolism, as well as palmityl-CoA, a substrate for fatty 
acid elongation, were the highest and 3rd-highest features in the cisplatin regressor, 
respectively; cisplatin has been previously shown to cause hyperlipidemia in patients with 
germ cell testicular tumors, and sensitivity to cisplatin was shown to be affected by fatty 
acid synthase activity as well as administration of omega-3 fatty acids, validating the 
observed interplay between cisplatin and lipid metabolism [395-397]. NADP+ and NADPH 
were the 4th- and 2nd-highest features in the cyclophosphamide regressor, respectively, 
suggesting that both NADH metabolism and NADPH metabolism are involved in the 
radiation-sensitizing effect of cyclophosphamide [117, 118, 398]. POR expression 
dominated the list of top features for the doxorubicin regressor, contributing nearly 45% of 
the cumulative feature importance scores (Figure 6-13). Interestingly, the POR NADPH-
consuming reaction had a lower relative weight than the NOS3 NAPDH-consuming 
reaction in the optimal multi-feature objective function for doxorubicin metabolism; 
however, while NOS3 flux may better differentiate drug-sensitive and -resistant cancers, 
FBA models predict that the POR reaction has higher absolute flux values and causes 
greater reductions in NADPH stores, thus having a larger impact on radiation sensitization 
by doxorubicin (Figure 6-14). 
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Figure 6-11. Top 50 features with largest mean absolute SHAP values for the 
cisplatin sensitizing-effect regressor, colored based on each feature’s original 
dataset. (Inset) Relative contribution of features from each dataset to the sum of 




Figure 6-12. Top 50 features with largest mean absolute SHAP values for the 
cyclophosphamide sensitizing-effect regressor, colored based on each feature’s 
original dataset. (Inset) Relative contribution of features from each dataset to the 




Figure 6-13. Top 50 features with largest mean absolute SHAP values for the 
doxorubicin sensitizing-effect regressor, colored based on each feature’s original 
dataset. (Inset) Relative contribution of features from each dataset to the sum of 




Figure 6-14. Comparison of NOS3 and POR flux magnitudes in doxorubicin-
sensitive and -resistant tumor models. 
6.4 Discussion 
Because many chemotherapeutics with redox activity such as cisplatin, 
cyclophosphamide, and doxorubicin have multiple mechanisms of action, it is unclear 
which of these mechanisms contribute most to differential activity in drug-sensitive and -
resistant tumors, as well as which confer the largest radiation-sensitizing effect. By 
implementing the mechanism of action of these three drugs into genome-scale FBA models 
of TCGA tumors and performing a novel multi-feature objective function screen, we found 
that maximization of multiple drug-related metabolic reactions or production of metabolic 
cofactors resulted in optimal correspondence between model predictions and known drug 
sensitivities in TCGA tumors, in agreement with the multiple observed mechanisms of 
action of these drugs (Figure 6-5). Feature weights provide an indication of the relative 
importance of different drug mechanisms to overall activity. Production of Cis-mtDNA 
had the highest feature weight in the cisplatin drug module, coinciding with experimental 
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studies demonstrating the significant impact of oxidative phosphorylation disruption on 
cisplatin-mediated oxidative stress (Figure 6-2) [106-108]. NADH production had the 
highest feature weight in the cyclophosphamide drug module; Magni et al. previously 
showed that overexpression of NADH-generating aldehyde dehydrogenase results in 
increased cyclophosphamide resistance in human hematopoietic cell lines, in agreement 
with model-predicted involvement of NADH in the major mechanism of 
cyclophosphamide activity (Figure 6-3) [118]. ATP production had the highest feature 
weight in the doxorubicin drug module, in agreement with previous studies implicating 
ATP-dependent ABC transporters in doxorubicin efflux and resistance (Figure 6-4) [399, 
400]. Minor features with lower objective function weights also agree with previous 
experimental associations with drug sensitivity, including ATP-dependent efflux of 
cisplatin and glutathionylated cisplatin, as well as NADPH-consuming conversion of 
doxorubicin quinone to semiquinone form via NOS3 and POR [401, 402]. Interestingly, 
ATP production had the highest feature weight for doxorubicin but lowest feature weight 
for cisplatin, suggesting that the relative contribution of redox activity versus drug efflux 
towards overall chemotherapeutic response differs between drugs. 
Implementation of optimal multi-feature objective functions for each drug module 
resulted in depletion of intracellular stores of GSH (cisplatin), NADH 
(cyclophosphamide), or NADPH (doxorubicin), all of which were upregulated in radiation-
resistant FBA tumor models (Figure 4-12). Although redox-directed mechanisms of 
radiosensitization by these drugs have not been definitively identified, these three cofactors 
have been previously implicated in activity of the corresponding chemotherapies as well 
as overall chemotherapeutic sensitivity. Cisplatin-resistant cells have elevated levels of 
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GSH and increased expression of glutamate-cysteine ligase, the rate-limiting enzyme for 
GSH synthesis [403, 404]. Additionally, GSH depletion with L-BSO resulted in 
sensitization of HNSCC cell lines to cisplatin treatment, as well as partially inhibiting DNA 
damage repair in ovarian cancer cell lines [405, 406]. Thus, cisplatin and radiation response 
could be interconnected by cellular glutathione stores. Similarly, as mentioned above, 
elevated levels of NADH caused by increased ALDH expression are associated with 
cyclophosphamide resistance [118]. Doxorubicin treatment in yeast was found to cause 
increased expression of pentose phosphate pathway genes involved in NADPH generation, 
possibly suggesting an initial depletion in NADPH levels following treatment and 
compensatory transcriptional regulation [407, 408]. Inhibition of PGD resulted in increased 
doxorubicin sensitivity in thyroid cancer cells [409]. Taken together, these findings suggest 
that the redox cofactors predicted from FBA models are directly involved in the mechanism 
of action of these chemotherapeutics; nonetheless, further studies are needed to validate 
chemotherapy-induced depletion of redox cofactors and resultant radiosensitization. 
 Metabolism of these three chemotherapeutics involves the production and 
consumption of multiple metabolic cofactors including ATP, NADH, and NADPH. Most 
kinetic models of drug metabolism either introduce artificial supply reactions of these 
metabolites or the kinetics of only one of the major cofactor suppliers; for example, supply 
of NADPH is often introduced solely by G6PD. However, previous modeling of redox 
metabolism has shown the importance of multiple redox cofactor-producing reactions 
towards the overall metabolic phenotype, especially in radiation-resistant cancer cells 
(Figure 4-16) [206]. Because genome-scale metabolic models already include all known 
metabolic pathways involved in cofactor production and consumption, use of these models 
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provides an advantage over conventionally-used kinetic models by fully integrating drug 
metabolism into the non-xenobiotic human metabolic network [7]. This not only results in 
more accurate predictions of cofactor utilization in drug metabolism, but also allows for 
genome-scale screens for the identification of novel metabolic enzymes which most greatly 
impact chemotherapeutic response. Ultimately, integration of genome-scale steady-state 
models with small-scale kinetic models of xenobiotic metabolism may provide optimal 




CHAPTER 7. CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Conclusions 
The overall goal of this dissertation was to make methodological advancements in 
the development and integration of multi-omic data into genome-scale metabolic models 
and machine learning classifiers, in order to accurately assess the role of redox metabolism 
in the tumor response to radiation therapy and radiation-sensitizing chemotherapies. By 
doing so, I was able to identify novel targets of redox metabolism in radiation-resistant 
tumors, predict radiation response in individual patient tumors through the use of metabolic 
biomarkers, and model the radiation-sensitizing effect of redox-based chemotherapeutics. 
7.1.1 FBA models of redox metabolism in TCGA tumors 
To create genome-scale models which accurately reflect the metabolism of 
radiation-sensitive and -resistant tumors, a novel bioinformatics platform was developed 
for integrating genomic, transcriptomic, kinetic, and thermodynamic parameters into 
personalized FBA models. By comparing model predictions from 716 radiation-sensitive 
and 199 radiation-resistant TCGA tumor models, I discovered that radiation-resistant 
tumors were capable of re-routing metabolic flux to optimize mitochondrial production of 
redox cofactors and increase ROS scavenging. Additionally, by performing simulated gene 
knockout screens and validating experimentally with siRNA gene knockdown, I identified 
metabolic genes (including G6PD, LDHB, PGAM2, and MTHFD1) which have 
significantly greater impacts on redox metabolism in radiation-resistant tumors and cancer 
cell lines across multiple cancer types. Finally, I took advantage of the personalized aspect 
of these metabolic models to generate metabolic flux profiles for individual radiation-
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resistant patients, which can be used to identify which targets in the redox metabolic 
network may be optimal candidates for targeted therapies. This work not only improved 
upon the methodological shortcomings of previous FBA models of cancer metabolism, but 
was the first to utilize genome-scale modeling to identify key metabolic differences 
between radiation-sensitive and -resistant tumors which could be exploited for improving 
radiation sensitivity. 
7.1.2 Machine learning classifiers for prediction of radiation response 
To identify potential biomarkers for the a priori prediction of radiation sensitivity 
in cancer patients, machine learning classifiers which integrate multi-omic data from 
TCGA were developed. The predictive accuracy of multiple machine learning approaches 
was compared, identifying a dataset-independent ensemble architecture with gradient 
boosting models and Bayesian optimization for accurate prediction of radiation response 
compared to previously-developed classifiers. In order to incorporate metabolomic 
information into machine learning predictions, FBA models were used to identify 
metabolites which significant differences in production between radiation-sensitive and -
resistant tumors; these metabolites were validated through experimental metabolomics 
studies of matched radiation-sensitive and -resistant cancer cell lines. Multi-omic and non-
invasive classifiers identified clinical patient subgroups where metabolic features involved 
in lipid, nucleotide, antioxidant, and immune mediator metabolism provided significant 
diagnostic utility in predicting radiation therapy response. This work made significant 
advancements by being the first to integrate FBA model predictions into machine learning 
classifiers for cancer treatment outcomes, identifying key multi-omic biomarkers with 
clinical utility for assessment of radiation response in individual cancer patients. 
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7.1.3 FBA models of radiation-sensitizing chemotherapeutics 
To determine which radiation-resistant patients could benefit from treatment with 
radiation-sensitizing chemotherapies, either alone or in combination with radiation 
therapy, the mechanisms of action of cisplatin, cyclophosphamide, and doxorubicin were 
incorporated into FBA models of radiation-resistant tumors. Optimal predictive accuracy 
of chemotherapeutic response was obtained by implementing a novel multi-feature FBA 
objective function screen, determining which metabolic reactions and cofactors are most 
important to the drugs’ redox-based mechanisms of action. Model predicted-response from 
all three drugs showed decreases in levels of redox cofactors which had been previously 
implicated in tumor resistance to radiation therapy. Finally, machine learning regressors 
were utilized to identify multi-omic biomarkers from radiation-resistant patient tumors 
which are associated with redox cofactor depletion and radiation sensitization by these 
therapies. This work was the first to utilize genome-scale modeling to assess the role of 
chemotherapeutic treatment on tumor redox metabolism and radiation sensitization. 
 
7.2 Future Directions 
7.2.1 FBA models of redox metabolism in TCGA tumors 
Although our bioinformatics and modeling approach towards predicting metabolic 
phenotypes in individual patient tumors using multi-omic data represents a significant 
methodological advancement over previous FBA models, additional improvements and 
integrations with other modeling strategies would further improve its accuracy and 
applicability. Currently, rates of metabolite transport through specific plasma membrane 
transporters are much less characterized than turnover rates of intracellular metabolic 
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enzymes, limiting the implementation of quantitative transport constraints [137]. Unless 
experimentally-measured metabolite uptake rates from samples of interest are obtained, 
constraints on uptake reactions are commonly set as binary (i.e. if a metabolite is present 
in the extracellular medium, intracellular uptake is unconstrained; otherwise, uptake is set 
to zero). A potential approach towards setting quantitative uptake constraints would be to 
relate membrane transporter expression with experimentally-measured extracellular 
metabolite concentrations (for example, from cell culture media or patient blood samples) 
to predict individualized metabolite uptake rates. In addition, regarding the application of 
FBA models towards studying redox metabolism, integration of important redox signaling 
and regulatory networks such as the Nrf2/Keap1/ARE pathway through methods such as 
integrated FBA (iFBA) could improve the accuracy of predicted reaction fluxes which 
utilize ARE-regulating genes including G6PD, PGD, IDH1, and ME1 [410-414]. Finally, 
the incorporation of FBA into agent-based tumor models using single-cell transcriptomic 
and mutational information may help explore the role of intratumor heterogeneity in redox 
metabolism and radiation responses [415, 416]. By simulating a multicellular system over 
time, the steady state metabolite import and export rates from one cell at a particular time 
point alter the import/export rates of these metabolites and resultant intracellular 
metabolism of neighboring cells at later time points; thus, dynamic metabolic behavior of 
the tumor and the impact of metabolic heterogeneity between cells can be assessed. 
FBA models of radiation-sensitive and -resistant TCGA tumors could be used to 
explore other aspects of genome-scale metabolism which impact radiation response and 
could provide insight into optimal radiation-sensitizing therapies. Differences in energy 
metabolism and ATP production between radiation-sensitive and -resistant cancers have 
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been previously identified, including the promotion of radiation resistance by upregulation 
of aerobic glycolysis (Warburg effect) [179, 417]. For example, elevated lactate levels have 
been shown to reinforce DNA damage repair via inactivation of histone deacetylase [418]. 
FBA models could be used to identify key metabolic enzymes associated with aerobic 
glycolysis and lactate production in radiation-resistant cancers for targeted disruption of 
tumor energy metabolism. Additionally, previous computational studies utilizing genome-
scale modeling have explored the role of dietary changes on metabolism and disease 
progression [419]. Metabolite import rates in personalized FBA models can be used to 
reflect a particular cancer patient’s diet, and the resulting impact on genome-scale tumor 
metabolism can be explored to identify optimal nutrition strategies for individual patients. 
The flexibility and genome-scale coverage of FBA models enables their utilizing in myriad 
applications for predicting metabolic phenotypes and discovering metabolic targets for 
improving treatment response. 
7.2.2 Machine learning classifiers for prediction of radiation response 
Although our novel approach towards integrating machine learning and genome-
scale metabolic modeling for the prediction of radiation response provides many 
enhancements in performance and biological insights compared to previous studies, 
additional improvements could be made. Analysis of the multi-omic classifier showed that 
tumor histology had the largest average SHAP value across all datasets (Figure 5-26). This 
suggests that additional features from tumor histological images could further improve the 
predictive accuracy of classifiers for radiation response. A convolutional neural network 
could be added as an additional base learner, with tumor H&E images from TCGA 
provided as input, to both enhance classifier predictions and identify novel connections 
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between tumor histological features and radiation sensitivity [420, 421]. Additionally, 
changes in both DNA methylation and microRNA expression have been implicated in the 
tumor response to ionizing radiation therapy and may alter overall patient sensitivity to 
therapy [422-425]. Inclusion of these features into the multi-omic classifier may yield 
additional multi-omic biomarkers for improved radiation response prediction. To ensure 
that the obtained pan-cancer classifiers and diagnostic biomarkers for radiation response 
are robust and not cancer type-dependent, an adversarial penalty could be added to the 
weighted log loss function to punish classifiers which discriminate based on the cancer 
type covariate [426]. Finally, because the TCGA database is biased towards patients with 
advanced disease compared to the general cancer patient population, the tumor 
pathophysiology and thus the multi-omic datasets from these tumor samples may not be 
reflective of early-stage disease patients, limiting the generalizability of the classifiers 
developed from these datasets. The inclusion of samples from another tumor database as 
either interspersed with TCGA samples or as a separate testing dataset could help improve 
the predictive accuracy and generalizability of these classifiers. 
While this study focused on the identification of diagnostic biomarkers for 
predicting response to radiation therapy, the integration of machine learning and metabolic 
models is a generalizable approach that could be used for many other applications in cancer 
biology and treatment. For example, kinetic computational models are widely used for 
studying chemotherapeutic metabolism, and genome-scale metabolic models have recently 
been adapted for the prediction of chemotherapeutic response [383, 427]. These tools could 
be used to obtain metabolic predictions from drug-sensitive and -resistant tumors, which 
can be integrated with other multi-omic datasets for identifying biomarkers for drug 
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response. Flux variance analysis could also be used to obtain individual reaction flux values 
across the human metabolic network for each patient tumor; integration into machine 
learning classifiers would then identify the metabolic reactions with activities most 
associated with treatment sensitivity or resistance, providing useful insights into cancer 
metabolism at a systems level. Finally, multiple types of model outputs, including objective 
values, reaction fluxes, and gene knockout predictions, can be integrated into machine 
learning classifiers to determine which types of FBA analysis provide the greatest utility 
in predicting metabolic phenotypes and should be given precedence in terms of 
computational resources and experimental validation. 
7.2.3 FBA models of radiation-sensitizing chemotherapeutics 
While FBA models of cisplatin, cyclophosphamide, and doxorubin metabolism 
suggested that the depletion of redox cofactors may contribute to the overall radiation-
sensitizing effects of these chemotherapies, further experimental studies are needed to 
validate these effects. After the depletion of redox cofactors following chemotherapeutic 
treatment is verified, pharmacologic inhibition of cofactor production (e.g. L-BSO 
treatment to prevent glutathione production) or siRNA knockdown of cofactor-producing 
genes (e.g. NADK to prevent NADP+ or NADPH production) can be used in radiation-
resistant cell lines to assess whether increased sensitivity to radiation treatment occurs. 
Subsequently, the contribution of redox cofactor depletion towards the overall 
radiosensitizing effect of these chemotherapies can be established by comparing cell 
viability following drug treatment with or without exogenous addition of the redox 
cofactors that are being depleted. Finally, the involvement of specific metabolic reactions 
identified from optimal multi-feature objective functions and the relative weights between 
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features can be validated through pharmacologic inhibition or siRNA knockdown of the 
associated enzyme-encoding genes.  
Integration of genome-scale modeling with kinetic models of xenobiotic 
metabolism can be used to combine time-resolved drug pharmacodynamics with network-
driven cofactor supplies for increased predictive accuracy. Similar integrative approaches 
for metabolic modeling have been developed previously for microbiological applications 
[428]. Feng et al. combined a genome-scale model of the bacterium Shewanella oneidensis 
MR-1 with kinetic-based bioprocess models to capture transient alterations in intracellular 
flux distributions with different growth stages [429]. Chowdhury et al. developed k-
OptForce for combining FBA with kinetic models incorporating substrate-level enzyme 
regulation to identify optimal network-wide intervention strategies for enhanced 
biochemical production [430]. Because both chemotherapeutic activity and redox biology 
rely on metabolic processes at short time-scales (ROS production, cofactor utilization) as 
well as longer time-scales (drug clearance, induction of gene expression changes), 
integrative modeling approaches may be necessary for accurate prediction of redox-based 
chemotherapeutic response and radiation sensitization in radiation-resistant tumors.  
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